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A qualitative study of decision-making about the
implantation of cardioverter defibrillators and deactivation
during end-of-life care
Holly Standing,1 Catherine Exley,1 Darren Flynn,1 Julian Hughes,2
Kerry Joyce,1 Trudie Lobban,3 Stephen Lord,4 Daniel Matlock,5
Janet M McComb,4 Paul Paes6 and Richard G Thomson1*
1Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK
2Policy, Ethics and Life Sciences Research Centre, Newcastle University, Newcastle upon Tyne, UK
3Arrhythmia Alliance: The Heart Rhythm Charity, Stratford-upon-Avon, UK
4Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
5Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
6Northumbria Healthcare NHS Foundation Trust, North Shields, UK
*Corresponding author richard.thomson@newcastle.ac.uk
Background: Implantable cardioverter defibrillators (ICDs) are recommended for patients at high risk of
sudden cardiac death or for survivors of cardiac arrest. All ICDs combine a shock function with a pacing
function to treat fast and slow heart rhythms, respectively. The pacing function may be very sophisticated
and can provide so-called cardiac resynchronisation therapy for the treatment of heart failure using a
pacemaker (cardiac resynchronisation therapy with pacemaker) or combined with an ICD [cardiac
resynchronisation therapy with defibrillator (CRT-D)]. Decision-making about these devices involves
considering the benefit (averting sudden cardiac death), possible risks (inappropriate shocks and
psychological problems) and the potential need for deactivation towards the end of life.
Objectives: To explore patients’/relatives’ and clinicians’ views/experiences of decision-making about
ICD and CRT-D implantation and deactivation, to establish how and when ICD risks, benefits and
consequences are communicated to patients, to identify individual and organisational facilitators
and barriers to discussions about implantation and deactivation and to determine information and
decision-support needs for shared decision-making (SDM).
Data sources: Observations of clinical encounters, in-depth interviews and interactive group workshops
with clinicians, patients and their relatives.
Methods: Observations of consultations with patients being considered for ICD or CRT-D implantation
were undertaken to become familiar with the clinical environment and to optimise the sampling strategy.
In-depth interviews were conducted with patients, relatives and clinicians to gain detailed insights into
their views and experiences. Data collection and analysis occurred concurrently. Interactive workshops with
clinicians and patients/relatives were used to validate our findings and to explore how these could be used
to support better SDM.
Results: We conducted 38 observations of clinical encounters, 80 interviews (44 patients/relatives,
seven bereaved relatives and 29 clinicians) and two workshops with 11 clinicians and 11 patients/relatives.
Patients had variable knowledge about their conditions, the risk of sudden cardiac death and the clinical
rationale for ICDs, which sometimes resulted in confusion about the potential benefits. Clinicians used
various metaphors, verbal descriptors and numerical risk methods, including variable disclosure of the
DOI: 10.3310/hsdr04320 HEALTH SERVICES AND DELIVERY RESEARCH 2016 VOL. 4 NO. 32
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Standing et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
v
potential negative impact of ICDs on body image and the risk of psychological problems, to convey
information to patients/relatives. Patients/relatives wanted more information about, and more involvement
in, deactivation decisions, and expressed a preference that these decisions be addressed at the time of
implantation. There was no consensus among clinicians about the initiation or timing of such discussions,
or who should take responsibility for them. Introducing deactivation discussions prior to implantation was
thus contentious; however, trigger points for deactivation discussions embedded within the pathway were
suggested to ensure timely discussions.
Limitations: Only two patients who were prospectively considering deactivation and seven bereaved
relatives were recruited. The study also lacks the perspectives of primary care clinicians.
Conclusions: There is discordance between patients and clinicians on information requirements, in
particular the potential consequences of implantation on psychological well-being and quality of life in the
short and long term (deactivation). There were no agreed points across the care pathway at which to
discuss deactivation. Codesigned information tools that present balanced information on the benefits, risks
and consequences, and SDM skills training for patients/relative and clinicians, would support better SDM
about ICDs.
Future work: Multifaceted SDM interventions that focus on skills development for SDM combined with
decision-support tools are warranted, and there is a potential central role for heart failure nurses and
physiologists in supporting and preparing patients/relatives for such discussions.
Funding: The National Institute for Health Research Health Services and Delivery Research programme.
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Plain English summary
Patients with heart problems may be at risk of sudden death and can be protected from this by animplantable cardioverter defibrillator (ICD). An ICD monitors the heart. If a life-threatening rhythm
occurs, the device will deliver electrical shocks to restore the natural rhythm. ICDs can improve survival, but
some patients can experience unnecessary shocks or develop psychological problems. Patients close to the
end of their lives can experience unnecessary pain and distress from shocks, and turning off the ICD
(deactivation) will prevent shocks and make the patient more comfortable. Shared decision-making
involves patients making decisions about their treatment in partnership with clinicians, after the risks and
benefits of different options have been explained to them, and enables them to make a choice that
reflects what is important to them. It is not clear if patients are appropriately supported to make an
informed decision.
We observed consultations in three hospitals and conducted 80 interviews with patients, their relatives and
clinicians to understand how best to improve the engagement of patients/relatives in decision-making with
clinicians about putting in ICDs and deactivating them towards the end of life. Patients had varying
knowledge about their heart condition and the function of ICDs. Clinicians often found it difficult to explain
fully the function of an ICD and its risks and benefits. The risk of a patient developing psychological
problems and the negative impact of the ICD on body image were rarely discussed. Patients/relatives
wanted to be involved in implantation decisions, with deactivation discussed at the same time. Clinicians
were anxious about early deactivation discussion. Opportunities throughout the pathway were identified for
discussion about the appropriateness of continued ICD therapy and deactivation.
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Scientific summary
Background
In the UK there are 100,000 sudden cardiac deaths per year. Implantable cardioverter defibrillators (ICDs)
are recommended for patients at high risk of sudden cardiac death [primary prevention (PP)] and for
survivors of cardiac arrest (secondary prevention). All ICDs combine both a shock function (to treat fast
heart rhythms) with a pacing function (to treat slow heart rhythms). In some cases, the pacing function
may be very sophisticated and can provide so-called cardiac resynchronisation therapy (CRT) for the
treatment of heart failure. CRT itself may be provided by a pacemaker (cardiac resynchronisation therapy
with pacemaker) or in conjunction with an ICD (cardiac resynchronisation therapy with defibrillator).
The majority of ICDs are used for PP and in people with chronic heart failure. They increase life expectancy
but may be associated with adverse effects (unnecessary or inappropriate shocks, device complications,
increased hospitalisation and anxiety and depression). Consequently, decision-making about an ICD for an
individual should consider the benefit of averting sudden death alongside possible future harms, including
adverse effects and the potential need for deactivation towards the end of life. We aimed to critically
explore patients’/relatives’ and professionals’ views about, and experiences of, ICD implantation and
deactivation, and to examine how this information could support better shared decision-making (SDM).
Objectives
Our objectives were to explore patients’, relatives’ and clinicians’ views and experiences of decision-making
about ICD implantation and deactivation; to establish how and when ICD risks, benefits and consequences
(including deactivation) are communicated to patients; to determine patients’/relatives’ and clinicians’
information and decision-support needs in the context of SDM; and to identify the individual and
organisational facilitators and barriers to discussions about implantation and timely decision-making
about deactivation.
Methods
Qualitative methods (observations, interviews and workshops) were used. To reflect a diversity of patients’
experiences, we recruited people before and after ICD implantation, as well as people who declined ICD
therapy, people considering prospective deactivation and bereaved relatives. Phase 1 involved observation
of 38 consultations with patients being considered for ICD at three different settings: one specialist
implanting centre and two district general hospitals. These observations facilitated ‘context setting’
(the nature of ICD consultations and decision-making interactions, including the patient’s journey through
different referral and care pathways) to inform our purposive sampling strategy and the content of
interview guides for in-depth interviews with patients, relatives and clinicians (phase 2). Patient participants
in phase 2 were recruited following an initial approach by a member of the clinical team. Bereaved
relatives (up to 18 months post bereavement) were identified via the physiologists at one tertiary care
centre and contacted via letter. Following return of a consent form, they were contacted by the research
team. Observations were recorded in field notes and all interviews were audio-recorded and transcribed
verbatim. Data collection and analysis occurred concurrently. Interactive workshops with clinicians and
patients/relatives were used to validate our findings and to explore their ideas on how the findings could
be used to support better SDM.
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Findings
In total, 38 consultations were observed across three sites (July 2013 to January 2015) and 80 interviews
were conducted with 44 patients/relatives (33 men and 11 women, aged 47–85 years), seven bereaved
relatives of ICD patients and 29 clinicians (implanting and non-implanting cardiologists, palliative care
clinicians, physiologists, psychologists and specialist nurses). Workshops with 11 clinicians and 11 patients/
relatives were subsequently facilitated
Patients and relatives want to be offered a choice and to be given balanced information about the
available options relating to ICD therapy, in particular the potential impact on psychological well-being
and quality of life in the short and long term. There was a lack of standardised methods used to convey
information about the nature of ICDs (and other options) and associated risks, benefits and consequences,
including a lack of tools to support an understanding of the information on benefits and adverse events in
the short and long term. Clinicians’ values about patients’ preferences for information and involvement
in decision-making and patients’ stated preferences were often discordant.
Patients and relatives want to know about deactivation in advance of implantation and to be actively
involved in decision-making. We found a lack of consensus/ownership among clinicians about who should
take responsibility for discussing deactivation with patients and relatives and when such discussions should
happen. Potential trigger points for deactivation discussions within the care pathway were suggested, in
alignment with the need for regular monitoring and review over time in terms of the clinical effectiveness
and appropriateness of continued ICD therapy.
Limitations
It was possible to recruit only two patients who were prospectively considering deactivation and seven
bereaved relatives. Consequently, the views and experiences of these groups may be under-represented.
With regard to bereaved relatives, the length of time post bereavement may have compromised accurate
recollection. This study also lacks the perspectives of primary care clinicians.
Conclusions
Patients and relatives want information about the surgical procedure to implant ICDs, balanced
information on the benefits, risks and consequences of ICD therapy, including involvement in
decision-making about implantation and deactivation, with a preference for these issues to be addressed
at the time of implantation. In particular, they want to know about the risk of adverse effects (including
potential psychological problems and negative effects of ICDs on body image), which is often not
conveyed to patients and may inhibit informed values-based decisions about ICD therapy.
The clinical rationale for offering ICD therapy should be clearly communicated to patients and their
relatives as early as possible in the patient pathway, potentially using codesigned information and tools,
including the live demonstration and manipulation of devices. There is a need for increased access to,
and a greater role for, psychological support from appropriately qualified mental health professionals,
including signposting to peer support groups. Patient/family member preparation for SDM with cardiologists
provided by clinicians with frequent patient contact (e.g. heart failure nurses) may be of value.
The issue of deactivation could be introduced early in the care pathway and raised again at subsequent
specific trigger points for more detailed and timely discussions with patients and their relatives. There is a
pressing need for evidence-based strategies to foster interprofessional learning and collaboration between
cardiology and palliative care teams in the context of ICD therapy.
SCIENTIFIC SUMMARY
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Future work
Multifaceted SDM interventions are warranted that also include a focus on skills development for SDM
(patients/relatives and clinicians), appropriate use of updated/revised decision-support tools, an exploration
of a central role of heart failure nurses and physiologists in supporting patients/relatives and defining the
role of primary care clinicians in providing ongoing care and initiating deactivation issues.
Funding
Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research.
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Chapter 1 Introduction
Overview of the research
This research study used qualitative methods to investigate patients’, family members’ and professionals’
views about, and experiences of, implantable cardioverter defibrillator (ICD) implantation and deactivation.
This chapter presents a synopsis of the study context, rationale, aims and objectives, including an overview
of the project team, patient and public involvement (PPI), ethics approval and the subsequent structure of
the report.
Context and rationale for the research
In the UK there are 100,000 sudden cardiac deaths per year,1 80% of which are attributable to ventricular
tachyarrhythmia.2 ICDs are recommended for patients at high risk of sudden cardiac death [primary
prevention (PP)] and for survivors of cardiac arrest [secondary prevention (SP)].2,3 All ICDs combine both a
shock function (to treat fast heart rhythms) with a pacing function (to treat slow heart rhythms). In some
cases, the pacing function may be very sophisticated and can provide so-called cardiac resynchronisation
therapy (CRT) for the treatment of heart failure. CRT itself may be provided by a pacemaker [cardiac
resynchronisation therapy with pacemaker (CRT-P)] or in conjunction with an ICD [cardiac resynchronisation
therapy with defibrillator (CRT-D)]. The great majority of ICDs are provided for PP for patients with chronic
heart failure. They increase life expectancy but may be associated with adverse effects, including
unnecessary or inappropriate shocks, device complications, increased hospitalisation and anxiety and
depression.4 Consequently, decision-making about an ICD for individuals should consider the benefit
(averting sudden death) against possible future harms, including adverse effects and the potential need for
deactivation towards the end of life.
Implantable cardioverter defibrillator implantation rates in the UK vary geographically and are increasing, but
the extent to which patients are engaged in decision-making, and what their information and support needs
are, is unclear.5,6 Shared decision-making (SDM), whereby doctors and patients make joint decisions informed
by best evidence and aligned with patient values and preferences,7 is associated with improvements in
patient involvement, knowledge and accurate risk perception, leading to informed values-based choices and
increased treatment adherence.8,9 There is a dearth of information relating to the role that potential ICD
patients can and want to have in the decision-making process and what potential recipients need to know
before they decide to have ICD therapy.5 It is unclear how possible benefits and harms are communicated to
patients during the clinical encounter and how patients make sense of this information. A 2014 review10
identified that patients faced with ICD-related decisions often misunderstood the functionality of ICDs,
or overestimated their benefit, and the authors recommended a SDM approach to achieve improved
patient outcomes.
At the end of life, shocks from ICDs may cause unnecessary pain and suffering to the patient and distress
for carers and family members.11,12 In these circumstances, deactivation may be the most appropriate
management. However, there is a paucity of evidence to reflect if, how and when deactivation
conversations take place in the UK.
There are clear gaps in the existing body of research with regard to the information needs and preferences
of potential ICD recipients with respect to both implantation and deactivation.
The outputs of this study help to address these gaps by providing data on current decision-making while
also establishing the information needs, values and preferences of ICD recipients, carers/family members
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and clinicians, so that decision-making involving patients can be effectively supported. Most patients are
not aware of the possibility of ICD deactivation when they have the device implanted and, for those who
are, it is unclear when, how and from whom [e.g. general practitioner (GP), cardiologist, heart failure
nurse, palliative care clinician] they receive this information.6,13,14 Little is known about how patients make
sense of information about ICDs and what patients’ information needs and preferences are with respect
to implantation and deactivation.5,6,15,16 By documenting current decision-making throughout the care
pathway, and by exploring patients’, family members’ and clinicians’ views of decision-making, we have
addressed these knowledge gaps to help determine how to better support SDM about ICD implantation
and deactivation.
Aims and objectives
Aim
To critically explore lay and professional views on, and experiences of, ICD implantation and deactivation
(towards the end of life) and to examine how this information can be used to support SDM.
Objectives
1. To explore patients’, family members’ and clinicians’ views and experiences of decision-making about
ICD implantation and deactivation (towards the end of life).
2. To establish how and when ICD risks, benefits and consequences are communicated to patients
(including deactivation).
3. To determine patients’, family members’ and clinicians’ information and decision-support needs in the
context of SDM.
4. To identify the individual and organisational facilitators and barriers to discussions about implantation
and timely decision-making about deactivation.
5. To inform (1) early-stage development of decision support for ICD implantation and (2) improvements in
advance care planning for ICD recipients.
Project team
The project was led by Professor Richard Thomson, expert in SDM, and Professor Catherine Exley, medical
sociologist and qualitative researcher, in close co-ordination with Dr Kerry Joyce, Senior Research Associate,
who was a co-investigator and responsible for the day-to-day project management until September 2014.
Dr Joyce’s role was taken over by Holly Standing, Research Assistant, from August 2014, with additional
support from Dr Darren Flynn, Senior Research Associate and Practitioner Health Psychologist, from
September 2015. The core project team met, on average, once a month to discuss the day-to-day
practicalities of running the project, recruitment and data analysis.
The Project Advisory Group consisted of members of the project team and Professor Julian Hughes
(Honorary Professor of Philosophy of Ageing and Consultant in Old Age Psychiatry), Dr Stephen Lord
and Dr Janet McComb (consultant cardiologists), Dr Paul Paes (Consultant in Palliative Medicine),
Mr Tom Bryden, Mr Tom Twedell, Mr Paul Cuskin and Mr Steve Whitely (patient representatives),
Mrs Trudie Lobban, Member of the Most Excellent Order of the British Empire (MBE) (founder and trustee
of the Arrhythmia Alliance: The Heart Rhythm Charity) and Dr Daniel Matlock (Consultant in Palliative
Medicine). The Project Advisory Group provided feedback and advice, and reviewed progress on all aspects
of the study.
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Patient and public involvement
Active, sustained and non-tokenistic engagement with patients is a crucial component of our research and
echoes our commitment to conducting research that supports patients in adopting a more proactive role in
decision-making. Public and patient engagement was initiated prior to the development of the outline
application and was led by one of the co-investigators, Dr Kerry Joyce. Mrs Trudie Lobban MBE, Founder
and Trustee of Arrhythmia Alliance, was contacted at the pre-application stage. Trudie enhanced the focus
of the project on patients’ needs by encouraging us to concentrate on both implantation and deactivation
decisions, explaining that deactivation is often a key issue that patients and relatives would like to discuss
in advance. In this way, deactivation would be addressed in advance rather than leaving it until close to
the end of life, when it is often the family/carers who are faced with making the decision rather than the
patient themselves, causing additional distress at an extremely emotional time. This benefit of early PPI was
used as an example of good practice by INVOLVE, a national advisory group ‘to support active public
involvement in NHS, public health and social care research’.17 Trudie subsequently joined the research team
as both a co-applicant and a member of our study advisory group. Trudie provided service user input into
all stages, including the development of patient/carer information resources, data analysis, report writing,
interpretation and dissemination of study findings. Two patient/carer representatives (with an interest in
end-of-life issues) joined the initial project advisory group. The Arrhythmia Alliance and the North of
England Cardiovascular Network also reviewed the research proposal and their comments were
incorporated, specifically with respect to strengthening the focus on decision-making across the care
pathway, including more than one secondary care centre and emphasising patient benefit.
Ethics approval
Ethics approval for this study was obtained on 26 April 2013 from the National Research Ethics Service
Committee North East-Sunderland (reference: 13/NE/0105). Two ethics amendments were subsequently
given a favourable opinion, on 14 November 2013 (to amend slightly the strategy for recruiting patients
to the study and to be able to include patients eligible for a defibrillator in combination with CRT) and
12 May 2014 (a change to the method of approaching bereaved relatives and widening of the eligibility
criteria to 12–18 months post bereavement). All potential participants were provided with information
about the study and there was an opportunity to address questions to the researchers prior to
participation. Individuals were informed that their participation was entirely voluntary and that they were
free to withdraw at any time without reason. All personal identifying information was removed to
protect confidentiality.
Structure of the report
Chapter 2 presents the background literature on the implantation and deactivation of ICDs, the rationale
for the current study and the study aim and objectives. Chapter 3 details the methods used to address the
study objectives, which consisted of observation of consultations, in-depth interviews and interactive
workshops. An overview of the context and the participants recruited within each of the three phases is
presented in Chapter 4. The findings of the interviews and workshops with reference to implantation
issues are presented in Chapter 5. Chapter 6 discusses the findings of interviews and workshops with
reference to deactivation issues. Chapter 7 presents a summary of the study findings, along with a
discussion in relation to the previous literature, the implications of findings for supporting better SDM
about ICDs, the strengths and limitations of the current study and future directions for research.
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Chapter 2 Background
In the UK there are 100,000 sudden cardiac deaths per year,1 80% of which are attributable toventricular tachyarrhythmia.2 ICDs are recommended for patients at high risk of sudden cardiac death
[primary prevention (PP)] and for survivors of cardiac arrest [secondary prevention (SP)].2,3 All ICDs combine
a shock function (to treat fast heart rhythms) with a pacing function (to treat slow heart rhythms). In some
cases, the pacing function may be very sophisticated and can provide so-called CRT for the treatment of
heart failure. CRT itself may be provided by a pacemaker (CRT-P) or in conjunction with an ICD (CRT-D).
The majority of ICDs are used for PP in patients with chronic heart failure. ICDs increase life expectancy
but may be associated with adverse effects, including unnecessary or inappropriate shocks, device
complications, increased hospitalisation and anxiety and depression.4 The reported incidence of adverse
effects varies greatly from 20% to 60%.4 Shocks may be painful and distressing and have been compared
to being kicked in the chest by a horse or being struck by lightning.18 Thus, decision-making about an ICD
for the individual should include the weighing up of benefits (i.e. averting sudden death) against possible
future harms, including adverse effects and the potential need for deactivation towards the end of life.
Implantable cardioverter defibrillator implantation rates in the UK vary geographically and are increasing,19,20
but the extent to which patients are engaged in decision-making and what their information and support
needs are, is unclear.5,6 SDM, whereby doctors and patients make joint decisions informed by best evidence
and aligned with patient values and preferences,7 is associated with improvements in patient involvement,
knowledge and accurate risk perception, which leads to informed values-based choices and increased
treatment adherence.8,9 There is a dearth of information relating to the role that potential ICD patients can
and want to have in the decision-making process, and what potential recipients need to be informed about
before they decide to have ICD therapy.5 It is unclear how possible benefits and harms are communicated to
patients during the clinical encounter and how patients make sense of this information. Indeed, data on
patients’ expectations of ICDs suggest that survival benefits might be substantially overestimated,21 and
improvements to how information on the clinical rationale for ICDs (including the fact that simple ICDs do
not confer any symptom or quality-of-life benefits) is communicated to patients and their relatives may be
warranted. It has been shown that patients eligible for different therapies might not be fully aware of the
benefits and harms of each option,15,16 and the psychosocial impacts of available treatment or management
options rarely feature in risk communication.22 We also do not know how decisions to implant an ICD
device align with what is important to the individual patient. However, recent work locally suggests that
patients who are more involved in decisions about ICD implantations may be less inclined to have a
device fitted.23
Near the end of life, shocks from ICDs may cause unnecessary pain and suffering for the patient and distress
for carers and family members.11,12 Currently, research suggests that one in four patients experiences shocks
during the last month of life.13 The end-of-life trajectory is difficult to predict for patients with end-stage
heart failure, although shocks do act as a marker of deterioration for some and may actually be a useful
trigger for the palliative process; in these circumstances, deactivation can be the most appropriate
management. Research from the USA suggests that clinicians discuss deactivation of ICDs with only a small
subset of patients and, in the majority of cases, these discussions take place only a few hours or days before
death.13 There is a paucity of evidence to reflect if, how and when deactivation conversations take place in
the UK. A focus group study with US ICD outpatients (approximately half of whom had experienced at least
one shock) found that none recalled discussions about deactivation or knew that deactivation was a
possibility.14 From patients’ perspectives, barriers to deactivation conversations included a reluctance to
begin advance care planning discussions and a lack of knowledge about ICD function.11,14 Reasons for
clinicians failing to initiate deactivation conversations were: a lack of knowledge about ICD function; poor
quality doctor–patient relationships; the assumption that responsibility for discussing deactivation lies
elsewhere; erroneous beliefs that patients are already aware that the device can be deactivated; and the
belief that clinicians can accurately predict which patients will experience shock (and distress) towards
the end of life.11,24 This research suggests a level of unease around initiating deactivation discussions.
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The consequence of this lack of discussion is unnecessary or unwanted shocks towards the end of life.
Indeed, one survey demonstrated that nearly half of all hospices in the USA had experience of a patient
getting shocked by their ICD because no one thought to have a discussion about turning the ICD off.25
The National Institute for Health and Care Excellence (NICE) guidelines2 on ICDs published in 2014 present,
very briefly, details about the possible need for ICD deactivation, and a regional policy for the deactivation/
reactivation of ICDs26 tends to be technical in style and the patient perspective is largely absent.
Furthermore, a critical review of six clinical practice guidelines27 for ICD therapy reported that they tended to
focus on evidence of device effectiveness, with minimal consideration of impacts on patient quality of life
and psychosocial well-being, including the involvement of patients/relatives in decisions.
The implantation and deactivation of ICDs present interesting ethical challenges. The ethical issues around
decision-making in connection with ICD implantation are, at first sight, no different from any other
treatment decisions. The patient must be able to consent to the treatment, he/she must have the capacity to
make the decision – by understanding, retaining, weighing up and communicating their decision – and
must make it freely without coercion.28 Furthermore, the decision can readily be discussed in terms of the
four principles of medical ethics.29 Thus, the person’s autonomy must be respected: they must be able to
make the decision themselves having been fully informed about the consequences of having or not having
the treatment. Implantation is undertaken in order to do the patient some good (beneficence). Unnecessary
shocks (which are painful and distressing), however, would be one way in which the person might be
harmed and would go against the principle that the doctor should do no harm (non-maleficence).
Finally, the principle of justice also seems pertinent because there are issues around resource allocation.
Another layer of ethical complexity is added to these more ‘mundane’ ethical considerations once
deactivation is considered. From a procedural perspective, within the framework of the Mental Capacity
Act 2005,30 if the patient has capacity, he or she should make the decision; if the person lacks capacity, a
decision must be made in his or her best interests. The purely ethical considerations around deactivation,
however, are clearly broader than the more straightforward application of the four principles. For instance,
the doctrine of ordinary and extraordinary means is clearly relevant to deactivation because, at the end
of life, shocks could be considered both ineffective (defined as no longer leading to the goal that was
originally intended) and, thus, futile as well as burdensome. This could, therefore, be considered an
extraordinary treatment and, as such, there would be no moral obligation to provide it.31 The temporality
of deactivation discussions is important here. Some of the ethical issues are underpinned by deeper
philosophical concerns, for example about the shape of our lives and about the role of health care within
our conceptions of life’s purposes. The importance we attach to how our lives end is relevant to a narrative
view of ethics.31 In addition, it may be that deactivation needs to be considered in the context of the
relationships of care and trust that exist between a patient and his or her health-care professionals. Finally,
the sensitive nature and difficulty of the discussions that might have to be had at implantation about
deactivation should alert us to the importance of the inner dispositions, which constitute the requisite
professional virtues of fidelity, compassion, prudence, fortitude and integrity.32 In other words, one
of the ethical requirements is that those involved in the sensitive conversations about implantation and
deactivation should approach patients in the right way, that is, they should be disposed correctly, which in
turn means that they should be on the patient’s side but should act in a manner that is true to all the
complexities that have to be weighed up in the course of the SDM conversation with the patient.
Despite these obvious complexities, there is a paucity of research on attitudes to, and practices around,
ICD deactivation6 and there have been few systematic attempts to develop decision support for either
patients or clinicians to facilitate conversations about ICD implantation and deactivation during end-of-life
care. Published research (mostly from the USA) is limited in two key ways. First, it tends to consider
decision-making in tertiary care (specialist centres), ignoring what happens earlier in the pathway. Second,
the research has generally not sought to change practice; rather, the description of patient experience is
viewed as an end in itself. The current study has increasing resonance with the prominence of SDM in NHS
reforms33 and the increasing importance attached to advance care planning.34 By documenting current
decision-making throughout the care pathway, and by exploring patients’, family members’ and clinicians’
BACKGROUND
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views of decision-making, we aimed to address these knowledge gaps and to better understand the
support needed to enhance SDM about ICD implantation and deactivation.
Rationale
Health need
Implantable cardioverter defibrillator implantation rates are increasing in the UK, with a 10-year mean
growth rate of 14.9% for ICDs from 2000 to 2010,35 with more recent figures showing a rate of 72 per
1 million in 2013/14 compared with 66 per 1 million in 2012,36 but with marked geographic variation.19,20
We do not know if, when or how the risks (including inappropriate shocks and psychopathology), benefits
(increases in survival) and consequences (including deactivation) of ICDs are discussed with patients, nor do
we know the extent to which patients wish to be engaged in decision-making about ICDs.5 In terms of
implantation decisions, we aimed to provide guidance on how to improve existing decision support and to
provide better support for SDM to ensure that implantation decisions are appropriate and fit with the values
and preferences of patients. With respect to deactivation decision-making, we sought to better understand
how discussions currently take place, and the information needs and preferences of patients at different
points in the patient journey, in order to feed into appropriate advance care planning. Together with the
ethical imperatives to conduct this piece of research, there are likely to be additional benefits in terms of
improving the quality of life for patients with ICDs throughout the pathway and especially when facing end-
of-life decisions. In addition, this research should help to reduce any anxiety in clinical staff and carers/family
members, given the absence of clear national guidelines/protocols, and to reduce complicated grief among
the bereaved associated with poor quality of death.6
Expressed need
Increasing importance is attached to SDM33 and advance care planning34 in current NHS strategy.
Decision-making about ICD implantation is a preference-sensitive decision for which the SDM model is
fitting. For example, potential risks (e.g. inappropriate shocks, device complications, psychopathology) and
possible consequences of an ICD (e.g. deactivation during end-of-life care) are likely to hold varying levels
of importance for different people when they are deliberating between having an ICD fitted or not.
Indeed, a recent study found that informed patients who are more involved in SDM may make decisions
that contrast to those driven by the strict application of evidence-based guidelines in a more traditional
and paternalistic approach to decision-making.37 This accords with the finding that decision aids used in
contexts in which both an invasive and a conservative treatment option are available result in a 25%
reduction in patients choosing the invasive option.8 Thus, there is a cogent, evidence-based argument for
the adoption of the SDM model in the context of decisions about ICDs, which is reflected in the American
College of Cardiology’s call for implementation of (and research into) models of SDM in cardiology.38
Furthermore, the existing evidence base shows that the topic of ICD deactivation is seldom discussed in
advance.13 The study sought to examine ways in which to address the timeliness of deactivation
conversations while exploring how these might best be supported.
Sustained interest and intent
Rates of ICD implantations are increasing and, with our ageing population, demand is likely to continue
to escalate in the future. From both an ethical and practical perspective (in terms of current resource
constraints), it is important that patients are supported to make decisions in line with their individual
values and preferences, thus ensuring that decisions are appropriate for each individual patient, and that
unnecessary or inappropriate implantations are avoided. In line with the increased importance of advance
care planning within the NHS, decision-making about future ICD deactivation is an important issue to
address, particularly in light of the absence of guidance on deactivation in current NICE guidelines.2 At a
regional level, the North of England Cardiovascular Network guidance26 on deactivation and reactivation of
ICDs goes some way to addressing this deficit, but the document is largely technical in nature, with neither
the patient perspective nor the importance of SDM featuring strongly. There is therefore potential for
these findings to inform both regional and national guidelines about ICDs.
DOI: 10.3310/hsdr04320 HEALTH SERVICES AND DELIVERY RESEARCH 2016 VOL. 4 NO. 32
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Standing et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Capacity to generate new knowledge
There are clear gaps in the existing body of research with regard to the information needs and preferences
of potential ICD recipients with respect to both implantation and deactivation. This study aimed to address
these gaps by providing data on current decision-making while also establishing the information needs,
values and preferences of ICD recipients, carers/family members and clinicians, so that decision-making
involving patients can be effectively supported. Most patients are not aware of the possibility of ICD
deactivation when they have the device implanted and, for those who are, it is unclear when, how and by
whom (e.g. GP, cardiologist, heart failure nurse, palliative care clinician) they receive this information. Little
is known about how patients make sense of information about ICDs and what patients’ information needs
and preferences are with respect to implantation and deactivation. Existing research in this area has been
conducted primarily in the USA and is limited to mainly descriptive accounts, which do not attempt to
change practice and which focus on decision-making in tertiary care to the detriment of understanding
and supporting decision-making earlier in the pathway.
Generalisable findings and prospects for change
By incorporating what is important to the individual patient in decision-making about ICDs, resources can
be better targeted to ensure that those people who, after discussion of the benefits and risks of device
implantation, make the decision to have an ICD are better equipped to deal with the consequences of an
ICD on quality of life and the possible need for deactivation towards the end of life. There is also likely to
be transferable learning about how to broach discussions about withdrawal of analogous assistive devices
during end-of-life care.39 This work is directly relevant to those working in clinical practice on individual
patient preferences for information giving, levels of involvement in decision-making and how best to
support patients and their families with regard to discussions about implantation and deactivation of ICDs.
The dual focus on both ICD implantation and deactivation decisions reflects the government’s stated
commitment to SDM,33 as well as the importance attached to advance care planning in the NHS.34
Against this backdrop, our study is timely, particularly with the observation that there is a need for better
understanding of how to implement SDM within existing services.7
Building on existing work
Members of our research team have led and contributed to several studies on variation in the use of
ICDs,19 patient involvement in decision-making about cardiac devices,23 patient and clinician perceptions of
ICD decision-making,40 and the development of decision support.41,42 To date, much of the existing (mostly
North American) evidence is concerned with what happens in specialist centres, with little consideration
of earlier stages of decision-making, particularly in secondary care for initial referral decisions. Equally,
there is little available evidence about how decisions on deactivation are made, but a strong suggestion
that these are generally made late, and close to death, without planning in advance.13 This study builds on
existing knowledge to (1) support the process of SDM with ICD patients and relatives and (2) disseminate
learning to improve advance care planning for ICD patients.
Aim and objectives
Aim
To critically explore lay and professional views about, and experiences of, ICD implantation and
deactivation (towards the end of life) and to examine how this information can be used to support SDM.
Objectives
1. To explore patients’, family members’ and clinicians’ views and experiences of decision-making about
ICD implantation and deactivation (towards the end of life).
2. To establish how and when ICD risks, benefits and consequences are communicated to patients
(including deactivation).
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3. To determine patients’, family members’ and clinicians’ information and decision-support needs in the
context of SDM.
4. To identify the individual and organisational facilitators and barriers to discussions about implantation
and timely decision-making about deactivation.
5. To inform (1) the early-stage development of decision support for ICD implantation and
(2) improvements in advance care planning for ICD recipients.
During the inception of the research, a US option grid, booklet and video was published to support
SDM about ICD therapy.43 Consequently, the final objective was amended to focus on the provision of
guidance to improve existing decision support and on supporting the process of SDM with ICD patients
and relatives.
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Chapter 3 Research methodology
Overview of study design
To understand fully the views and experiences of those involved in decision-making about ICD
implantation and deactivation, and how such discussions are enacted in practice, requires the use of
qualitative methods. In this study, we used a combination of observations of consultations, in-depth
individual interviews and interactive group workshops. The study was not longitudinal in nature, that is,
we did not follow a particular cohort of patients throughout the care pathway. To reflect the diversity and
range of patients’ experiences, we recruited people before and after ICD implantation, as well as people
who declined ICD, people considering prospective deactivation and bereaved relatives. We also adhered to
the consolidated criteria for reporting qualitative research (COREQ) guidelines.44
Patients can be referred for an ICD for either PP of sudden cardiac death or as SP after they have
experienced a cardiac arrest. PP patients are likely to have more time to discuss and reflect on their decisions
about an ICD than those patients who are referred for SP. With this in mind, and because of the different
nature of the decision-making process (after a cardiac event), we focused pre-implantation interviews on
patients referred for PP. However, to achieve sufficient numbers and to understand fully the nature of
decision-making for the two different groups, we did not exclude patients with SP ICDs. We also included
patients eligible for, or living with, CRT: patients eligible for a CRT device can also choose to have CRT alone
or CRT-D. The decision is presented to patients as the option of having something to improve symptoms or
the option of having something to improve symptoms as well as something to increase the chances of living
longer. It is important, therefore, that we captured this group of patients in our sample to understand the
full range of options available and the nuances of the decision-making process. Moreover, CRT-D is a
common option for ICD patients, and excluding this group of patients would limit how representative the
study sample was in terms of the wider population of defibrillator patients.
Data collection and analysis for this study followed the principles of the constant comparative method.45
This is an iterative process whereby data collection and analysis occurred concurrently, with earlier
interviews informing subsequent ones and continuing until no new information emerged. The initial
phases used observations and interviews to explore lay and professional views and experiences of
decision-making about ICD and CRT-D implantation and deactivation. Observations were conducted at
one specialist centre, where ICDs are implanted, and at two district general hospitals (DGHs), with ICDs
implanted at one of these. We selected these study sites because they provide different pathways to ICD
implantation and, therefore, may provide different insights into decision-making between implanting and
non-implanting clinicians, and the importance of different organisational approaches, such as the role of
the specialist nurse. Our rationale was to understand patient/clinician interactions, information sharing and
decision-making in implanting centres and to explore what happens earlier in the pathway by including
two DGHs offering contrasting approaches to patient referral, one of which was cardiologist led and the
other of which was nurse led. In-depth interviews were conducted with patients, family members and
clinicians at the above sites. We also recruited from two additional sites (one in tertiary care and the other
in secondary care) to conduct clinician interviews. For the deactivation conversations, patients and family
members were recruited through cardiac physiologists, cardiologists or palliative care physicians directly
involved in the patients’ care.
In the final stage of the study, these data were used in the interactive group workshops with patients/
family members and clinicians to validate the findings of the initial phases and to provide a vehicle to
explore their ideas and views about how the findings could be used to support better SDM about ICD
implantation and deactivation, as well as to inform advance care planning for ICD recipients.
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Phase 1: observations
In order to understand decision-making across the care pathway, non-participant observation46 was
conducted by two researchers (KJ and HS) to familiarise themselves with the clinical environment and
patient pathways. Specifically, we were interested in learning more about:
(a) the nature of ICD consultations (how ICDs are portrayed within the clinical encounter, the focus and
duration of interactions, who interacts with whom, who initiates/ends interactions, how the physical
environment might constrain/promote the delivery of good-quality decision-making)
(b) the nature of decision-making interactions (how information is shared and by whom, how risk
communication is enacted and by whom, how the topic of possible future deactivation is approached
and by whom)
(c) the patient’s journey through the care pathway (what happens and when, key decision points
regarding ICDs and how are these negotiated, the stage of the pathway at which risks, benefits and
consequences – e.g. possible future deactivation – are communicated to patients).
Patients received a letter about the study with their outpatient appointment letter explaining that a
researcher might be present at his/her clinic appointment to observe the consultation. This letter included
clear details of how to opt out of the study (see Appendix 1). The letter of invitation included an opt-out
reply slip which patients could return to the receptionist/member of clinical team on arrival to enable the
opportunity to opt out without having to approach the issue face to face. The consultant cardiologist
further relayed the information at the beginning of the consultation and offered a final chance to opt out.
Patients had the opportunity to reflect on their decision and discuss their participation in the study with
family members/significant others before deciding whether or not to participate (there was usually a period
of several weeks between appointment letter and actual appointment). We chose an opt-out process of
consent for the observations for three reasons: (1) we wished to avoid overburdening patients at a time
when they are already receiving large volumes of information about ICDs; (2) clinicians would be seeking
written consent for device implantation so asking for written consent to observe the consultation may
result in confusion over what the patient is actually consenting to; and (3) obtaining written consent would
lengthen the consultation and place additional demands on the consultant cardiologist.
Experienced qualitative researchers (KJ and HS) observed consultations with patients being considered
for ICD. Initially, it was hoped that we would also be able to observe consultations that focused on
deactivation, but this was not possible because of the nature and timing of these discussions. It is
unknown how many deactivation conversations took place during the study period. We were made aware
of very few deactivation conversations, and in some cases the researchers were not notified in time to
permit attendance and observation of these consultations.
Our observations helped to understand how conversations about ICD implantation and subsequent
deactivation are enacted. Our approach avoided imposing structure on the observations and brief field
notes were written up immediately after the observation period.47 Prior to beginning data collection, a pilot
observation was conducted opportunistically, after which the researcher discussed the consultation with
the consultant cardiologist in order to shape an observation grid and coding frame as a guide to their
note-taking around the key components of a typical ICD consultation (see Appendix 2). This included, but
was not limited to, discussions of diagnosis and checking understanding; communication of the risk of
sudden cardiac death; presentation of the ICD, with risks and benefits information; and the impact of the
ICD on quality of life and, in some cases, the capacity of the ICD to change the mode of death. It should
be noted that this is not a deep ethnographic study and the purpose of the observations was to provide
context for subsequent interviews. Consequently, the observations enabled us to understand how decision-
making about ICD implantation and deactivation was enacted in different settings and the nature of ICD
consultations and decision-making interactions (what is said and what remains unsaid), including the
patient’s journey through the care pathway. Notes were taken by hand either during or immediately after
the consultation in order to minimise the presence of a researcher within the clinic environment.
Observations at each site took place prior to beginning recruitment for phase 2, thus providing local
RESEARCH METHODOLOGY
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context and helping to inform the purposive sampling strategy and interview guides for in-depth interviews
with patients, relatives and clinicians.
Phase 2: in-depth interviews
Interviews were conducted by KJ and HS with patients (aged > 18 years), partners/relatives (aged > 18 years)
and clinicians to explore understandings and experiences of, and the factors that influence, decisions about
(1) ICD implantation, and (2) deactivation towards the end of life. We excluded patients and family members
who lacked capacity to participate in the study and patients and family members who were unable to speak
English. Interviews were conducted at a time and place convenient to the interviewee. The majority of
interviews were conducted face to face, but a small group of people preferred to be interviewed by
telephone. We ensured that patient and family member interviews were conducted during times when
support from the clinical team was available in the event that any of the interviewees experienced undue
distress. We also made participants aware of sources of support and further information where necessary,
including Arrhythmia Alliance, Patient Advice and Liaison Service, and Cruse bereavement support
(appropriate information was included in the participant information sheet and was reiterated at the
beginning of the interviews).
One-to-one, in-depth interviews are the method of choice where the issue under investigation requires
detailed exploration of sensitive issues. In-depth interviews are particularly instructive where the current
evidence base is limited,47 as they enable space and flexibility for the interviewee to shape the issues
discussed, rather than the direction being predetermined by the researchers’ interests or hypotheses. The
interviews investigated how decision-making about ICDs is currently undertaken and if, and at what stage,
device deactivation is addressed; patients’ and clinicians’ information and support needs regarding ICDs in
general and regarding deactivation in particular; patients’, carers’ and clinicians’ views about how best to
support decision-making about the implantation and deactivation of ICDs; and individual and organisational
facilitators and barriers to discussions about implantation and timely decision-making about deactivation.
Purposive sampling was used to capture a broad range of views and experiences and, as data collection
progressed, we deliberately sought out individuals who had different views or experiences to challenge our
analysis. During recruitment we sought to interview people about both implantation and deactivation
decisions and purposively sampled so that the views and experiences of the following groups of patients
and/or family members were included.
With regard to implantation decisions:
l before implantation – patients referred for an ICD from secondary care
l before implantation – patients recruited from implanting centres who elected to have a
device implanted
l after implantation – ICD patients who had a device implanted (we purposively sampled to capture a
range of experiences from those recently implanted to others who have lived with the device for up to
12 months)
l declined ICD – patients who were referred for an ICD but who declined [at either secondary (declined
referral) or tertiary (declined device) stages of the pathway].
With regard to deactivation decisions:
l patients who were prospectively considering device deactivation
l bereaved family members (4–18 months post bereavement).
Where possible, we sought to interview prospectively patients who were considering deactivation via
tertiary care (e.g. advanced cancer patients). However, discussions about deactivation often take place only
a few days (or even hours) before death,13 which presented practical and ethical issues with regard to
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interviewing patients and relatives. Where deactivation was close to the end of life, and we were unable to
speak to patients, we sought to interview family members of patients 4–18 months post bereavement.
Our aim was to continue with interviews until no new information emerged (theoretical saturation). The
interview schedule focused on understandings of and feelings about ICDs; experiences of decision-making
about implantation; if, where, when and how ICD deactivation was discussed; availability and appropriateness
of information; preferences for information and decision support; and exploration of patient pathways. In
addition, we included some specific prompts to tap into the values and ethical viewpoints that underpinned
peoples’ decisions. Interviews were audio-recorded with written consent, transcribed verbatim and
anonymised. Permission was sought from participants to retain contact details for the purposes of inviting
them to participate in workshops in phase 3.
Clinician interviews
As already noted, clinicians were recruited from the five sites (two tertiary care centres and three DGHs)
in total. By including two additional sites, we were able to purposively sample a range of views and
experiences that took account of geographic variation in the referral pathway. Increasing the potential
sampling population also served to protect the anonymity of clinicians who participated in the interviews.
Clinician interviews considered both implantation and deactivation decisions and involved purposively
sampling a range of clinical specialties including secondary and tertiary care cardiologists, heart failure
nurse specialists, cardiac physiologists and palliative care physicians. Copies of the letter of invitation for
participation in an interview, participant information sheet, consent form and interview schedules can be
found in Appendix 3.
Recruitment strategy for interviews
A summary of the recruitment process is shown in Figure 1.
Decline invitation to participate
Decline (do not return consent to contact form)
Patient approached by a member of the clinical team, asked if he/she is interested in taking 
part and talked through the letter of invitation and the participant information sheet. 
Member of the clinical team emphasises that participation is voluntary and is not related to ongoing care
If patient is interested in participating he/she will be asked for permission for his/her contact 
details to be given to the researcher and will be asked if the researcher can contact him/her after 48 hours. 
A member of the clinical team advises potential participants to take the information 
home, read it and consider whether or not they want to participate
Written consent is obtained before the interview takes place 
(in person for face-to-face interviews or by returning consent form by post in prepaid envelope 
supplied in information pack for telephone interview option)
Researcher makes telephone contact at least 48 hours after receiving the patient’s contact details.  
Researcher addresses any questions and, if patient is still interested,
 arranges a convenient time for the interview
Interested in participating in the study
Interested in participating in the study
Interested in participating in the study
Decline (after discussion changes mind)
FIGURE 1 Recruitment process for patient interviews.
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We used a slightly different approach to recruit bereaved relatives: a letter of invitation, together with an
information sheet, was sent by post to bereaved relatives identified by the physiologists at the tertiary centre,
which holds a register of all those people who died with an active ICD in situ and all those people who had
their device deactivated before death. We included both groups of patients in our approach (i.e. those who
had their device deactivated before death and those whose device was deactivated afterwards). If interested
in participating, the individual was asked to return the accompanying consent to contact form. In the first
instance, we contacted bereaved relatives 4–6 months post bereavement; however, we were faced with low
levels of participation so the eligibility criterion was widened to 12–18 months post bereavement. It was
also made clear in the invitation that relatives could choose to be interviewed with a friend or family member
if preferred. Equally, if those people contacted did not feel that they were the most appropriate person to
complete the interview, they were invited to pass the information on to whoever was most closely involved
in the care of their loved one. The letter about the research was accompanied by a cover letter from a
cardiologist member of the study team (see Appendix 3). The purpose of the covering letter was to reassure
potential participants that the researchers had no access to the clinical data of their loved one and to
emphasise that there was no obligation to take part in the research. The consultant’s contact details were
also included in the letter to provide a point of contact in the instance that someone encountered distress
from our recruitment approach.
Data analysis: interviews
Data collection and analysis was an iterative process.45 NVivo version 7 (QSR International, Warrington, UK)
was used to facilitate data management and retrieval. The research team (KJ, HS, CE initially, then HS and
CE) met regularly to discuss emergent themes and to resolve any discrepancies and determine theoretical
saturation. Independent coding and cross-checking by members of the research team (KJ, HS, CE) helped
to ensure validity of interpretation. A common coding frame was used across all data sets to allow for
comparison between the different data sources. Data were examined for deviant cases.47 The emergent
findings were discussed on a regular basis with other members of the active research team as well as with
the wider study advisory group.
Phase 3: interactive group workshops with clinicians and
patients/relatives
Two interactive group workshops (2 hours in duration), involving Microsoft PowerPoint (Microsoft
Corporation, Redmond, WA, USA) presentations, small group work and plenary discussions, were
conducted with (1) clinicians and (2) patients/relatives. These were aimed at validating the findings of the
initial phases and as a vehicle to explore their ideas and views about how the findings could be used to
support better SDM about ICD implantation and deactivation, as well as informing advance care planning
for ICD recipients.
Workshops were audio-recorded and were facilitated by two researchers (DF and HS). Field notes were
taken during workshops, which were audio-recorded.
Recruitment of workshop participants
Patients/relatives and clinicians who had provided written consent to be contacted about later stages
of the study were invited to take part in the workshops. The Northern England Cardiovascular Disease
Strategic Clinical Network lead also e-mailed a request for participation in an attempt to recruit additional
clinicians who had not participated in the earlier phases of the research. Patient representatives of
Cardiomyopathy UK (www.cardiomyopathy.org/), Pumping Marvellous (http://pumpingmarvellous.org/) and
the British Heart Foundation (www.bhf.org.uk/) were also invited to attend the patient/relative workshop,
which took place in a community setting.
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Data collection and analysis strategy for workshops
The clinician workshop took place within a tertiary care centre. Following an overview of the aims,
objectives and methods, including a brief overview of SDM, attendees were presented with a summary of
the key findings from phases 1 and 2 and were invited to comment on whether or not they resonated
with their views and experiences in a group plenary. This was followed by group work, in which attendees
were allocated to one of two small groups to consider the following issues, with reference to the generic
question ‘How can patients and their relatives be better supported to make informed values-based
decisions about ICD implantation/deactivation in partnership with clinicians?’:
l Who should discuss the pros and cons of ICDs with patients/relatives?
l When should a discussion about the pros and cons of ICDs with patients/relatives take place?
l What information should be provided to patients/relatives?
l How could specific barriers to SDM be overcome?
The workshop concluded with key issues identified from each small group being discussed in a plenary
session. A copy of the clinician workshop slides can be found in Appendix 4.
The patient/relative workshop was convened in a community setting. The structure was similar to the
clinician workshop, commencing with an overview of the study aims, objectives and methods, including a
brief overview of SDM, followed by a summary of the key findings from phases 1 and 2 and a subsequent
opportunity to comment on/discuss them within a group plenary session. This was followed by small group
work that also focused on eliciting their ideas on how the findings could be used to support better SDM
about ICD implantation and deactivation. A structured small group exercise with reference to a summary
of preference-sensitive decision points and opportunities for discussions with patients/relatives across the
generic heart failure pathway (Figure 2) was used to elicit their ideas on the following questions:
l What information about options (ICD, CRT-D or doing nothing/active monitoring) should be provided
to patients/relatives?
l Who should discuss the pros and cons of the options (ICD, CRT-D or doing nothing/active monitoring)
with patients and their relatives?
l When should a discussion with patients and their relatives about deactivation of ICDs/CRT-Ds
take place?
A copy of the patient/relative workshop slides and structured exercise can be found in Appendix 4.
Field notes and transcriptions of audio-recordings from the workshops were subjected to functional
content analysis (use of a priori and emergency coding with the specific function of identifying generic
categories of information) for discussion with the wider research team to establish whether or not the
descriptions of our findings (presented in Chapters 5 and 6) accorded with the understandings of the
participants, and to inform recommendations on how to support better SDM about ICDs.
RESEARCH METHODOLOGY
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Chapter 4 Profile of participants in each phase of
the study
Phase 1: observations
A total of 38 consultations involving clinicians and patients being considered for both ICD implantation
and deactivation were observed across three sites (July 2013 to January 2015). Consultations ranged in
length from around 10 to 30 minutes.
l Site 1: a tertiary care (implanting) centre – 29 observations of two different cardiologists consulting
with their patients.
l Site 2: DGH, nurse-led clinics – three observations of two heart failure nurses consulting with patients.
l Site 3: DGH – six observations of one cardiologist consulting with patients.
Owing to a lesser frequency of potential ICD candidates seen in secondary care clinics, and the difficulties
in managing to observe a consultation (owing to some patients showing improvement in the repeat echo
and discussion of the possibility of an ICD or CRT-D no longer being appropriate), lower numbers of
observations were conducted in secondary care than initially anticipated.
Phase 2: in-depth interviews
A total of 80 interviews were undertaken with patients/relatives and clinicians (Table 1).
Fifty-one interviews were conducted with patients and/or relatives in total; of these, seven interviews were
conducted with bereaved relatives. Forty-four interviews were undertaken with patients: 33 men and
11 women, aged between 47 and 85 years [mean 68.4 years, standard deviation 10.3 years]. The majority
of patients (n = 34) had been offered an ICD for PP and 10 people had received one for SP. Eleven patients
had a diagnosis of cardiomyopathy and the remaining patients (n = 33) were diagnosed with ischaemic
heart disease. Twenty-seven interviews were conducted with patients alone and 17 were conducted with
patients along with a family member (usually a spouse) present. The largest proportion of patients was
recruited via tertiary care following implantation of an ICD, or they were recruited in tertiary and secondary
care contexts while considering ICD therapy. We were able to interview eight patients who declined an ICD
(one of whom accepted CRT but not the ICD), but only two people who had decided in advance to have
their ICDs deactivated were interviewed. Of the seven bereaved relative interviews, four were with spouses,
in each case the widow of the deceased. A further three group interviews were conducted. These included
two interviews with the spouse and daughter of the deceased and one interview with the son and
daughter-in-law of the deceased. Our sampling strategy was successful in recruiting the range of medical/
clinical specialties involved in the treatment and care of ICD patients across the pathway.
Phase 3: interactive group workshops
A total of 11 clinicians participated in the group workshop from the following specialties: two physiologists;
two implanting cardiologists; two consultant cardiologists; one palliative care consultant; one clinical
psychologist; two heart failure nurses; and a public health registrar working with the Cardiovascular Clinical
Research Network. The patient/relative workshop was attended by 12 participants: five patients, six relatives
and a patient representative from a charitable organisation.
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TABLE 1 Interviews conducted with patients, relatives and clinicians
Patient and family members (and context) n
Patient interviews
Pre implantation (secondary care) 4
Pre implantation (tertiary care) 9
Decliners (secondary care) 5
Decliners (tertiary care) 3
Post implantation 18
Post implantation (experience of psychological sequelae) 3
Prospective deactivation 2
Total patient interviews 44
Bereaved relatives interviews
Bereaved spouse 4
Bereaved spouse and daughter (dyad) 2
Bereaved son and daughter-in-law (dyad) 1
Total bereaved relatives interviews 7
Total patient and family member interviews 51
Clinician group (and context)
Implanting cardiologists (tertiary care) 5
Cardiologists (secondary care) 5
Arrhythmia nurses (tertiary care) 1
Secondary care and community heart failure nurses 6
Cardiac physiologists 4
Health psychologists 2
Palliative care clinicians 6
Total clinician interviews 29
Overall total 80
PROFILE OF PARTICIPANTS IN EACH PHASE OF THE STUDY
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Chapter 5 Findings: implantation issues
In this chapter, we present our analysis related to implantation, where we have drawn on and combineddata from all three phases of the study in order to critically examine the different perspectives and
experiences of those involved in decision-making about ICDs. To protect anonymity, all participants have
been given pseudonyms; when presenting patient quotations, to give further context, alongside names
we provide information about age and if the ICD had been given for PP or SP.
This chapter begins with a description of themes on how ICDs are presented to potential recipients,
outlining the key information that should be given to facilitate SDM as demonstrated using data from
interviews and workshops with patients, family members and clinicians. This is followed by a discussion of
some of the key factors involved in decision-making. Finally, the potential impact on the outcome of the
key actors involved in the decision-making process is discussed.
Information provision to patients/relatives about the rationale
for implantable cardioverter defibrillator therapy
As discussed in Chapter 1, the pathway to receiving an ICD is complex as there are a number of potential
routes by which patients may come to be offered a device. The patient’s pathway is dependent upon
several factors, including if the device is being offered for PP or SP. Furthermore, the pathway for PP
patients may also vary depending on if the patient’s heart failure is being managed in the community or
in a secondary care setting. Here, we outline some of the key information provided to patients when
deciding whether or not to have an ICD implanted.
The purpose of the pre-implantation consultations was to establish the patient’s need for an ICD.
The interviews and workshops indicated that there was variability in the timing of the initial ICD discussion.
In particular, patients who were being managed for heart failure in a secondary care setting sometimes
had an initial discussion about the device before accepting a referral to an implanting centre (and some
patients declined the device at this point). However, it was evident from the observations, interviews and
workshops that the majority of patients had limited knowledge about the device at the time of the
implanting centre consultation. This may be due to one or more possibilities, most probably a combination
of patients being unable to recall fully or to understand information provided on ICDs prior to referral to
the implanting centre or limited discussion about ICDs before referral.
Conveying information on risk of sudden death and the implantable cardioverter
defibrillator role in modifying this
Patients’ levels of awareness regarding their risk of sudden cardiac death appear to be dependent on
whether the device is offered for PP or SP. For the majority of patients, including those sampled in this
study, the device is more commonly offered for PP purposes. As such, these individuals are less likely
to have any prior awareness of their risk of dangerous arrhythmias and sudden cardiac death. This
information was often met with shock and disbelief by patients and their families; interviewees described
difficulties processing the offer of the device:
She [wife] went through a period of time saying ‘you’re 48 years old there’s nothing been wrong with
you, you haven’t fainted, you haven’t been sick, you’re not off work’, you know,’ you’ve never been
off work’, blah de blah de blah . . . ‘But why are they fitting anything?’
Dan, 48 years old, PP, post implant, ICD
Patients’ responses indicated that they often had difficulty marrying the idea that they needed an ICD with
their own views of their health status. Their experiences and perception of themselves did not fit with their
preconceived categories of people who may need life-saving medical intervention.
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Furthermore, it was acknowledged by clinicians that the role of ICDs as a protective medical intervention
may make it harder for some patients to process:
I wouldn’t say there are common misunderstandings. I think the bit that people have difficulty with is
about understanding risk. And so the idea is that they’re a risk modifier. It doesn’t remove risk . . . and
we’re not talking about an absolute ‘oh you’re going to die without having this’. It’s all about
modifying risk and I think that’s a very difficult concept for many people.
Dr Rosemary, implanting cardiologist
The quotation above indicates that there are potentially two complex issues that need to be conveyed to
patients in terms of risk. There is the patient’s risk of experiencing a dangerous arrhythmia and there is
also the ICD’s role in managing this risk. Understanding the role of the ICD as a risk modifier is discussed
in greater detail in Function of the device and Fostering patients’ and their relatives’ expectations about
living with the device.
Data from the observations and clinician interviews show that communicating risk information repeatedly
emerged as a challenging aspect of the information-giving process. Clinicians used different ways of
presenting such information to patients. Particular reference was given to numerical risk information and the
extent to which this was a useful tool in consultations. However, although it was acknowledged that
numerical risk data could be useful, clinicians had concerns about the extent to which patients are able to
make sense of such information. For example, Dr Oak described how he used elastic language in the first
instance to convey risk information to patients, followed by numerical information if considered ‘helpful’:
No, no, no I don’t use numbers. I, I do later on, when I come to the end, but I start off not by using
numbers. I use words like, ‘Very unlikely, but, but slightly more likely than somebody to whom one
could compare.’ Whether that be me, if they look about the same age, or slightly older than me, or
there’s no one else, or if there’s somebody with them like a partner or I might say, ‘Your friend who
isn’t known to have heart disease’. But I then say, ‘It could still happen to me or it could still happen
to them because we don’t know what my arteries look like.’ Or something like, I might say something
like that to emphasise the fact that it’s not, I, I want to try and get a few things over, firstly that it’s
not a very, very high risk, because always they go away thinking they’re going to die in the next
10 seconds or the next week, and they may have to wait quite a while for this thing to be put in. And
secondly because in absolute terms, actually the risk isn’t that high on a day-to-day basis. And, and so
I try, I try and get that over and I try and say, ‘The risk is not very high but it could happen, and it’s
something that could happen over years rather than weeks or months, even though, of course, it’s a
day-to-day risk.’ . . . But then I do, later on, say that, ‘The, the absolute risk is of the order of 1%–5%
depending on where they fit in the . . .’. Or sometimes I might say, if I don’t, you know, if the
conversation’s gone in a way which I think might, numbers might not be helpful, I, I say, ‘Very low
risk, moderate risk or, or at the higher end of the risk.’
Dr Oak, implanting cardiologist
During observations, clinicians, including Dr Oak, largely gave patients verbal comparisons rather than
numbers to position the patient in terms of their risk of sudden cardiac death. Many clinicians indicated
that they tried to tailor the manner in which they presented information in response to cues from the
patient. On the importance of tailoring information, see Tailored information below.
Function of the device
In addition to conveying risk information, establishing the need for the device involves explaining the
functioning by which the device manages a patient’s risk of sudden cardiac death. Through the observations
of clinic appointments, interviews and workshops, it was evident that there was no standard way in which
clinicians delivered this information; rather, clinicians developed their own methods. One approach in
particular that stood out as being particularly useful for patients in understanding the function of the device
was personification or anthropomorphism.
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Defibrillators are mechanical devices, electrical devices that in and of themselves will not make you feel
any different, and, but the device that . . . we would use for you would not make you feel any better,
would not make you feel any different, its job essentially is to help you live as long as you can by
taking away the risk of an arrhythmic or a heart rhythm abnormality, not that it does away with the
heart rhythm abnormality, but it allows it to be treated in a way that it wouldn’t be treated if you
didn’t have a paramedic in your chest if you like.
Dr Birch, implanting cardiologist explaining to a patient
Personifications, for example describing the ICD as a paramedic or a sentry, appeared to be a useful means
of explaining the role of the ICD, as this enabled the device to be presented in a way that was both easy
to understand and easily memorable. The success of such techniques was evidenced by the ease with
which many patients were able to effortlessly recall these during the interviews when asked what they
remembered and understood about the function of the device:
It’s like a sentry; it’s on guard, waiting.
Iris, 76 years old, PP, post implant, CRT-D
Furthermore, it is possible that such techniques will also have a role in fostering positive views about the
device, humanising this piece of machinery that is being fitted to the body.
As noted earlier in Dr Rosemary’s quotation, the ICD is a risk modifier rather than a risk eliminator; as
such, it is essential that patients understand that, even with the device in place, it is still possible for them
to experience an arrhythmia that could kill them. It was evident in the patient and relative interviews that
many did not appreciate or fully understand this distinction:
The only thing that puzzles me now is why it never shocked . . . why didn’t the ICD shock him to put it
right? . . . so when he did die 2 days afterwards, I rang up to see if I could keep the appointment just
to question, would that ICD have shocked him while he was in there, when he had collapsed?
You know.
Mary, bereaved relative of ICD patient
Several of the bereaved relatives expressed misunderstandings regarding the role of the ICD in managing
their deceased relatives’ condition and were confused as to why the device had failed to activate and save
the patient’s life. This appeared to be particularly acute in cases in which the device had never given a
defibrillation and the patient had died.
Implantation procedure
The data from this study demonstrate variation in the extent to which patients felt informed about the
implantation procedure itself, suggesting the need for attention to be given to discussing the practicalities
of the procedure during pre-implantation consultations. Some patients reported that they were ill prepared
for the experience. For example, one patient recounted her shock at the number of clinicians involved in
the procedure:
I can’t remember the amount of people [in the operating theatre], I counted at least 10 . . . That was
fright, that was, actually that was quite intimidating because you’ve got all these people, again you’re
lying flat in a bed, strapped down going, ‘Oh . . .’, ‘I’m just here to . . .’, ‘Oh that’s lovely’.
Molly, 60 years old, PP, post implant, CRT-D
Being unprepared about the implantation procedure had the potential to be distressing for patients, which
could leave them feeling vulnerable and exposed. The possibility of discomfort and distress during
implantation is enhanced by the use of local anaesthetic as the patient is conscious and cognisant
throughout the procedure.
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Tailored information
Both patients and clinicians recognised the importance of adequately informing patients about the ICD in
order to allow them to make an informed decision. Clinicians must endeavour to strike a balance between
giving patients as much information as they need without overloading them with information.
It will range from people who will just say, ‘Well, if you think it’s in my best interest, I’ll happily go
along with it’, versus the others who want to know the chapter and verse.
Dr Thyme, non-implanting cardiologist
Yes. I’m, I’m an intelligent man. I have always wanted doctors to tell me. Dr Ash, the cardiologist in
[DGH S04], some people find very difficult because one of the nurses described it to me is that he
thinks out loud and you get all the information that’s going through his brain. Now I want that, I can
handle that. I don’t want it neatly packaged into something that, talking down to the patient, they
think I’ll be able to handle . . . I like that, I like to be told what it is they want to do, why, and what it’s
going to be like.
Bob, 67 years old, PP, pre implant
Dr Ash was aware of the challenge of communicating information about ICDs and of the difficulty of not
being able to provide patients with a definitive answer regarding the ‘best’ option for treatment/
management/prevention of sudden cardiac death:
I suspect a lot of patients leave the room maybe more bewildered than when they came I because I’m
not able to, sort of, say, ‘look, this is what you should do.’ Some patients say, ‘What should I do?’ and
it’s very hard to advise them, but again, if they say them I just try and tell them what I’d want my dad
to do, if they were my dad or something like that.
Dr Ash, secondary care cardiologist
The above quotation reflects an issue of recognising the value of expert advice but also that the patient’s
values and preferences may differ from the clinician’s. The patient was asking for advice ‘What would you
do?’. As a result the clinician can be drawn into saying what their values and preferences would be if
he/she was making a decision for themselves, as opposed to using reflective listening to explore and elicit
a patient’s preferences and values.
Both clinicians and patients recognised the variation between individuals about the level of information
they wanted. Some people wanted very detailed information and others preferred to be told the key
points. One suggestion to improve the process of providing information was that a menu of options could
be provided to patients allowing them to choose the level of information they desired:
I know there’ll come a point where you [clinicians] don’t want to overload people with information
and then it’ll be up to people, somehow, to decide, ‘I don’t want lots of information, give me, I don’t
know, the bronze information, not the silver or the gold.’ But I’m a gold one, I want it all ’cause it’s
going to be important for me. ’Cause I’ll only be thinking about it anyway. So if you can think of it
and you think you should tell your patient, tell your patient. I think . . . there will be a way to say it
that is the right way for everybody. And I know not everybody wants all the information. But I need it
from the medical people.
Gwen, 53 years old, PP, post implant
However, some patients expressed frustration in eliciting the level of information they desired from the
clinicians that they encountered. Clinicians suggested that they sometimes based their assumptions on
what patients wanted to know and their desire for involvement in the decision-making process, based on
their clinical judgement (as opposed to explicitly using strategies to elicit patients’ information needs and
desire to engage in decision-making). Furthermore, patients such as Ted (56 years old, PP, post implant,
ICD) also expressed a desire for information to be tailored to issues of key importance to their lives:
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Ted: ‘Well that’s an issue I don’t want to touch on’ that kind of thing, ‘Well actually it’s an issue that I
want to talk about’, you know, it might, ‘It’s affecting my life.’ So there needs to be more emphasis
on that, the support element.
Interviewer: So listening and empathy?
Ted: Listening and empathy, but it’s because what affects one person doesn’t affect somebody else.
Tailoring information to the specific issues of importance to individual patients was a challenge for
implanting cardiologists, who had often never met the patient prior to the consultation about
implantation. Consequently, owing to the lack of therapeutic alliance, the preferences and values of
patients were unknown to clinicians and, if not skilfully elicited, hindered tailoring of information to enable
patients to make an informed implantation decision.
Written information
In addition to information that can be given verbally, ICD information booklets are also available;
information booklets referenced by participants in this study included those developed by the British Heart
Foundation and Arrhythmia Alliance. Our study indicated that these could potentially be a useful tool for
patients when deciding whether or not to have an ICD. One of the key benefits of this written information
was that it is a resource that patients can refer back to following their consultation. It was suggested that
it may be useful for these information booklets to be supplied to patients who may be eligible for an ICD
in advance of their implanting centre consultation, which would afford patients the opportunity to
formulate potential questions that they may have about the device.
It might be sort of, ‘In the event that you have to have, at some later date – take this.’ Because – and
that was the first time – I sat down and read it, or lay down and read it, and you know, I come to
understand it all.
Patrick, 78 years old, SP, post implant, ICD
However, it was evident in both the clinician interviews and the clinician workshop that there were
concerns that providing patients with information about ICDs prior to their attendance at the implanting
centre may raise expectations of receiving a device among individuals who may later be found to be
ineligible by the implanting clinicians.
No I would want to make sure they were eligible before I went into any information about how it is
and . . . some people have actually said that it’s been mentioned in the past, I might give, I tend to
give the British Heart Foundation ICD leaflet. I’ve posted that to a lady this week who’s seen a
cardiologist and, in fact, it was the patient’s daughter who asked me, was asking me questions, so I
felt as though she was leading round to something, so, I was a little non-committal and she said, she’s
been told she might need a special pacemaker.
Nurse Mint, heart failure nurse
Furthermore, some practical issues were also identified regarding written information. The first relates
to the availability of the information. Disparities were evident in the extent to which the information
booklets were available across the different NHS trusts included in the study. Indeed, clinicians reported
experiencing issues maintaining an adequate supply of the booklets, particularly those that needed to be
paid for, such as those from the Arrhythmia Alliance.
Second, although patients, and their families, expressed a preference for information that comes from
trusted sources such as well-known charities, some clinicians expressed some reservations about the
information contained within these. As a result, some clinicians preferred to develop their own information,
as this afforded them the opportunity to alter and update the contents as they thought necessary.
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Some of the national information is wrong, you know? People writing things, and you look at it, and
you go, ‘That’s the wrong thing to say’, you can’t correct it . . . In the BHF [British Heart Foundation]
book, it tells defibrillator patients they get two kinds of shocks. Well an electric shock is an electric
shock. I wouldn’t describe it as two kind of shocks. So patients say ‘is that the big one or the little
one?’ and you go . . . it’s hard to say ‘well actually that nationally revered, you know, venerated
organisation, is not well written’, so each department tends to develop their own, rather than going
for a generic thing . . . If somebody misinterprets something, I can rewrite it much easier.
Ms Forsythia, physiologist
However, this preference for having local information at different NHS trusts, each of which develops its
own resources, further compounds the issue of providing standardised and reliable information to
all patients.
Patients also indicated that GP letters could be a potentially useful source of information. However, this
was the case only if the letters were written in non-technical and jargon-free language (plain English).
Patients expressed frustration upon receiving letters that they were unable to understand:
You see I don’t understand what I can, what these anterior segments is, I haven’t a clue. That’s what
the echocardiogram showed. An ejection fraction of, you know. If I had a criticism I would say, ‘please
use layman’s language’.
Emily, 84 years old, PP, pre implant
Presenting implantable cardioverter defibrillator therapy as a choice
As with the great majority of medical interventions, having an ICD implanted is a choice; patients always
have the option of not having the ICD. However, there was clearly variation in the extent to which
patients, and their families, perceived that they had a choice about the ICD, with many viewing the device
as a necessity:
I don’t think we ever thought that [there was a choice] because when it was presented to him about
the ICD it was a case of, ‘If you don’t have this done–’, well, in fact that was the words of one of the
consultants. I wasn’t there at the time, but Alan told me that she had said to him, ‘If you don’t have
this in you could die’.
Cathy, bereaved relative, SP, deactivated post mortem
This suggested that the option of not having an ICD is not always presented as a valid choice to patients
facing implantation.
Importance of time and checking on patient understanding
In both individual interviews and the workshop, clinicians expressed concerns about patients’ abilities to
retain the information given to them. Although they said that they endeavoured to provide the patient
with as much information as they needed, clinicians often believed that much of this was forgotten soon
after the consultation. However, having time to reflect was an important factor in patients’ decision-
making processes:
It took us 2 or 3 month you [know], ’cause I didn’t even read the leaflet. I just tossed it to one side
when I first got it . . . [partner’s name] read it first and she says, ‘You want to read this.’ ‘Aye, I’ll read
it tomorrow, aye, I’ll read it tomorrow.’ And I eventually did read it, you [know]. But I thought to
myself, ‘I’ll read it in my time.’ You [know]?
Alex, 53 years old, PP, pre implant
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For patients being offered an ICD for PP, being afforded time to consider the information, discuss with
appropriate others and return to clinicians with any additional questions was perceived as
extremely beneficial.
Dr Elm had prepped me, and I’d been able to talk to [name of GP] about it in advance, I didn’t,
incidentally, get on the web . . . So, I mean, I think where I am placed, and particularly having
cardiologist [secondary care] and the rehab nurses, and . . . I’ve talked a little bit about it to [first
name], the GP. I think I’ve had lots of chances to talk about it.
Bob, 67 years old, PP, post implant, ICD
However, SP patients, for clinical reasons (i.e. to minimise the risk of an early recurrent episode) were often
given little time to consider their decision. Nonetheless, as SP patients have also experienced the trauma of
a recent cardiac event, this may further limit their ability to process information given to them about
the ICD.
Perhaps there needs to be a checking of understanding. Perhaps that’s necessary. Because I’m sure I
probably seemed awake and alert and I very quickly realised that, you know, I, I was in hospital – You
know, I woke up and thought, you know, ‘I’m in hospital’ . . . But obviously what I now realise was
traumatic for my body obviously did have these effects that lasted longer than possibly it was obvious
that it had done.
Isobel, 67 years old, SP, post implant
These data suggest the need for checks to ensure that patients have retained the necessary information
about the device. Such checks of understanding would be useful throughout the pathway between the
initial implanting consultation and the decision, as well as beyond any implantation.
Fostering patients’ and their relatives’ expectations about
living with the device
There was variation in the extent to which patients were aware of the therapeutic purpose of the ICD or
the negative impacts of living with an ICD. One important aspect of this was the understanding that the
ICD is a risk modifier that offers potential survival benefits; however, a simple ICD does not confer any
symptom improvement to the recipient (some devices such as a CRT-D, a specialist form of pacemaker,
can offer symptom improvement). Erroneous expectations of symptom improvements and quality-of-life
benefits are likely to influence patients’ decision-making.
I try to make a very clear distinction between feeling better and living longer. And I try to make it
quite clear, if it’s a straight ICD, that this is not about feeling better, this is about prolonging life
expectancy, so that their anticipation is not that they will feel better as a result of that process.
Dr Thyme, non-implanting cardiologist
Such confusion about the likelihood of symptom improvement was often related to a conflation of ICDs
with other devices with which the patient was more familiar, such as pacemakers. As such, a major aspect
of the information giving process is to distinguish between these devices.
I don’t think they realise what that box is actually going to do for them. I think a lot of people think,
‘I’m getting a pacemaker’. That’s what they, because their friends have got one and sometimes I say,
‘But yours is a very special device, yours has got other properties’, and they’ll say, ‘oh have I got the
sort of, the deluxe model’.
Nurse Mint, heart failure nurse
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As pacemakers are more widely utilised in the treatment of heart failure and have been around for several
decades, many patients being offered an ICD possess some prior knowledge of these devices. Many
patients have heard of pacemakers and often know someone, such as a friend or family member, who has
received this type of device, whereas relatively few patients have prior knowledge of an ICD. Clinicians
have to ensure that patients understand the differences between these devices and that they are aware of
which device they are being offered.
We batter that [calling the ICD a pacemaker] out of them. Because there is a strong disincentive to call
it a pacemaker, because it causes so much confusion. So any time a defibrillator patient says they’ve
got a pacemaker in we say, you know ‘it’s like a pacemaker, but don’t use that word because it
causes confusion with everybody’.
Ms Forsythia, physiologist
In addition to the potential for unrealistic expectations about improvements to symptoms, if patients
erroneously believe that they are receiving a pacemaker, this may leave them potentially unprepared for
the defibrillating function of the device. Despite clinicians’ reported attempts to try and prevent patients
from confusing ICDs with pacemakers, it was evident that there were still some patients who possessed a
degree of confusion, several of whom referred to the ICD as a pacemaker throughout their interview:
She [cardiologist] said she had sent a letter to [implanting centre S01] for putting my name forward for
a pacemaker.
Jim, 80 years old, PP, pre implant
Furthermore, one bereaved relative expressed no knowledge of the fact that her husband had a
defibrillator, believing that he had only a pacemaker.
The key difference between ICDs and pacemakers is the ICD’s capacity to deliver a defibrillation.
Defibrillation is the main function by which the device mediates the patient’s risk of sudden cardiac death.
In addition to the inability of a simple ICD to offer symptom benefit, patients should be made aware prior
to implantation that the device has the potential for adverse impacts on quality of life. The experience of
defibrillation itself has the potential to be distressing to patients.
Your ICD will not improve your quality of life and we know that in some patients it makes their quality
of life worse, particularly those who are unhappy with inappropriate shocks or those who get very
obsessed with their heart function and their device.
Dr Rosemary, implanting cardiologist
Although the defibrillation, or shocking function, is the key mechanism by which the device may extend
a patient’s life, it is also this function that has the potential to be psychologically distressing. Indeed,
several patients were interviewed who had experienced psychological sequelae following the experience
of shocks.
Variations were apparent in the manner in which clinicians discussed the defibrillations; many employed
humorous comparisons:
Well, a lot, a lot of people tend to say it’s like a, being kicked in the chest by a camel, but, or, I mean I
don’t know how they know that’s what it feels like. But it’s, it’s, it’s a bit of a kinda, I think it’s a bit
of a lighter way to tell them, so that they know it’s going to cause a bit of discomfort, but kinda not,
not quite making light of it.
Mr Broom, physiologist
As with anthropomorphising the device, comparing the shocking function of the device to being kicked in the
chest by a horse or camel may be useful, as this is an image that might be easily recalled by some patients.
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Another common method employed by clinicians to illustrate the shocking function of the device was to
hit the desk very hard and suddenly. These methods appeared to be successful in instilling in patients the
appropriate expectations of the defibrillation. Discussion of the shocking function and how this may be
experienced appear to be an essential element of the information given to patients pre implantation.
Impact of the implantable cardioverter defibrillator on
physical appearance
Another important consideration in decision-making is the potential impact of the ICD on the appearance
of a patient’s body.
A patient I’ve already met but, mentioned but who is considering having an ICD fitted and she is very
body conscious. She’s a young woman and she did talk about, ‘well what will it look like? Well,
what’s that going to be like, having this thing that’s visible?’ . . . So that was certainly a concern
for her.
Dr Aspen, psychologist
However, our data suggest that this was not an isolated incident. For example, Dan felt self-conscious
about the physical appearance of the ICD:
I think one of the big subconscious things for me, in, for a personal point of view, is how protruding
it is, you know, when I, when I take me [sic] shirt off, you know, it’s quite evident that it’s there.
I thought in my mind’s eye at the time, that, where you know, that it would be a lot more you know,
less sightly to see. You know, it, they are a fairly big thing, if you like. I am, I am a fairly slight person
anyways and I think, for me, consciously, if I was away on holiday and was having to take me top off
anywhere, subconsciously that’d be on my mind.
Dan, 48 years old, PP, post implant, ICD
It was evident that not all participants in this study felt fully informed about the size of the device prior to
implantation. Some, such as Phil (68 years old, SP, post implant, ICD), discovered, following implantation,
that the device was much larger than they had expected:
Phil: They said it was about the size of a box of matches . . . They should of [sic] said, what was it,
Swan Vestas [Republic Technologies (UK) Ltd, High Wycombe, UK]!
Interviewer: A big box of matches? So it was bigger than you expected it to be?
Phil: And a damn site more painful.
Implantation scars, and the way in which the device can protrude, can leave some people feeling
self-conscious about their changed bodies, and others reported experiencing ongoing pain or discomfort:
Yeah, it hurts when I lie on me [sic] left side and I find that very strange. It’s as though, where’s it
[going] to [fall] out. And actually sometimes when you, you go over the scar it hurts, it’s very strange
. . . But when I lie on my left side and I’m like in a really comfortable position, oops, no it wakes me
up. It’s as though it’s squashing together. And it’s, you can see it. Now you know where they go in
. . . It’s a neat scar, but it’s got a lump . . . Well I was told, because, I’m not exactly Twiggy, you
wouldn’t see a thing which just shows that’s wrong.
Molly, 60 years old, PP, post implant, CRT-D
Those patients, and their families, who were able to see the ICD before the procedure reported that this
was useful. Furthermore, this was something that was reinforced at the ICD support group.
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And she, she did show the size and they did explain how they put them in. She did, she explained
everything . . . they even passed one around. ’Cause they passed the one, they passed a pacemaker
around as well to show you the difference. But do you know, they’re getting smaller all the time
’cause his is quite round and large, and it’s evident, you can see it. But I’ve seen some on the telly and
they’re not, they’re not very big.
Wife of Burt, 74 years old, SP, post implant, ICD
Being able to see and touch the device appeared to facilitate patients’ development of realistic
expectations regarding the impact of the device on their bodies.
Many people are involved in implantation decisions
At its core, SDM involves more than two actors. The findings of this study indicated that decision-making
around ICD implantation, consistent with other preference-sensitive decisions,45 often involves multiple
actors, including the patient and implanting clinician dyad but also family members, significant others and
other clinicians.
Clinicians
It was evident from the study data that clinicians have a key role in implantation decisions. Depending on
the patient pathway, there are various clinicians who may be involved, including heart failure nurses and
both non-implanting and implanting cardiologists. Implanting cardiologists have a key role in the process
of decision-making about ICDs. Implanting cardiologists were often viewed as the experts to whom the
decision should be deferred by many of the patients interviewed. This is perhaps not surprising when
patients are referred to specialist tertiary care services, and this is likely to imbue these ‘specialist’ clinicians
with more ‘status’ than others. Many patients felt that if the implanting cardiologist believed that they
needed the device, then they would accept and follow this advice:
I mean, if he says I’ve got to have one I will, I will have one. I mean I’m, wouldn’t say, ‘Oh no, no, I’m
not having one’ you know. If he thinks I should have it I’ll have it . . .
Doris, 73 years old, PP, pre implant, CRT-D
Although there were exceptions, the majority of patients expressed how they trusted and valued the
clinicians’ expert opinions, but this was balanced against what they themselves regarded to be important:
There comes a case where you’re dealing with professionals, it’s like any business if you’re dealing
with a professional, you’ve got to look at his advice, weigh it up, and in the main, you should go with
that professional’s advice. After you’ve done your various . . . your own checks and balances. Well you
must, otherwise you’re wasting your time. Why go to a financial adviser if you’re going to listen to
him and then ignore what he tells you?
Adrian, 76 years, PP, post implant
In addition to the implanting cardiologist, interviewees often suggested a role for other health-care
professionals, in particular those with whom they already had a relationship. Many patients were already
under the care of a heart failure nurse with whom they had a continuing relationship, in contrast to their
relationship with an implanting cardiologist.
Dr Oak had a big file there, but that’s all he knew of me. Where, I mean [heart function nurse]’s seen
me since I first came out of coronary care, and she knows the bits that frighten me and that sort
of thing.
Bob, 67 years old, PP, pre implant, ICD
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Patients valued the opinion of those clinicians who they felt knew them personally and welcomed the
opportunity to discuss their decision with these trusted others.
Data from both clinicians and patients indicated a potential role for psychologists in the decision-making
process. Under current practice, psychologists are not routinely involved in the pre-implantation assessment
of patients. Indeed, several clinicians (non-psychologists) indicated that they used their clinical judgement
to assess the risk of a psychological impact on patients of ICD implantation:
If I see someone where there is that potential, where I get a gut feeling that it’s a potential issue.
Somebody who has had a history of mental health issues in the past or someone who comes across as
being quite anxious and introverted, then I would often talk about . . . that I’ve had some patients
where this has had a real negative impact upon how they view life and they have become very
obsessed with their heart or with their device and it’s had a really negative impact in that way. I might
briefly mention something like that but I wouldn’t routinely talk about it.
Dr Rosemary, implanting cardiologist
Participants in the patient workshops indicated that they would have appreciated some specialist
psychological support at the time of implantation and stated that the psychological impact had been
greater than expected. This appeared to be particularly acute among SP patients who had experienced a
cardiac event prior to the implantation of the device:
A lot of patients, especially the secondary prevention are, you can see them, they are like rabbits in
headlights. It’s such a shock, they’ve had a cardiac arrest recently, they, all of a sudden they’ve got this
big lump of metal in their chest to keep them alive and it’s, it’s probably pretty daunting.
Mr Jasmine, physiologist
As such, it was suggested that early contact with psychologists may be beneficial during the decision-making
process and this could facilitate the development of a relationship that stretches beyond implantation.
I mean there are, there are quite a few that have psychological issues of this device that’s going to give
them a shock, to a point when, I think we had one patient in particular, who has had psychological
issues since, more or less, day one. It’s got worse and worse, to a point where it is now turned off
because he said if he didn’t get it turned off he’d pull it out his chest. So that’s how they can
affect people.
Mr Jasmine, physiologist
It was evident from the interviews with those who had experienced shocks that this had the potential to
leave a lasting psychological impact:
I thought me whole chest had exploded. I didn’t even think what it was when it happened, you know,
you just . . . I know why they don’t tell you, you know, they hadn’t prepared me for it but I don’t think
they should . . . No, because . . . I was on diazepam for ages after it ’cause you think it, if it happens
again it happens again. I didn’t know whether I was supposed to stand up or what I was supposed to
do ’cause they didn’t tell you, tell me what to do if I was shocked mind. That’s something I think, that
would be a good idea, ‘If in the event you do get a shock this is what you do.’
Florence, 67 years old, SP, post implant, ICD
The experience of a defibrillation was extremely unpleasant for the majority of patients and had the
potential to have a lasting psychological impact. Access to psychological support throughout the ICD
pathway may be helpful to reduce this impact.
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Family
Beyond clinicians, other important actors involved in the decision-making process included a patient’s
significant other and family members. Although variation was evident in the extent to which patients
chose to engage family members and significant others in the decision-making process, the majority of
patients chose to include at least their partners in the decision. Clinicians appeared to recognise the
importance of partners in the decision-making process and recognised that they would have their own
concerns about the device relating to what to do if the device discharged and their own safety, for
example. Some of the clinicians referred to the work they undertook to engage the partner as well as
the patient:
And again it often seems to be the partner that takes the bulk of the stress with them, the patient is
often come across anyway quite philosophical of what has done is what is designed to do, ‘I’m still
here and just get on with it’. It’s usually the partner looking completely frazzled by the whole thing
and terrified and really stressed about it all and you often spend a lot more time talking to the partner
than the actual patient.
Dr Sage, implanting cardiologist
Furthermore, it was also suggested that engaging partners and significant others in the implantation
discussions had an added benefit in that there would be an additional person to absorb and
retain information.
Patients
A potential role was also identified for other ICD patients. Speaking to someone who had been through
the same experience was clearly of value but, importantly, was seemingly different from speaking to
a clinician.
It all gets a bit abstract. It’s very difficult to put my finger on it. But it was, it was definitely there, a
certain, just a certain quality. I don’t know. And it’s not empathy, he [other patient] was empathic,
’cause we didn’t dwell on emotional, emotionally on things. It was him imparting his knowledge to
me actually. He was sharing it with me and it was a real feeling of sharing. If I had to bring it into a
couple of words, it was sharing and it was on a, it was meeting as equals. That, that really was what
was happening.
Gwen, 53 years old, PP, post implant, CRT-D
Several patients indicated that they felt it might be beneficial to speak to someone who was already living
with the device:
Anybody who’s living with one, even if you can just phone them up or, oh no, that would be difficult
’cause you can’t give out numbers. But there must be a way you can get to talk to somebody, or even
talk to people before you have it done saying, you know, ‘He hasn’t told us much what they do . . .’
Of course that might put people off so it’s maybe not, that’s not a good thing.
Molly, 60 years old, PP, post implant, CRT-D
Patients also recognised that talking to other patients would be valuable to support decision-making about
whether or not to accept an ICD, as it would present opportunities to gain a realistic view of life with the
device. Furthermore, there was a suggestion that contact with other patients and/or patient groups could
continue to have value throughout the patient pathway.
Many patients appreciated interactions with clinicians who elicited and took into account their own values
and beliefs. Patients’ own values were an essential component in the decision-making process about ICD
implantation. The decision-making process involves a weighing of the benefits of having the device against
the potential risks/adverse effects, the relative importance of which will depend on an individual patient’s
values. For example, some patients indicated that they initially thought that the costs of the device in terms
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of hospital visits outweighed the potential benefit of the device as an insurance against sudden
cardiac death:
I didn’t like the idea of the faff of repeatedly . . . ’cause he’d sort of mentioned that I had to come
back to, for battery recharges, for this and for, and for all the . . . And I felt like I was kind of OK
really. So as an insurance policy it didn’t really sell it to me, because it seemed like an awful lot of
effort for a chance thing.
Mark, 47 years old, PP, post implant, ICD
In the case of Mark, it was not until he perceived an increase in his risk of sudden cardiac death coupled
with a change in his personal circumstances following the birth of his first child that he was willing to
reconsider device implantation.
Patients living with heart failure are likely to be faced with increasing levels of disability affecting their
everyday lives; as such, the possibility of the device facilitating the patients’ involvement in these activities
could be an important decision-making factor. This was particularly evident among patients offered a
CRT-D, as these devices could potentially alleviate their symptoms:
Keeping up with my family who are young, walking along with my children who are in the late teens
and twenties, my peers, socialising, lots of things that, like, you know, preparing a meal. So I talked
about those mundane things with him and what they were like. And he, you know, he said, ‘Even
given all the risk that are there’, ’cause the risks are substantial, I suppose. That I really wanted an end
to these problems if that was possible. So it was how much I wanted it. It was almost as if, we know
that there, there are potential problems but it’s, kind of, is it worth it for what you might get out of
that? Even though there are no promises, because all the way he said, ‘There are no promises that it’ll
make any difference’.
Gwen, 53 years old, PP, post implant, CRT-D
In addition to the mundane activities of daily life, patients also expressed certain valued activities that they
were not prepared to give up. As such, decision-making about device implantation was balanced against
their ability to keep doing these activities.
I mean as long as I can keep playing bowls and what have you I’m quite happy, you know, so . . .
Doris, 73 years old, PP, pre implant, CRT-D
Some patients indicated that maintaining a high level of quality of life was more important to them than
the potential survival benefit offered by the ICD:
Because I know if I get started on some other procedures it’s going to affect my life. Now I don’t
know how much life I have got left in me. Let’s live it what I’ve got. And I’m OK. So if all of a sudden
you say I have to go into hospital and I’m gonna be, I can’t do this for 6 month and I can’t do this,
I am going to be sitting around a loppy dog that will drive me around the bend and that is wasting
my life. By the time I am fit enough to do the things, I might not be fit enough to do the things if you
follow my lead.
Ernie, 83 years old, ICD decliner
A specific factor that influenced patient decision-making was the driving restrictions imposed by the
presence of the ICD. According to guidance from the Driver and Vehicle Licensing Agency, in all cases of
ICD for sustained ventricular arrhythmia associated with incapacity, driving must stop for 6 months from
the date of implantation (and resumption of driving requires fulfilment of specific criteria), while ICD
implantation is a permanent bar to group 2 licensing (bus and lorry drivers); as such, it has a strong
influence on patient decision-making.48 For some patients, the prospect of not being able to drive
outweighed the potential benefits conferred by having the device. The impact of driving implications was
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particularly acute among those who lived in rural areas who were heavily dependent on their cars for their
independence. Clinicians recognised the importance of driving restrictions on decision-making. As such,
clinicians tried to manage the impact of this information by carefully timing where it was placed in the
consultation. There was the suggestion that discussing this restriction too early could have the potential to
cause patients to dismiss the idea of the device:
I’ve tried to wait to tell them about driving at the very end of any discussion. That’s where I’ll say ‘No,
driving’, not in the initial discussion . . . ’Cause if you tell them they can’t drive for another year,
6 months, day 1, first thing, that’s it, they don’t listen to anything else.
Mr Jasmine, physiologist
For many patients, the ability to drive is a quality-of-life issue. Retaining quality of life and the ability to
engage in these valued activities may outweigh the potential benefits that the ICD confers in terms
of survival.
A final consideration in decision-making was patients’ perceived ability to live with the shocking function
of the device. Clinicians suggested that a perceived inability to live with the uncertainty of when the device
might fire was one of the most common reasons why patients chose not to have the device implanted:
It’s about whether or not they would want to live with something that could give them a shock,
perhaps it’s the way I explain it I guess. But it, there are a few people of an anxious disposition who
go away and who chose not to have it.
Dr Oak, implanting cardiologist
Information provision about defibrillations at the pre-implantation stage may facilitate the development of
strategies to cope more effectively with anxiety issues that may arise once the device has been implanted.
It is also important to note that the defibrillating function of the ICDs also has the potential to alter the
patient’s mode of death. While the ICD is activated, patients are unlikely to experience a quick and
unexpected death. Some patients may have preferences for how they wish to die, which may influence
their decision-making about ICD implantation:
Well one that springs to mind is the guy who wants to drop down dead out walking with his mates
and that . . . it was very clear . . . it wasn’t so much him declining it was him telling me what he
wanted and me saying what he wants is not compatible with this device, therefore, don’t have it.
Dr Rosemary, implanting cardiologist
The shocking function of the ICD and its potential to alter the mode of death may actually be incompatible
if a patient has specific preferences regarding death. However, a patient’s values about his or her mode of
death, or about the perceived benefit of the ICD, may not be stable over time. As the patient ages, the
survival benefit offered by the ICD may be viewed less positively, and the potential for a quick and
relatively painless death may be viewed more positively. As such, the impact of the device on a patient’s
mode of death is something that should be considered and returned to regularly while the patient is living
with the device; as the patient’s condition changes, so too may their opinion of the device.
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Chapter 6 Findings: deactivation issues
In this chapter we outline some of the key features concerning decision-making about ICD deactivation,including how and when conversations about deactivation occur, as well as their content and the
barriers and facilitators to these types of conversations taking place. This chapter begins by outlining some
of the issues concerning the deactivation discussions; in particular, this focuses on the timing of these
discussions and who is, and who should be, involved. This includes an outline of what clinicians, patients
and their relatives said about current practice regarding these discussions. We examine participants’
suggestions for how discussions about deactivation could be improved. It is important to note that we
were able to interview only two people (Fred and Nancy) who had chosen to have their ICD deactivated.
Both people were in receipt of palliative care, and Nancy had been experiencing unpleasant shocks prior to
deactivation. We also interviewed seven bereaved relatives about their experiences, but some of these
people had not been aware that their relatives had had an ICD (see Fostering expectations about living
with the device in patients and their relatives). Nonetheless, the wider group of patients, their families and
clinicians had important views on this issue.
Implantable cardioverter defibrillators are devices intended to prevent the occurrence of sudden cardiac
death as the result of an arrhythmia. Once the patient has been fitted with the device the battery lasts, on
average, 5 years before it requires replacing. Over the time of living with the device, it is possible that the
patient’s condition may change; they may experience deterioration in their heart failure or they may
develop another life-limiting condition, such as cancer. As a result, it may no longer be appropriate for the
device to remain activated. If the device remains activated during the last months, weeks or days before
death, the patient is at risk of experiencing unpleasant and potentially distressing shocks, and the device
could be considered to be potentially prolonging the suffering of these individuals, taking away the
possibility of a relatively quick and painless death.
Timing of deactivation discussions
Our data provide evidence of different views of clinicians and patients/family members about whether or not
patients should be informed about the deactivation of ICDs prior to implantation. There appear to be several
potential opportunities across the patient pathway when these discussions could be held and these are
discussed in relation to their respective benefits.
Both patients and clinicians were asked about their opinions of when was the best, or an appropriate, time
to discuss deactivation. In particular, we elicited views about the appropriateness of advance discussions
where the issue of deactivation is introduced pre implantation. It was apparent from our data that there was
a lack of consensus between patients and clinicians, and among clinicians, regarding the appropriateness of
advance deactivation conversations. One argument for the inclusion of deactivation in pre-implantation
discussions was the suggestion that this information could influence how the patient feels about the device
and may therefore be an important factor to inform their decision-making about implantation.
It’s a tricky one. But I think that would be the ideal place [for deactivation discussions], would be
before [implantation]. ‘Cause once you’ve got it, if you then decide that, ‘Well I don’t really want that
because of X, Y and Z’ . . . then it seems to have ‘Had I known . . .’ decision. I think if it’s going to be
talked about it should be talked about beforehand, definitely.
Mr Jasmine, physiologist
Indeed, patient interviews suggested that some patients, such as Fred (70 years old, SP, deactivated ICD
patient), regretted the decision to have the device implanted when they were faced with deactivation:
Fred: I think if there was more discussion about them and about the whys and the wherefores.
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Interviewer: So back at the time, before you have it implanted, kind of, more look to the future and
what might happen?
Fred: Definitely . . . I think at the time when I had the heart attack, and before the ICD, if I’d have
known what was coming, I wouldn’t have had it . . . I definitely wouldn’t have had it, no.
Interviewer: And is that because of the personal impact on you or is that, for you, or are you back
thinking about the costs again there?
Fred: I think it would be both. I think I am practical – if nothing’s going to help, nothing’s going to
help, and that’s what it is about. And what’s the point in clutching at straws?
Fred’s misgivings about the device took into account both personal and broader health service (economic)
factors. Overall, he felt that the decision to have an ICD was a mistake. Furthermore, Fred’s account
indicates that his view is not specific to the ICD, but rather reflects his feelings about medical interventions
more broadly; he had also decided to discontinue enzyme replacement therapy, as he no longer perceived
any benefit from it. Fred’s account indicates that he might have benefited from greater discussion of the
future and the potential outcomes of the ICD at the time of implantation, as these factors were important
in his decision-making.
A number of clinicians, in particular palliative care physicians, drew comparisons between heart failure and
oncology services, and the manner in which medical interventions are presented:
It’s not exactly a parallel situation, but it’s not dissimilar to chemotherapy. I don’t give chemotherapy,
but obviously I work closely with oncologists who do and many of those I’ve seen having the
discussions and many of the discussions I’ve heard about subsequently have explained that, ‘This
treatment may have beneficial effects but we’d need to review the effectiveness with repeat scans
after a certain interval, and there may be a time when it’s no longer appropriate.’ I think anything that
you do to somebody needs an exit strategy as well as an entry strategy.
Dr Basil, palliative care clinician
Dr Basil highlights how chemotherapy is not presented as something that will be used indefinitely for the
remainder of the patient’s life, but rather as something that will be routinely reviewed for its appropriateness
and clinical effectiveness. He indicates that such an approach would be appropriate for ICD patients, as it
would highlight that there may come a point when the device is no longer appropriate, enabling patients to
develop realistic expectations regarding the long-term outcomes of the device.
Furthermore, advance discussions about deactivation can provide patients, and their families, with an
awareness that deactivation is a possibility in the future.
And that sounds like, you know, not putting the patient first, but if you can have an easier
conversation [about deactivation] with the patient then the patient will feel more comfortable having
that conversation. And so it’s not just to make it easier to have the conversation for us, it’s to make it
easier for the patient to have the conversation as well, and all the family. And it’s just a simple
sentence, ‘Your device will be switched off at some point, you can’t live forever’, you know.
Nurse Cypress, heart failure nurse specialist
Several clinicians spoke of advance discussions in terms of ‘sowing a seed’ by introducing the potential
need for deactivation early so that it can be built upon in subsequent consultations. As Nurse Cypress
suggests, the advance discussions do not need to be in-depth, unless specifically desired by the patient,
but rather should present an opportunity to start to set expectations and understandings about the future.
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As such, when the time comes that deactivation is a consideration, this will be a concept with which the
patient, and their families, are familiar.
Indeed, some clinicians recounted experiences where advance discussions had successfully facilitated the
end-of-life pathway:
I think the family certainly were aware that the ICD needed to be deactivated at some point. So, I
think the cardiologist had had a conversation previously, not to say, ‘We need to deactivate it now’,
but to say ‘there will be some point that we need to deactivate this’ because the gentleman has been
becoming more frail over the preceding months. So it wasn’t a complete shock for the family and they
recognised that that was what was happening, that the patient was dying and they wanted their dad
to be as comfortable as possible.
Dr Buckthorn, palliative care consultant
The findings suggest that early advance discussions about deactivation can be useful and may facilitate a
realisation in patients and family members that a patient is approaching the end of his or her life. Advance
conversations about deactivation and other end-of-life issues allow for planning, whereby the patient may
be moved away from an active treatment plan to a more palliative approach. Clinicians indicated that, in
their experiences, difficulties in the deactivation process occurred when there had been a failure to engage
with the patient about future possibilities and appropriate planning had not taken place. Failure to plan for
the end of life often resulted in deactivation decisions occurring in the last days or hours of the patient’s
life, or not at all, and deactivation decisions being made quickly.
[If] they’ve got some other problem like cancer and are reaching the end of their life, and we have to
make decisions quite quickly, unless it’s been thought through already, about their ICD.
Dr Mulberry, palliative care consultant
It seems that there is often a failure to recognise when a patient is approaching the end of life. In these
instances, where deactivation often occurs out of necessity because the patient is close to death, the
patient often cannot be engaged in the decision, and there were even some instances recounted of
occasions on which deactivation did not take place until post mortem.
In spite of participants acknowledging the benefits of advance discussions about deactivation, our data
suggest a lack of agreement regarding the timing of these conversations. For example, there appeared to be
variation in the extent to which clinicians chose to engage in these discussions at the time of implantation;
some gave only cursory attention to these issues:
Well again, not in any great detail perhaps sadly. But so it’s often a throwaway line along the lines of,
‘If it’s, if it’s shocking you when it shouldn’t or you’re dying of something else then the, there is the
option to switch it off.’ And I’ll be honest, not everyone has that discussion.
Dr Oak, implanting cardiologist
Others indicate that the issue of deactivation was not part of their routine implantation discussion at all:
Generally I don’t because of the . . . at that point in time they’re not really . . . it doesn’t seem quite
the right time to have that conversation. I mean, it’s certainly something I would think about. But I
can’t think that I’ve ever had a ‘we’re going to put this in and think about deactivating’ conversation.
I mean it might be something that perhaps we should think about. Certainly, I don’t as a matter of
routine and I can’t think . . . I’ve ever had a conversation, ‘well, we’re going to put this in but we
could turn it off at some point if you want’ conversation. . . . it’s slightly counterintuitive to think about
end-of-life care at the time you are implanting the device.
Dr Rosemary, implanting cardiologist
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Furthermore, it was apparent that some clinicians were opposed to the idea of including deactivation in
the pre-implantation discussions, believing that too much focus on this idea at the time of implantation
could be potentially harmful:
Yeah. The biggest decision is, is death. That’s the biggest decision, and we [physiologists] have to
disagree with everybody else, that death cannot be mentioned when you’re putting a defibrillator in
too strongly. How could you? How could you say to a patient, ‘We’re going to give you this device
that’s going to save your life, but when you’re going to die, think about this conversation, now.’ It just
doesn’t work. I think you’d be, you’d be giving mixed messages. So we have in the waiting area,
our sole means of communication is, there is an Arrhythmia Alliance leaflet up that says, ‘Dying’.
Hopefully, that, that is enough for a family member, sitting waiting for dad or mum to come out.
They’ll look and go, ‘Oh I hadn’t thought of that.’
Ms Forsythia, physiologist
Ms Forsythia suggests that raising the issue of deactivation at the time of implantation has the potential
to cause confusion and distress, giving patients mixed messages. Rather than engage in potentially
uncomfortable conversations about death and the end of life, it seems that it is hoped that the literature
available in the waiting room might be read and help patients and/or their families come to the realisation
themselves that it is something that they may need to consider.
In addition to concerns about the appropriateness of including a discussion of deactivation at the time of
implantation, clinicians also expressed concerns about the ability of patients to retain this information if it
was given earlier in the pathway:
It’s no different to other aspects of medicine where if you’re able to offer somebody a cure to a
problem, then that is the thing that they most need and most want, and whether they’re in that
position to be able to take on board any of those things and really embrace it, I’m not so sure about
. . . I think it would be a mistake to try and move everything upstream and say that when we put the
ICDs in we need to be having much more upfront discussions about end of life ’cos I just don’t think
it’s realistic for patients.
Dr Mulberry, palliative care consultant
However, an alternative approach was suggested, whereby deactivation forms part of an ongoing
conversation that is introduced early on, potentially at implantation, and is then followed up throughout
the patient pathway:
. . . [deactivation] should be acknowledged at the time of insertion, so that when they come for checks
that they’re not just coming for checks of how frequently it’s fired and how they’re doing. Discuss the
relative burdens and risks of having it and how they feel about continuing to have it.
Dr Buckthorn, palliative care consultant
Trigger points for discussions about deactivation
In addition to implantation, it was suggested that the issue of deactivation should be returned to
throughout the patient pathway, to ensure that patients are informed and involved in these decisions.
One suggested means of insuring that deactivation conversations take place in a timely manner was to
identify trigger points for the discussions and to build these into the care of ICD patients.
It would be good to make sure that there was a trigger there to just be saying ‘Has this patient
changed significantly? Is the ICD still appropriate? Should we be initiating a discussion about it?’
would be useful.
Dr Mulberry, palliative care clinician
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I suppose it can be kind of key points in someone’s illness as well and whether things like hospital
admissions for whatever reason, something that’s a necessity to a change and care environment,
means that something has potentially changed, erm, and almost a kind of near-miss.
Dr Echinacea, palliative care clinician
These trigger points could occur at different stages throughout the patient pathway to ensure that these
conversations were conducted with all relevant individuals. These may include the development of another
life-limiting condition, a deterioration in the patient’s heart failure, recurrent hospital admissions or listing
on a palliative care register. The production of do not attempt resuscitation (DNAR) forms or advanced
directives were suggested to be the final trigger point by which to indicate that deactivation conversations
should have occurred. It seemed from the interviews that this was not current practice and a recognition
that the ICD needed to be deactivated often did not occur until very late in the end-of-life pathway, if
at all:
And unfortunately what does happen is that it takes the patient to be really on their death bed and
then they’ve got no, they’re not cognitive, well they’re not aware, they haven’t got the cognition that
things are going to be switched off and but that their, it’s the families that suffer the trauma as well,
you know.
Nurse Cypress, heart failure nurse
Failure to engage in deactivation conversations can cause distress for both the patient and their family if
the device needs to be deactivated when the patient is in the last moments of life.
Finally, a need for deactivation to be an ongoing consideration in the care of ICD patients was identified:
[It] isn’t a one-off it’s an ongoing dialogue and an ongoing process; and not something that you can –
I would imagine, it’s not something that you can do in a ten minute outpatient appointment.
Dr Echinacea, palliative care consultant
It was suggested that, rather than there being one time point for deactivation discussions, the decision-making
process should take place over time:
I think that the discussion is not a one off, it’s going to be part of a series of consultations, which
perhaps take place with their, their usual specialist at a more frequent interval than they would have
been used to having a review in the past.
Dr Basil, palliative care consultant
As Dr Basil indicates, the decision-making process may be an escalation of the reviews that the patient is
used to having. The ideal pathway would include an introduction to the idea of deactivation at the time of
implantation, which is revisited across the pathway, as and when necessary, and conversations may
become more frequent as the patient’s condition deteriorates.
Actors involved in deactivation decisions
A key theme that emerged from the data was the lack of clarity regarding whose responsibility it is to
instigate deactivation conversations and engage patients in the decision-making process. There are several
key groups of clinicians who may be appropriate to discuss the deactivation decision. These include
cardiologists, palliative care clinicians, physiologists, heart failure nurses and primary care clinicians.
The following sections explore participants’ accounts of each of these.
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Potential increased role for cardiologists in deactivation decisions?
Clinicians from other specialisms suggested that cardiologists may be best placed to make deactivation
decisions, but stated that deactivation created a conflict between withholding or withdrawing treatment in
the context of end of life:
The decision about switching off the ICD had come from the cardiologist – whereas, I think it would
be very difficult as a non-cardiologist to make the call; whereas when it was a cancer diagnosis then it
was – I suppose it was that decision about: Well, we wouldn’t be offering resuscitation to this person
but . . . it – again, I suppose it’s that withdrawing or withholding treatment while they’re deemed the
same; and I think particularly for ICDs it’s a very physical act that you have to do . . . than just – it feels
to be a slight difference . . .
Dr Echinacea, palliative care
Although implanting cardiologists are arguably the most knowledgeable about ICDs, they have limited
involvement in the care of patients following the ICD implantation; they are unlikely to have regular contact
with the patient, and, thus, they may not be best placed to take the lead on deactivation discussions.
I’m not sure how many of these patients are, or the patients that it’s relevant to switch the ICDs off –
I’m genuinely not sure how many of them are seeing cardiologists, a lot of the patients I end up
seeing are housebound really, so they’re not having regular contact with the [cardiologist], and that
causes a problem.
Dr Mulberry, palliative care consultant
As the above quotation suggests, this problem may be particularly difficult for patients who are being
managed in the community, who are unlikely to come into contact with cardiologists, particularly those at
the tertiary centre. As such, it is problematic to assume that these clinicians will take the lead on
deactivation discussions. This indicates a need for other clinicians to be involved in and to raise these
discussions, such as GPs and heart failure nurses.
Furthermore, some patients recounted difficulties expressing their preferences about deactivation to
cardiologists who were focused on active treatment:
My experience just with Dr Acacia at DGH N08, and what he actually said, ‘Well, you’ll basically drop
down dead as soon as I switch it off.’ It was so unkind. I wouldn’t dare say that to anyone . . . Like I
say, it was just my wife saying, ‘Oh, I’m not ready for that. I couldn’t watch that, Fred.’ So we left it.
And I think that’s what Dr Acacia was up to – ‘At least go home and talk about it.’ You know, I
wasn’t going to change my mind; I just didn’t want a heart transplant.
Fred, 70 years old, SP, deactivated ICD patient
Fred described how, having found out that his heart function had deteriorated significantly and that he
was nearing the end of life, he had decided that he wished to withdraw from medical interventions.
However, upon requesting this from the cardiologist at his local hospital, he reported being told that he
would die immediately. Although Fred was aware that this was untrue, it was extremely distressing to hear
and had a big impact on his wife. Fred indicated that he believed this to have been a manipulation on the
part of the clinician to try and force him to reconsider the possibility of having a heart transplant.
Heart failure nurses’ and physiologists’ roles in deactivation decisions
During the clinician interviews and workshops, significant emphasis was given to the role of heart failure
nurses and physiologists in deactivation conversations and decision-making, as they had regular contact
with the patients. In their interviews, some of the heart failure nurses demonstrated how they had opted
to take on responsibility themselves for engaging in these discussions, and which they worked into their
routine visits.
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And maybe not on that visit [first] but maybe a subsequent visit, I would draw the conversation round
to the fact that, you know, as everybody’s life draws to a close, this ICD device will try and activate,
and I have actually seen it activating on a dying patient before and it wasn’t pleasant, that one day the
decision will have to be made that this box will have to be deactivated, you know, in the most
sensitive way that I can, because when the heart naturally wants to stop and end of life is drawing
nigh that this box would try to deliver a shock, it would be unpleasant, unkind. Two words I also use
for the more mature patient is that, when we all get to that stage of life where it’s the dying stage of
life, I use the words: dignity; respect – older people really, really want, that is one of the main
requirements of when life’s limited and that somebody, either the spouse or the children, will have to
make the decision about switching the box off. I’ve found most people are quite accepting of that fact
and that there’s been no huge adverse, oh shock, and they think, ‘well, oh yes, if I’m going to die’,
and, as I said before, some people think, ‘well if I’ve got cancer then I don’t want my heart to keep
going on’, so they accept that it will have to be turned off at some stage and I always like to involve
the patient in this conversation and the decision-making, rather than leaving it to, potentially, an
elderly wife to make that decision. In my experience, as I say, most people accept this as part of the
whole package.
Nurse Mint, heart failure nurse
These data suggest that early engagement in deactivation discussions may facilitate the involvement of the
patient in the decision-making process, and that patients can respond well to this conversation about the
end of life, as they understand that this is a natural part of life.
As well as heart failure nurses, it is arguably physiologists who have the most regular contact with ICD
patients following implantation. Patients attend physiologist clinics yearly, if not 6-monthly, to check the
functioning of the device (the timing depends on whether or not the patient has a remote monitoring
system; those with remote monitoring are required to attend yearly check-ups, whereas those without
remote monitoring are required to attend 6-monthly check-ups). As such, these appointments were
suggested as potential opportunities to engage patients in discussions about deactivation:
I suppose as physiologists we see the patients on a regular basis to follow the device up. So I think
realistically we could do it. But we’re a bit kinda focused, because we do the follow up clinics, but
then we don’t know, we don’t tend to learn much more about the patients from a medical point of
view. So like we don’t see other concerns like where a GP would see more, more of the general kinda
medical concerns and that. We just tend to see the patients and check the device and kind of say
‘It’s fine.’ So although I think we are in a good position some ways, I think maybe there are other
professionals out there who are in, in a position to do it as well.
Mr Broom, physiologist
This quotation alludes to some of the potential challenges to physiologists taking on this responsibility.
First, physiologists are primarily trained to deal with the technical side of the ICD, such as checking if the
device has fired and tweaking programming; they may have received limited training in communication
skills. In particular, they are unlikely to have received training in how to manage difficult and potentially
distressing conversations such as deactivation. A second issue is that of time. Like all clinicians,
physiologists are confined by time constraints, and it would be potentially problematic and unrealistic to
expect them to engage with deactivation decision-making in the timeframe currently available to them
for consultations.
Palliative care role in deactivation decisions
The findings of this study also indicate the need for a greater involvement from palliative care services for
cardiac patients. Palliative care services were recognised as having an important role in patient care as
patients approach the end of life. However, it was also noted that significant work would be required in
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order to build a relationship between cardiology and palliative care services, where a link does not
traditionally exist:
I think that’s been proven in different studies or different area where there are good heart failure and
palliative care, where there’s joint working there’s been huge investment of time. Clinicians are keen
to invest that time. So I can’t say directly but I think it’s to do with that historical link and actually we
don’t see a huge number of people here in the hospice here referred with end-stage heart failure.
That may change and I hope it does, but I think it will take some investment of time in the hospice.
Dr Buckthorn, palliative care consultant
Dr Buckthorn indicates that one of the potential barriers to a relationship between palliative care and heart
failure services is a historical link with oncology services. Indeed, it became evident through the interviews
and workshops that there were differences in the provision between the different sites involved in the
study. Whereas some NHS trusts had invested time and effort in establishing a relationship between
palliative care and heart failure services, others had not; as such, the level of involvement patients had
from palliative care was dependent upon their location.
Where palliative care services were involved in the care of ICD patients only at a late stage, the impact they
could have was limited. Some bereaved relatives, such as Shirley and Lynn (the wife and daughter of an
ICD patient deactivated pre mortem), indicated that they received little support from palliative care
services, as there was a failure to recognise that the patient was nearing the end of life:
Shirley: Ours was a bad experience.
Lynn: And I think it’s because – in my view it’s because he wasn’t cast, as he left the hospital, as
palliative, but I don’t know how.
Lynn and Shirley’s account of their relative’s end-of-life experience indicated that it had been rushed and
stressful, for both the patient and his family. There had been limited involvement of palliative care and
little planning in advance; the patient’s ICD was deactivated eventually but only hours before his death.
They indicated that earlier involvement from palliative care services would have been beneficial; however,
they were not sure at what point in the pathway this would be.
Palliative care clinicians themselves expressed frustration at cardiologists who they felt often left
conversations and decision-making about deactivation to them rather than taking responsibility for leading
these discussions themselves:
Subsequently I spoke to the, I couldn’t get hold of the consultant himself, but to the registrar who’d
also seen the patient in clinic and I said, ‘What was the plan regarding the defibrillator?’, ‘Oh, Doctor
so and so’s going to discuss that with him the next time he comes to clinic.’ And that struck me, it
struck me then that it was quite a reticence to discuss deactivation of the devices, even when the
specialist who’d arranged for it to go in had referred to another specialist for the patient to discuss
end-of-life care . . . I thought that was a bit of surrendering of responsibilities to be honest.
Dr Basil, palliative care consultant
Dr Basil clearly viewed cardiologists as capable of engaging patients in deactivation discussion; however,
this was something that they were reticent to do, preferring instead to pass these responsibilities on to
other specialties.
Rather than being the responsibility of a specific group of clinicians, some participants suggested that it
was more important that discussions and decision-making took place with someone with whom the
patient was familiar and comfortable. Who is involved in the decision-making process is likely to be
patient dependent and to vary according to the patient’s condition and where they are in the pathway.
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For instance, for patients who are being managed in the community, the responsibility would probably fall
to heart failure nurses and GPs. However, cardiologists may be more actively involved in patients being
managed in secondary and tertiary care.
It’s hard to say ’cos I think that for any given patient somebody’s going to be taking the lead and it’s
not always clear-cut by role who that should be, so it may either be the GP, it’s conceivably a heart
failure nurse, it’s conceivably a MacMillan nurse or our palliative care service, and I think that’s
probably right but there will be some situations where cardiologists are leading that, although as
people deteriorate and they become housebound, that becomes a bit greyer, but I think what all of
those other people need is to be able to access the cardiologists who’ve discussed if they’re thinking
of switching it off.
Dr Mulberry, palliative care clinician
The patient and the importance of their family in deactivation decisions
Clinicians recognised the importance of engaging patients in discussions about deactivation and
establishing the patient’s wishes in terms of continued therapy:
Patients who do have terminal illnesses, we talk them through the consequences of turning it off too
early, versus turning it off too late . . . So, a patient who has cancer, I suppose, is the biggest one. You
say, ‘Well, what’s your quality of life, now? Do you still want to be rescued?’ ‘Yes, I do definitely. I’ve
still got things to do.’ ‘When do you think that things are going to change?’ ‘Well, I don’t know.’ ‘So,
you let us know when you think things are changing.’ We don’t want shocks delivered to patients in
their last 24/48 hours of their life. I think we’re all in agreement with that.
Ms Forsythia, psychologist
It is important that patients, and families, are engaged in discussions and decision-making about
deactivation. However, several of the interviews with bereaved relatives suggested that it had fallen to
them to raise the issue of the ICD when their loved one was at the end of life:
So, we were given the opportunity of what to do, but, whatever we did he wouldn’t recover.
So, we chose to withdraw the breathing machine and the tubes and everything and just keep him
comfortable really. The consultant was walking out and I said, ‘What happens with the’ because we
said not to resuscitate him, a DNR [do not resuscitate], and they wrote that on the notes. I said,
‘What happens to this implant that he has, the device? Oh, they didn’t know, did they?’.
Ivy, bereaved relative, ICD patient deactivated pre mortem
These individuals expressed concerns that this responsibility should not fall to patients, as they may lack
the capacity to raise the issue of the ICD in these situations:
I’m thinking about my father-in-law who’s got early onset Alzheimer’s. He probably would forget that
he had a device, so it wouldn’t cross his mind to mention it. Neighbours of ours both have dementia.
If it happened to one of them . . . you’re reliant upon medical staff who are completing the operations
to read the notes and understand. If the patient doesn’t understand or if the patient forgets.
Katy, bereaved relative of ICD patient deactivated pre mortem
In Katy’s experience of her father’s death and ICD deactivation, clinicians had not recognised that he had
an ICD that needed to be deactivated. Katy’s father had what was referred to as an unrecoverable stroke,
and the decision to turn off life-support had been made by the family. However, the implications of this
for the ICD had not been identified by the clinicians, and it had been the family who raised the issue of
what should happen to the device. This had caused them some concerns about what would occur in the
case of other patients who may not have the capacity to raise the issue of the ICD and who may not have
close family or friends to do this on their behalf. Katy suggested that important information about a
patient, such as the presence of an ICD, could be recorded in such a way that it can be accessed by
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health-care professionals in an urgent situation. This could also potentially be used to draw attention to
the ICD, and the fact it needs to be deactivated, towards the end of life.
You would think, in this day and age, with all the communication facilities that we have, that you
could just provide a QR [quick response] code that somebody could scan to find out what medication
you’re on, what devices you have, what illnesses you have. Things that you need to know before
operations.
Katy, bereaved relative, ICD patient deactivated pre mortem
Other relatives interviewed, such as Shirley and Lynn (the bereaved wife and daughter of ICD patient
deactivated pre mortem), felt that their decision to have the device deactivated was over-ridden
by clinicians:
Lynn: He wasn’t really progressing and it was obvious that he was really end of life. So we decided all
we wanted to do was to bring him home. And then Nurse Cypress who’s the heart failure nurse at the
DGH S02 and came out to see him and we talked – he was compos mentis, we talked about – he
knew he was dying.
Shirley: And he wasn’t frightened to die.
Lynn: He wasn’t frightened and he knew he was dying and he planned everything, and we talked
about deactivating the device. Nurse Cypress phoned up the consultant at the Implanting Centre 1
and she said his heart looked alright and she didn’t feel it was time to deactivate it.
Shirley and Lynn recounted how after coming to a decision regarding deactivation with their relative’s
heart failure nurse, with whom they had an established relationship, this decision was over-ridden by
someone else, which made the end-of-life experience more distressing as the patient had to be
deactivated in the last hours of life.
Benefits of advance deactivation discussions for patients and
their families
During the interviews with patients, it was evident that advance discussions had the potential to position
the idea of deactivation as something positive:
Well there are the end-of-life considerations. I’ve read somewhere something . . . And I thought,
‘Oh yes . . . well I’m aware that, that this could happen. I think, yes, if, if I was seriously ill and near
the end of life I wouldn’t want the thing shocking me.
Isobel, 67 years old, SP, post implant
For Isobel, being informed about deactivation, and that this may at some point be an issue that she needs to
consider, was not a frightening or distressing concept; rather, she recognised that the shocking function of
the device would be inappropriate as she approached end of life and it was not something that she wished
to experience. As such, the potential to deactivate the device in advance of this was viewed positively.
Furthermore, awareness of deactivation and having advance conversations about deactivation afforded
some patients a sense of control over their situation.
I went and I looked and found out. It gave me a bit of feeling of, sort of, control. You haven’t really
got great control or any autonomy I suppose. But it gave me a sense of that, really. And it was as if I’d
left no stone unturned and my eyes are wide open about what I was going through.
Gwen, 53 years old, PP, post implant, CRT-D
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Throughout her interview it was obvious that Gwen desired to be fully informed about the CRT-D and the
potential outcomes of life with the device. At times she described frustration in her encounters with
clinicians, where she faced difficulties eliciting the level of information she desired. Gwen expressed how
having information about the CRT-D was important as she wished to process the potential outcomes in
advance. This could then be retained and returned to at such point in her future at which it needs to be
dealt with.
Furthermore, it was evident among some of the bereaved relatives whose partner had been deactivated
pre mortem that deactivation of the ICD was viewed positively and was seen as a natural part of the
end-of-life process:
You can’t fire, start a car when there’s no petrol in it, yeah? . . . Yeah, I’ve made this up . . . It’s no
good firing your starter motor, starting your car, when there’s no petrol in it. So it seems that this
thing [ICD] was superfluous.
Janet, bereaved relative of ICD patient, deactivated pre mortem
Janet’s husband had reached a level of deterioration at which she could recognise that he was coming
towards the end of life, or, to follow her analogy, ‘out of petrol’, and, as such, she no longer saw the ICD
as having a purpose. The device firing in the event of a dangerous heart rhythm would do little to change
his overall condition; at this point, the purpose of the device as a protection against sudden cardiac death
was futile.
Barriers to timely deactivation decision-making
Themes identified in the context of ICD deactivation included several salient barriers to timely discussions
with patients/relatives: reticence of secondary/tertiary care clinicians to discuss end-of-life care, and
mechanisms for appropriate identification of patients who would benefit from a discussion about
deactivation, as well as ethical issues.
Reticence of clinicians and patients to engage in end-of-life conversations
Reticence among clinicians to engage in conversations about end-of-life issues appeared to act as a barrier
to timely decision-making about deactivation. Indeed, palliative care clinicians suggested that the culture of
cardiology, which often focused on achieving a fix for problems, may be a barrier; discussing deactivation
may be seen as akin to admitting failure, that there is nothing more you can do for this patient:
With a 10% ejection fraction [a measurement for the amount of blood the left ventricle pumps out
with each contraction which is used in diagnosing and tracking heart failure] you just think, really?
What are we going to achieve with this? So in many ways it doesn’t surprise me that there’s a
reluctance to talk about that, as with a lot of medicine often that’s kind of seen as a failure of what
we’ve tried to achieve, whereas in palliative medicine we try to embrace it as a natural part of the life
death cycle. But I don’t know that’s the same view that all clinicians would hold.
Dr Echinacea, palliative care consultant
It was suggested in both interviews and the clinician workshop that training in delivering bad news and
engaging in difficult conversations would be extremely beneficial to many clinicians. This may be likely to
instil greater confidence in clinicians undertaking these conversations.
. . . there’s a great need still to help people with their general communication skills, and specifically
their communication skills around end-of-life planning discussions. Better skilled clinicians would have
more confidence to embark on these discussions and, you know, more, more readily accessible set of
tools to have the discussion in the first place, that’s a large part of it.
Dr Basil, palliative care consultant
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In addition, there was a sense from some of the clinicians, particularly cardiologists, that death and
end-of-life issues were not something that the majority of patients were comfortable discussing:
There’s a time when people want, want to talk about death and stuff like that. Most patients don’t,
they come to see you ’cause they want to get better. They don’t want to be told, ‘Well, you’re going
to die.’ So they don’t want to talk about it, so it’s hard to bring it up if they don’t want to talk about
it. And so there is an appropriate time to bring these things up, but not, you know, these are patients
who, you know, you only put defibrillators in if you think their prognosis is reasonable, isn’t that right?
So I think, at that stage, I don’t think it’s, they don’t want to hear that.
Dr Elm, non-implanting cardiologist
Dr Elm indicated that he perceives a conflict in discussing issues pertaining to death when patients are
seeing him in order to be better. However, the extent to which this opinion was based on direct
interaction with patients who had expressed their desire not to engage in these conversations or was just
an assumption that he held about the type of information patients wished to receive in a clinical
interaction was not clear.
Indeed, our data suggest that patients and their families preferred to be informed about end-of-life issues
in advance. Furthermore, some interviewees actually recounted how they had tried to initiate discussions
about the end of life with health-care professionals but that these had been dismissed. In Gwen’s account
below, she indicates that her attempt to elicit information about the impact of the ICD on end-of-life
issues was dismissed by the health-care professionals. She suggests that this was because they did not
view her as being in a category of patients who require a conversation about the end of life because this
was an event that was still some way in the future for her:
I asked a nurse about end-of-life matters and she was quite ready to dismiss it and not talk about it
with me. So she didn’t, so I never had a chat with anybody about it. I’ve just read about it. But it was
important to me, so I went and looked it up myself . . . I thought, ‘This is what it must be like for the
nurses . . .’ This is somebody coming to get one implanted, and she’s 50, OK. She’s not in that box
[near end of life]. She’s not one of those. So it’s not time. But actually it’s very important for me to
think about that, right at the end, because I think about things in detail and what that might mean.
And, for me, it’s important to visit it emotionally, think about it, and come to some sort of terms with
it, and then I can leave it. And when it arises later on I will refresh, ‘Yeah OK, I know about this and
this is something to consider.’ I have to, sort of, pick it all apart and look at that detail. I know not
everybody, I think most people mustn’t want to do that, because if most people wanted to do that, by
now, it would be, the nurse would’ve said, ‘Oh yeah, that’s what happens. And at the end of your life
we like to turn into part of your, if you’re a DNR [do not resuscitate] then we do this and so on and
we’ll need to tell your family and it’s part of the process.’ So I think, ‘oh well, I must be out of, a bit
out of the ordinary, either ’cause I’m younger’, although I wouldn’t have thought I’m the only young
person who’s got a device, by any means. I’m not even as young as some. But it must be something
that they, that certain nurses who are dealing with, maybe the palliative care or something like that,
might be the ones who talk about it more. But it was just left out.
Gwen, 53 years old, PP post implant, CRT-D
Gwen’s desire to engage in these conversations indicates that there is not a ‘one-size fits all’ approach
to discussing and dealing with end-of-life issues. Although a minority of patients may wish to delay
considering these issues until they are directly faced with them, most patients, like Gwen, wished to gather
information in advance that they can return to when the time comes, preferring to have an awareness of
what the future is likely to hold.
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Identification of patients who would benefit from a discussion
about deactivation
Another potential barrier to timely deactivation discussions was the difficulty in identifying patients who
needed to engage in these decisions. The reasons for this were two-fold. First, heart failure is relatively
unpredictable in its trajectory, meaning that many patients experience cycles of deterioration and
improvement, which makes it difficult to judge when the patient is approaching the end of life.
We have to recognise, of course, some people won’t want their devices to be turned off and, and
there is a big difference between people who are reaching the end of their lives from cancer, which is
more or less fairly predictable trajectory, not entirely, but rather more than less. Compared with
something like heart failure where you can suddenly become very unwell, but suddenly get quite a lot
better again, even though you may only be expected to live for another small number of months.
Dr Basil, palliative care
A second issue is the relatively limited knowledge about ICDs that exists outside the cardiology specialty,
so that identification of devices suitable for deactivation would not necessarily be a priority for many
clinicians. Indeed, some of the bereaved relatives’ accounts discussed earlier, such as those of Shirley and
Lynn and Ivy, indicate that the presence of the ICD was not identified by clinicians. There was a suggestion
that there may be the need to raise the profile of ICDs:
‘Cos I think, in everything that . . . people have got to remember . . . so I’m thinking about even people
who have come in to A&E [accident and emergency] who will have ICDs, there’s so much that has to
go on in terms of assessment and management, but that will probably be on the back burner but it’s
about just raising the profile of ICDs.
Dr Mulberry, palliative care
It was argued that raising the profile of ICDs would facilitate the earlier identification of patients for whom
deactivation may be a possibility. In particular in the acute and community settings this could facilitate the
identification of patients earlier in the end-of-life pathway. The workshop with clinicians indicated that
there would be particular difficulties in identifying historical ICD patients who may have been fitted with a
device for several years and were now possibly approaching the stage at which deactivation would be
appropriate. If these individuals were not being routinely followed up by cardiologists or heart failure
nurses, it would be unlikely that they would be engaged in much discussion about these issues. Clinician
participants indicated that in some hospitals measures were already in place to counter some of the issues
discussed above. Specifically, there were measures to try to educate non-specialist clinicians about ICDs.
However, barriers were also described in attempts to engage clinicians outside the specialty of cardiology
in education sessions about the devices:
I think the problem is sometimes with these sessions, like if you offer them out, people think that
’cause they’re cardiology related, it’s only for cardiology staff, kind of thing. But they don’t realise it’s
for anyone. But I think them kind of sessions work, so if you, and they have like a training manual in
the hospital, if you offered like a course, just like an hour’s course or something, where you are
explaining, just to talk, talk through with them, and if you had like a range of staff I think that would
really help.
Mr Broom, physiologist
Clinicians spoke of their frustration at having engaged a patient in the deactivation decision-making
process only for this not to be followed up by other clinicians:
I hate it when you have an initial discussion with a patient, but then nobody tells you until the last
minute, and you think, ‘Oh, it’s not what I wanted for this man. I wanted it to be better organised.’
Sometimes, we get it better than others, and that’s where we have lots of teams of people involved.
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The Macmillan nurses, and, well, everybody who was involved in that team process, goes, ‘I have had
a patient with a defibrillator in, I know who to ring’, and that’s how it works.
Ms Forsythia, physiologist
This failure to continue the decision-making process through the patient pathway meant that deactivation
was often rushed when it became apparent that the patient was in the last days or hours of life.
Ethical concerns: deactivation as analogous to assisted suicide
Another barrier to timely deactivation was concern about the ethical connotations of withdrawing
treatment. There was some suggestion that deactivation could be, and was, viewed by some of the
patients as akin to suicide:
[A] patient who’s a Roman Catholic priest actually still refuses to have it switched off even though he
should have ’cause he considers that similar to suicide basically . . . I’ve told him very clearly I think it’s
inappropriate, he’s not going to have it switched off, that’s fine. I don’t think we can switch it off
against his will. I don’t think? So we just have to leave it there and if it keeps on defibrillating so be it
. . . the worry about him is he’ll just be kept unnecessarily alive ’cause the poor guy is just at the end
of his life now.
Dr Ash, secondary care cardiologist
It was evident that some patients held erroneous beliefs that the ICD was keeping them alive and, as such,
were uncomfortable with the idea of deactivation, assuming that this would lead to immediate death.
I don’t want to be euthanised . . . Natural is all. And I think my life is sort of natural, if I might put it,
I don’t want to, euthanasia doesn’t come into my . . . if I die I die and I suppose there are some people
say ‘Well if it’s a painful death just turn it off’. No, not me.
Richard, 76 years old, PP, post implant
An interesting conflict is apparent in Richard’s account. He appears to believe that dying with the device in
place but activated would be a natural death and that deactivating the device would result in an unnatural
death. However, there is no acknowledgement of the unnaturalness of having a device such as an ICD
fitted to the body.
It was suggested that such concerns about deactivation may be related to a lack of understanding about
the limits of the device:
I think recognising that in that context they would die with an ICD whether or not there was a rhythm
which could be shocked.
Dr Buckthorn, palliative care clinician
Dr Buckthorn highlights the importance of understanding the limits of the effect of the ICD, the purpose
of which is to protect against dangerous heart rhythms; however, it is not infallible and cannot protect
against the development of other life-limiting conditions.
Furthermore, it was suggested that the view of deactivation as akin to suicide could be inadvertently
reinforced by the type of language used to refer to it:
Like I say the switching off I, is, it just sounds so final and, I don’t know, like you’ve got, like switching
off life-support, I suppose that’s the analogy that springs to mind.
Dr Echinacea, palliative care clinician
Indeed, clinicians indicated throughout the interviews that they modified the language they used in order
to increase the acceptability of deactivation conversations.
FINDINGS: DEACTIVATION ISSUES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
I always use examples with my patient, say, ‘If you were dying of cancer would you want something to
be firing in your chest when you’re breathing your last with your family around you?’ And that sort
of makes ’em think, ‘Yeah, well if that’s what it’s going to do’ that might make them more accepting
of why and, and when it’s to be switched off, you know.
Nurse Cypress, heart failure nurse specialist
A number of clinicians reported using a similar technique to create a hypothetical situation in which the
patient may have developed another life-limiting condition. The purpose of this was to establish in a
patient’s mind the potential of a possible turn of events whereby the functioning of the ICD may no longer
be appropriate. This would facilitate in the patient a positive view of deactivation as something that would
alleviate potential pain and suffering in the last days of life, rather than a negative thing.
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Chapter 7 Summary and conclusions
The combined analysis of our data provides detailed insights into clinicians’, patients’ and relatives’ viewsand experiences of decision-making about ICD implantation and deactivation (objective 1), including
how and when ICD risks, benefits and consequences are communicated to patients (objective 2). This
enabled the identification of patients’, family members’ and clinicians’ information and decision-support
needs in the context of SDM (objective 3), including a range of facilitators and barriers to patient
engagement in preference and values-based discussions about implantation, and timely decision-making
about implantation and deactivation (objective 4). During the inception of the research, an option grid and
video was published in the USA to support SDM about ICD therapy.43 Consequently, the final objective
was amended to focus on the provision of guidance to improve existing decision support and on
supporting the process of SDM with ICD patients and relatives.
Summary of implantation issues
During the pre-implantation period, patients reported variable levels of knowledge about the severity and/
or gravity of their condition and the associated risk of sudden cardiac death. In particular, patients being
considered for ICD therapy as a PP strategy were frequently unaware of the clinical rationale for ICD
therapy until their consultation with a tertiary (implanting centre) care specialist. This contributed to some
patients, and their relatives, experiencing negative reactions such as a sense of shock and disbelief. This
appeared to confound their capability to process adequately the information being conveyed to them
about the rationale for the ICD and to differentiate ICDs from CRT-Ds and pacemakers (the latter of which
was a core issue in relation to patient confusion and unrealistic expectations about the benefits of ICD
therapy). Interviews with clinicians affirmed these findings. They acknowledged that communicating the
rationale for ICD therapy, and the fact that the simple ICD does not confer any symptom or quality-of-life
benefit, was a challenging task. Patients often reported being unaware of the availability of choice,
including no active therapy (no ICD) as an option available to them.
Clinicians were observed to use, and reported the use of, metaphors to describe the function of an ICD
(e.g. anthropomorphising the device by describing it as a sentry on guard duty against cardiac events)
alongside the use of verbal descriptors and numerical risk information during consultations with patients.
The use of verbal descriptors (using elastic language such as low, medium and high risk) was influenced by
clinicians’ perceptions of their patients’ capability to comprehend probabilistic information.
Issues related to the need to understand the rationale for ICD therapy (i.e. as a risk modifier, as opposed to
a risk eliminator, for sudden cardiac death and not as a treatment to improve their symptoms) was also
evident from interviews with bereaved relatives of ICD patients.
The primary function of an ICD is to deliver a shock (defibrillation) that has the ‘benefit’ of preventing sudden
cardiac death. However, appropriate and, in particular, inappropriate defibrillations (shocks) can be extremely
distressing for patients and are likely to be a key contributing factor to the development of mental health
problems such as depression and anxiety. Clinicians used a range of metaphors to describe the experience of
defibrillation from an ICD, ranging from likening a shock to being ‘kicked in the chest by a camel’ to using
physical actions such as ‘hitting a desk with their fists’ to evoke a vivid image in patients’ minds.
Variability in the way in which clinicians related information about the outcomes of implantation on
appearance (owing to the protrusion of the implanted device in patients’ chests and post-surgical scars)
was also evident. Interviews with patients revealed that they were often not fully informed about these
important implications, including potential negative consequences in terms of perceived body image. There
was also evidence from patient interviews that information about the surgical procedure to implant an ICD
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in terms of the complexity and the use of local (as opposed to general) anaesthesia was not always
conveyed by clinicians prior to implantation, which was a source of considerable distress to some patients.
Patients, relatives and clinicians acknowledged the importance of providing ‘balanced’ information on the
risks and consequences of ICD therapy, including the provision of information on the surgical procedure
used to implant the device. However, concerns were raised about the detrimental impact of information
overload, and there was a need to identify and fulfil the information needs of individual patients/relatives, as
well as to gauge their desire for involvement in decision-making, which patients often felt was suboptimal.
Many patients reported experiencing frustration at clinicians’ failures to recognise/address their personal
information needs, which would help them to form personal preferences and values in relation to the
options available. In many cases, this went beyond the prevention of sudden cardiac death to considerations
about their values towards mode of death and the impact of ICDs on their capability to retain a driving
licence, which was key to quality of life for many. This was compounded by a lack of time and opportunities
for the development of a rapport with patients in consultations; indeed, on many occasions, the implanting
cardiologist had not previously had any contact with the patient prior to the implantation consultation.
Clinicians expressed variable access to, use of and perceived value of patient educational materials
produced by charities such as the British Heart Foundation and the Arrhythmia Alliance, which could
further compound the issues of patient understanding about the rationale for ICD therapy, including an
awareness of the associated benefits, risks and consequences of ICD implantation before, during and after
any implantation procedure.
This was further complicated by clinicians often reporting that patient retention of information was
suboptimal; a common remedial strategy suggested by clinicians was ‘information checks’ during
subsequent clinical contacts across the pathway.
Adequate time for patients and their relatives to reflect on information provided by clinicians and the
options available was considered an important prerequisite for engagement in effective SDM. Consistent
with other contexts, multiple actors were important influences on decision-making about ICD therapy,
including expert and trusted clinicians (in particular heart failure nurses with whom many patients in the
current study had developed a close and continuing relationship) and close family members.
Summary of deactivation issues
We identified evidence of differing views of clinicians and patients/family members about whether or not
patients should be informed about the deactivation of ICDs prior to implantation. However, our data
suggest that patients, and their families, preferred to be informed about end-of-life issues in advance. Such
discussions could be hypothetical in nature, offering an introduction to the idea that a patient’s condition
may deteriorate or that they might be diagnosed with an additional life-limiting condition, at which time
the shocking function of the device may no longer be considered appropriate and may diminish the quality
of life remaining.
These views were shared by some clinicians who described an initial discussion to ‘plant the seed’ regarding
deactivation and to address unrealistic expectations about ICD therapy, but other clinicians intimated that
deactivation was not a routine component of the pre-implantation discussions; this was driven by a clinical
belief that discussing end-of-life issues alongside a device to prevent cardiac death (which appeared to be
an illogical juxtaposition of information on implantation and deactivation) may lead to harm to patients, in
particular for patients offered ICD therapy as a SP strategy following a recent cardiac event.
Indeed, there was a lack of consensus among clinicians about when in the pathway a conversation about
deactivation should occur. Introducing the idea of deactivation prior to implantation appeared to be a
particularly contentious issue, with some clinicians expressing concerns about the distal nature of this
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‘advance decision’ that may or may not have to be implemented; however, others were concerned about
the potential for information and/or discussions about deactivation carrying a risk of communicating mixed
messages to patients.
However, we identified evidence of decisional regret associated with a lack of patient awareness about the
long-term consequences of ICD therapy related to deactivation; for example, one patient reported that if
he was aware of the issues around deactivation, then he would not have chosen to have an ICD. Clinicians
also described patients/relatives experiencing difficulties in the deactivation process owing to a failure to
engage with them about future possibilities that inhibited them from developing appropriate planning for
end-of-life care in the context of ICD deactivation.
Potential trigger points for deactivation discussions embedded within a formalised protocol were suggested
by clinicians to ensure that opportunities for appropriate and timely discussions about deactivation could
occur with patients and families, with an emphasis placed on the need for regular monitoring and review
over time in terms of the clinical effectiveness and appropriateness of continued ICD therapy, a process
described by one palliative care clinician as ‘an entry and exit strategy’ when discussing the option of ICD
therapy. Specific trigger points that could result in a deactivation discussion included diagnosis of an
additional life-limiting condition, deterioration in heart failure, frequent hospitalisations and placement on
a palliative care register, with the production of a DNAR order being a final trigger point. However,
clinicians suggested that there might be difficulties with, and challenges to, introducing a formalised
protocol with regard to identifying trigger points for historical cases in which patients had been living with
an ICD for a number of years and are unaware of deactivation issues. Nevertheless, opportunities to
identify historical cases could be facilitated via ‘trigger points’ such as appointments for battery
replacement, or, where patients are being cared for in the community, appointments with their GPs
(emphasising a potential role for primary care clinicians in deactivation discussions).
A lack of consensus on who is best placed to initiate discussions about deactivations at these trigger points
was apparent from interviews with a range of clinical specialists involved in the ICD patient pathway.
Assertions that cardiologists are best placed were based on their expertise with the device itself, but were
countered by arguments that other clinicians, such as primary care clinicians and heart failure nurses, are
more closely involved in an individual patient’s continuing care (and thus are more familiar with their
preferences and values). There were also calls for greater involvement from palliative care clinicians, but a
key barrier was a lack of perceived interprofessional collaboration in the care of cardiac patients in some of
the research sites. Palliative care clinicians themselves expressed frustration at cardiologists who they felt
often surrendered conversations about deactivation to them.
Consistent with implantation issues, patients and relatives valued having an expert and trusted clinician,
with whom they had developed a positive therapeutic alliance, to initiate a discussion about deactivation.
A role for heart failure nurses or physiologists in initiating deactivation conversations was highlighted by
patients, as they had the most established relationships and continued contact with them. However, nurses
are clinically trained, whereas physiologist training is focused on the technical elements of ICD function;
therefore, currently nurses may be better placed and more likely to have had appropriate training for
engaging patients/relatives in deactivation discussions than physiologists. For physiologists to take
responsibility for initiating discussions about deactivation, this would involve taking on additional duties
that, at present, are not recognised as part of the physiologist role.
The crucial role of patients’ preferences and values in making decisions about deactivation was
acknowledged, including the benefits of decisions about deactivation being made in advance, which
would provide patients with a sense of control over their situations. Interviews also emphasised that
decision-making does not occur outside consultations in a social vacuum; rather, the patient’s family is
often closely involved in deactivation discussions and decisions, frequently acting as a patient’s proxy
towards the end of life if no advance discussion had taken place.
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Summary of the barriers and facilitators to shared decision-making
in the context of implantable cardioverter defibrillator therapy
Arguably the most salient barriers to SDM were discordant clinician and patient/relative preferences and
views on information needs with regard to ICD therapy. These were strong contributing factors to:
(1) patients expressing variable levels of knowledge about the severity/gravity of their condition and
associated risk of sudden cardiac death, including details about the surgical implantation procedure for
ICDs, and, importantly, the clinical rationale for ICD therapy (i.e. as a risk modifier as opposed to a risk
eliminator for sudden cardiac death and not as a treatment to improve their symptoms); (2) clinicians’
variable disclosure and methods of conveying information about the benefits, risks and consequences of
ICD therapy; (3) patients lacking awareness of choice, in particular, the reasonable ‘preference-sensitive’
option of no active therapy (no ICD); (4) clinicians avoiding discussions about end-of-life issues, which, to
some extent, was driven by beliefs about the ‘illogical juxtaposition’ of presenting information about
implantation alongside deactivation (beliefs that patients would be harmed by discussing end-of-life issues
alongside discussing a device to prevent cardiac death); and (5) a lack of consensus among clinicians about
when in the pathway a conversation about deactivation should occur (and who should do this) with perceived
suboptimal interprofessional collaboration in the care of cardiac patients in some of the research sites.
Facilitators to SDM in the context of ICD therapy were close involvement of a patient’s relatives in the
decision-making process (in the context of deactivation, this facilitated acting as a patient’s proxy towards
the end of life); the existence of positive therapeutic alliances with expert and trusted clinicians (and the
role of heart failure nurses, GPs and, possibly, physiologists in the deactivation discussions); the provision
of sufficient time for patients and their relatives to reflect on information provided to them; clinicians using
strategies such as information checks across multiple consultations; raising deactivation as a possibility
(which also served to address unrealistic expectations about ICD therapy); and potential trigger points for
deactivation discussions being embedded within a formalised protocol for appropriate and timely
discussions about deactivation.
Interpretation of findings in relation to the literature on shared
decision-making
Several themes identified in the current study resonate with findings of previous research on SDM about
ICD therapy and the wider theoretical research on SDM.
The involvement of multiple actors in the decision-making process in the context of ICD therapy is
consistent with the concept of ‘distributed decision-making’, which describes decision-making as a
continuing event taking place over multiple encounters with a range of different people.49 This was driven
to a large extent by the complexity of the ICD pathway, the multiple clinicians involved, the close
involvement of relatives and the widening of this complexity when end-of-life issues emerge. As seen in
other preference-sensitive decision-making contexts, such as decision-making about thrombolysis in acute
stroke care,42 patients valued the views and support of expert and trusted clinicians (in this context, heart
failure nurses with whom many patients in the current study had developed a close and continuing
relationship) and close family members.
Sepucha and colleagues50–52 describe the concept of decision quality, whereby preference/value-concordant
decisions are made by patients who are knowledgeable about their condition, the options available to
them and their personal preferences and values associated with the options. Our findings suggest that
information exchange in SDM encounters should go beyond the presentation of options, with information
on the clinical rationale for ICD therapy, including the patient’s diagnosis, also playing an integral part in
engaging patients in SDM to enable them to understand their condition and probable prognosis. This is
particularly important given that simple ICD therapy does not have symptom or quality-of-life benefit and
the appropriateness of presenting a ‘do nothing’ option (i.e. no ICD therapy) as a valid choice.
SUMMARY AND CONCLUSIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
Our findings concur with previous research that reported that patients/relatives want to be actively involved
in decision-making about implantation and deactivation, and the majority want to be informed about
deactivation at the pre-implantation stage,53 which can have important benefits such as an improved sense
of control for patients, while preparing both patients and families for later end-of-life discussions. Patients
and relatives want to be offered a choice and sought balanced information about the available options
[pros and cons, in particular, the potential impact on psychological well-being and quality of life in the
short and long term (deactivation)], and involvement in decision-making. Patients/relatives who participated
in the group workshop unanimously agreed that patients would benefit from a clear overview of the
pathway and associated decision points (see Figure 2) to facilitate the process of SDM.
However, we identified a range of issues that may have inhibited good SDM and prevented patients from
making quality decisions about ICD therapy.
Consistent with previous research,15,16,24,54 several patients in our study held erroneous beliefs about the
benefit of ICD therapy and seemed unaware of the adverse effects of ICDs and the potential threats to quality
of life, such as the risk of psychological problems, driving restrictions and a negative impact on body image.
Clinicians’ values (beliefs/attitudes) and their patients’ preferences for information and involvement in
decision-making were often discordant with each other, in particular with respect to the timing of
deactivation discussions. We found evidence that clinicians relied on their clinical judgement to ‘diagnose’
their patients’ preferences for information about ICDs, including the method of conveying risk information
(e.g. Dr Oak described how he used elastic language in the first instance, followed by numerical
information if perceived to be ‘helpful’, to convey risk information to patients) and their desired level of
involvement in decision-making. However, research has consistently shown that clinicians are typically very
poor at accurately ‘diagnosing’ their patients’ preferences.55,56 In the SDM literature, this has become
known as the ‘silent misdiagnosis’, as clinicians are often unaware of their patients’ preferences or make
incorrect assumptions and are unaware of the consequences that this might have for patients.57
This silent misdiagnosis was evident in our findings and has important implications for SDM in the context
of ICD implantation and deactivation. Misdiagnosing patient/family member preferences can:
l Act as a salient barrier to engaging patients and relatives in SDM, which may result in patients
receiving treatment and care that they do not want, or would not choose if they were fully informed.
l Foster the development of unrealistic expectations of ICD therapy, in particular when risk information
(outcome probabilities) is presented using different methods that can have a differential impact on
perceptions of risk and decision-making in both clinicians and patients.58
l Lead to missed opportunities for optimising the costs of ICD treatment to the NHS by reducing any
unwarranted variation in their use across the UK,59 as previous research has shown that patients often
choose less conservative options when they are informed about the available options. In the context of
our study, we found evidence that patients being considered for ICD implantation were often unaware
of the option to ‘do nothing’.
We found evidence of another type of silent misdiagnosis in the context of ICD therapy, with regard to
clinicians’ perceptions of a patient’s future disposition in terms of the impact an ICD may have on their
psychological health and well-being. In the context of ICD therapy, this may provide an argument for the
wider involvement of psychologists as further sources of ‘expertise’, which patients could use to more
accurately identify their treatment preferences in order to inform their decision-making at the pre-implantation
stage. In addition, for ICD patients who experience anxiety and depression following implantation, greater
awareness and referral (self or clinician) to the NHS Improving Access to Psychological Therapies service may
be a further preference-sensitive option that could be presented to patients.
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We identified evidence of clinicians’ gatekeeping of information regarding ICD therapy. In addition to
unmet information needs regarding implantation and deactivation, the option of not having an ICD was
not always presented as a valid choice to patients. One possible reason for this is that clinicians may be
less inclined to offer no active therapy (no ICD) as an option to patients who have experienced a cardiac
event (SP). Furthermore, such patients themselves may be less inclined to consider having no intervention
as their experiences of a cardiac event may instil in them a more acute perception of the potential benefits
of ICDs. In PP, the balance of risks and benefits, the course of underlying disease and varying patient
values may mean that not having an ICD is a more valid option.
A further key barrier to the provision of information on risks and benefits at the pre-implantation stage
was the view held by some clinicians in our study that providing patients with information about ICDs prior
to attendance at the implanting centre may raise patient expectations of the device, when later they may
be deemed to be ineligible for an ICD by the implanting cardiologist.
Congruent with previous research,11,24 we identified a reticence among clinicians about raising the issue
of deactivation with patients and relatives (especially pre implantation), including a lack of consensus
on who should initiate discussions about deactivation and their timing across the pathway. In previous
research,6,13,14,53 many patients and relatives reported not being informed about deactivation until a patient
was nearing the end of life, when early discussion (pre implantation) would have been their preference.
In contrast, several clinicians in our study held the view that discussing deactivation at the pre-implantation
stage would cause unnecessary distress or send mixed messages about ICDs; however, this is also contrary
to research that reported that the great majority of patients did not believe that this would lead to
increased anxiety in patients or relatives.53 Inattention to deactivation in NICE guidelines2 and a regional
policy for the deactivation/reactivation of ICDs26 is likely to have been another factor influencing clinicians’
decisions to refrain from discussing deactivation of ICDs with patients and relatives.
Nevertheless, this withholding (intentionally or not) can have negative consequences, such as patients
experiencing decisional regret and poor satisfaction with care received. We found evidence of decisional
regret associated with a lack of patient awareness about the long-term consequences of ICD therapy
related to deactivation. As well as a salient barrier to patient engagement in SDM, it is also felt by some
authors that withholding information violates three principles that underpin international clinical research
ethical guidelines, namely, respect for persons or autonomy, beneficence or a favourable balance of risks
and potential benefits and justice or a fair distribution of the benefits and burdens of research.60
How can the silent misdiagnosis and gatekeeping of information be addressed to overcome these key
barriers to patient engagement in SDM? The literature can be dichotomised into ‘clinician pull’ and
‘patient push’ (or vice versa) interventions, including strategies targeting both sides of the consultation.
Patients’ preferences for involvement is influenced by demographics, experiences of illness and medical
care, their beliefs on involvement and the interactions and relationships they experience with health-care
professionals, which are likely to develop and change over time.61,62 Good SDM requires two kinds of
expertise, namely clinicians’ knowledge of efficacy and outcomes of treatment options and patients’
expertise on their values and preferences with regard to the available treatment options.63 This assumes
that patients possess both the willingness and capability to engage in SDM. Arguably, the latter is a
prerequisite of the former, with active involvement in SDM requiring patients and clinicians to have
acquired a complex range of knowledge, behaviours (skills) and confidence to enact those skills. This does
not preclude the value of decision aids, but, as Flynn64 asks, ‘can a decision aid be a useful adjunct to the
clinical process if patients lack awareness of the value of SDM; and perhaps crucially do not have the
experience, knowledge, skills and/or confidence to engage meaningfully in discussions with clinicians
about their healthcare?’.
Patient activation is a behavioural concept, which is important for active patient engagement and
participation in SDM about their treatment and care, and is defined as ‘an individual’s knowledge, skill,
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and confidence for managing their health and health care’.65 Low patient activation is an important barrier
to SDM and there is evidence that this can be ameliorated with behavioural interventions,66 which appear
to be more effective when they are tailored to support the individual’s level of activation (tailored
coaching) and focus on skills (e.g. question formulation) and confidence building,67 which have been
shown to be effective in increasing patient activation for up to 12 month post intervention.68
Clinician push interventions can take many forms to increase the willingness and capability for SDM
in order to actively support their patients to engage in SDM and, ideally, will be underpinned by an
evidence-based implementation strategy to embed SDM in clinical systems and patients pathways.69
A multicentre implementation project, MAking Good decisions In Collaboration (MAGIC) programme,70
underpinned by a theory-based model of SDM skills,69 was designed to explore how SDM can be
embedded in both primary and secondary care settings
More than 270 clinical and non-clinical staff (including NHS management and general practice staff)
participated in MAGIC. They were provided with the following active ingredients of the
MAGIC programme:
l skills development and engagement, for example introductory and advanced skills development
workshops for participating clinicians
l support with developing and implementing (or adapting existing) decision-support tools (brief patient
decision aids)
l facilitation and peer support, for example action learning forums that involved regular meetings with
MAGIC staff and clinical teams to share experiences and learning
l support to involve patients, which included activities such as convening patient forums and a patient
activation intervention designed to increase awareness of SDM and as a prompt to initiate SDM
discussions known as ‘Ask 3 Questions’ (What are my options? What are the possible benefits and
risks? How can we make a decision together that is right for me?).
An independent evaluation of MAGIC71 found evidence that the programme successfully improved
participants’ understanding and awareness of SDM and developed their skills and confidence to use
SDM in practice; supported clinical teams to test and develop SDM tools and approaches; made changes
to clinical practice; and provided opportunities to hear and understand the patient experience of SDM,
which (via role-play exercises) facilitated connections between the theory of SDM and its use in routine
practice. This challenged a key barrier to SDM: ‘we are doing this already’. The importance of training was
heavily emphasised, with a key learning point being the aphorism ‘attitudes and skills trump tools’.
The lack of formal incentives for clinicians to engage in SDM has been discussed in the literature; for
example, the existing incentive structure ‘Qualities and Outcomes Framework’72 can, in effect, disincentivise
engagement in SDM.71,73 However, there is a recent legal precedent from the UK Supreme Court in 2015,
whereby clinicians are now required to take ‘reasonable care to ensure that the patient is aware of any
material risks involved in any recommended treatment, and of any reasonable alternative or variant
treatments’.74 This precedent in UK law provides a strong incentive for clinicians to refrain from
information gatekeeping and may lead to improved SDM by increasing their willingness (and wider
infrastructure support) to engage in continuing professional development on SDM.
Implications for the development of decision-support tools
In addition to being an essential prerequisite for effective SDM, the provision of comprehensible and
balanced information on the clinical rationale for ICD implantation (and the associated surgical procedure)
and deactivation (and associated potential short- and long-term benefits and risks to daily quality of life)
is critically important for patients’ adaptation to the device to reduce the risk of emotional distress.75–79
Research has shown that 25% of ICD recipients experience depression or anxiety problems,80 with the
majority receiving no formal treatment for psychological problems.81 Only 3 out of 44 patients in our
study disclosed psychological problems attributable to device implantation, which is lower than previous
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research. This may be due to different methods of data collection, which influence the disclosure of mental
health problems (surveys vs. interviews), the timing of interviews and the different rates of comorbidities
(chronic heart failure, chronic obstructive pulmonary disease, cerebrovascular disease and renal failure)
which are reported to be important predictors of depression in ICD patients during the first 12 months
post implantation.82
Patients in our study demonstrated concerns about the impact of the ICD on the appearance of the body.
Previous research has suggested that the impact of the device on body image may be particularly acute for
women, owing to a cultural focus on their sexual attractiveness.83 Indeed, concerns about the impact of
the device on appearance have been suggested as the primary reason for women to opt for submammary
device placement.84 However, the findings of our study suggest that the impact of the ICD on body image
is a concern for both male and female patients. A study of ICD patients from Sweden and Denmark
found that approximately 60% of patients reported receiving information on potential detriments of the
device to psychosocial/sexual functioning.85 In our study, the impact of the device on psychosexual
functioning was not raised as an issue, which may reflect cultural differences regarding the discussion of
sexual topics between Sweden and Denmark and the UK. These findings suggest that it is important for
information on psychosocial issues to be considered for inclusion in consultations and in updates to
existing decision-support tools for use in the context of ICD therapy. Therefore, in addition to the moral
imperative for SDM, informing patients about the risk of psychosocial problems could potentially reduce
any negative impact on quality of life and reduce the risk of psychological morbidity; viewed this way,
SDM is also a therapeutic intervention.86
We identified a lack of standardised methods used to convey information about the nature of ICDs
(and other options) and their pros and cons, including tools to support the acquisition of probabilistic
information on the latter in both the short and long term. These issues are consistent with those reported
by clinicians when conveying information to patients and relatives on risks and benefits of treating acute
stroke with and without thrombolysis.87
Owing to the lack of robust decision-support tools until recently, it is not surprising that clinicians reported
variable techniques to communicate risk about ICD therapy, in particular the use of elastic language
(low, medium and high) and percentages that can cause difficulties for patients’ understanding and
interpretation.88,89 Using numerical methods of communicating probabilities, and, in particular, natural
frequencies with identical denominators and time horizons for outcome probabilities, can improve risk
perceptions90 (e.g. out of 100 patients like you with heart failure who are implanted with an ICD, 25 will
experience depression/anxiety to a level that warrants treatment over a 12-month period). Graphical
methods, such as pictographs, to present natural frequencies (and other numerical outcome probabilities)
also have a substantial evidence base (notwithstanding patients’ levels of health literacy) to demonstrate
that they can improve risk perception.91 Nonetheless, to account for individual patient preferences, multiple
methods of presenting probabilistic information are recommended.92–94
The impact of tools will also be enhanced when they are underpinned by an auditable structured
development and testing process (ideally, co-produced and co-designed in partnership with patients/
relatives and clinicians/researchers so that they reflect their perspectives, priorities and lived experiences)
and utilise evidence-based methods to convey probabilistic information (using the methods described
above) on outcome states deemed to be important by patients/relatives.94
Strengths and limitations
The strengths of our research approach are numerous. We provide a clear audit trail of the methods and
processes for generating the findings of our study (dependability). The first phase (observation) enabled
us to familiarise ourselves with the clinical setting and provided us with important insights about the
decision-making environment, the actors involved and the nature of ICD consultations, in order to optimise
our sampling and data collection strategies (interview guides). Combining data collected from multiple
perspectives – clinicians, patients and family members – alongside the use of peer debriefing
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(from members of the research team and steering group) and ‘sense checking’ of findings within
interactive workshops served to maximise the likelihood that our findings are an accurate conceptual
interpretation of participants’ views and experiences.
The findings of our study relating to how to broach discussions about the withdrawal of analogous
assistive devices during end-of-life care are also likely to be transferable to how to broach discussions with
patients about the withdrawal from, for example, renal dialysis.39
A limitation that may be inferred from our sampling strategy is the small number of interviews undertaken
with patients who were prospectively considering deactivation. However, from the outset of the project,
the study team was aware that this would be a difficult group to sample. Consequently, the views and
experiences of this group may be under-represented. The level of difficulty experienced with the
recruitment of bereaved relatives was greater than unexpected. As a result of these difficulties, we
expanded the inclusion criteria for this group from 4–6 months post bereavement to 4–18 months.
Although this approach was successful in increasing the number of bereaved relatives recruited into the
study, given the sometimes protracted period of time post bereavement, accurate recollection of the
deactivation event and associated issues may have been compromised to some extent.
As the focus of our study was on decision-making about ICDs in secondary and tertiary settings, this study
lacks data from the perspective of primary care clinicians such as GPs and practice or district nurses.
Suggested areas to consider in the future development of services
l The clinical rationale for offering ICD therapy would benefit from being clearly communicated to
patients and their relatives as early as possible in the patient pathway by skilled clinicians supported,
where available, by codesigned information and tools, including live demonstrations and the
manipulation of devices to support informed consent and SDM.
l Patients desire more information on the surgical procedure to implant ICDs to support informed
consent and SDM, which can facilitate the development of positive/protective preparatory coping
strategies to minimise any impact on psychological well-being (decisional regret) and perceived
body image.
l Increased access to, and a greater role for, psychological support from appropriately qualified mental
health professionals throughout the ICD pathway.
l Signposting to support groups for patients with lived experience of heart failure/ICD therapy and their
relatives, while acknowledging that these options are preference-sensitive and that patients would
benefit from being provided with sufficient information to make an informed values-based decision.
l There is a lack of consensus/ownership among clinicians about who should take responsibility for
discussing deactivation. To address this, the issue of deactivation could be introduced early in the
pathway and formalised within a standardised protocol with specific trigger points to enable more
detailed and timely discussions with patients and relatives about deactivation.
Recommendations for future research
We identified a number of important areas that are prerequisites for good SDM and for maximising the
likelihood of patients making ‘high-quality’ values-based decisions. The following would be fruitful avenues
for further research:
l Developing and evaluating the use of risk communication tools that convey balanced information on
the benefits, risks/adverse effects and short- and long-term consequences of ICD implantation and
deactivation (identified by our research as being important for patients), including training on SDM
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skills and risk communication techniques for clinicians involved in the treatment and care of
ICD patients.
l Developing and evaluating training for clinicians (SDM, risk communication and delivering bad news to
patients/engaging in difficult conversations, which should be viewed as a key skill as part of the SDM
process in this context).
l Developing theory-based patient activation interventions for patients and their relatives early on in
the pathway.
l Developing ICD-specific decision quality measures (implantation and deactivation).
l Developing appropriate interventions to prepare patients (in particular those in tertiary care) and family
members for SDM with cardiologists throughout the ICD pathway provided by clinicians with frequent
patient contact (e.g. heart failure nurses) who can act as centralised points of contact outside
tertiary consultations.
l Updating existing decision support for ICD implantation and deactivation decisions informed by our
findings (available options and associated risks, benefits and consequences) as part of national
decision-support material to reduce any unwarranted regional/national variation in ICD therapy and
other health-care domains. Such tools would benefit from being codesigned in partnership with
patients and clinicians in both primary and secondary care. A decision-support tool for ICD deactivation
would potentially benefit from being embedded within advance care planning processes to ensure
sharing of this information with all clinical staff across care settings (e.g. the Electronic Palliative Care
Co-ordination systems that are being rolled out nationally).
l Exploration of the role of primary care clinicians and information sharing between and within primary
and secondary care clinicians involved in the care of ICD patients, including palliative care.
l Developing a central role for heart failure nurses, physiologists and primary care clinicians in terms of
providing ongoing care/initiating deactivation issues.
l Fostering evidence-based strategies for interprofessional learning and collaboration between cardiology
and palliative care teams in the context of ICD therapy.
l Carrying out multicentre service evaluation studies of enhanced ICD pathway (training, tools and role
extensions described above).
All the decisions around ICD therapy in the current study were taken in particular points in time and are,
therefore, shaped by that context. Future research might consider the use of longitudinal interviews to
explore the trajectory of experiences.
Strategy to translate findings into continuous professional
development learning and training
Our approach to mobilisation of knowledge is multifaceted. First, a summary of the study findings will
be produced for the Arrhythmia Alliance and Cardiomyopathy UK for distribution to patients/relatives.
We shall also host a half-day dissemination event in 2016 in collaboration with the Arrhythmia Alliance
and Cardiomyopathy UK, at which patients, family members and clinicians can discuss the study
findings. Second, we shall present the findings at meetings of the Arrhythmia Alliance and other relevant
patient organisations, as well as work with our advisory group and the Northern England Cardiovascular
Network, to publicise the findings to clinicians and academics more broadly. Third, we shall present the
findings to practitioners and academics in the field at national and international symposia. To engage
with practitioners in the cardiology community, we shall present the findings at the Heart Rhythm
Congress, and to connect with other academic audiences we plan to present findings at the Palliative
Care Congress, the International Shared Decision Making Conference and the British Sociological
Association Medical Sociology Conference. We shall also publish the study findings in a peer-reviewed,
high-impact-factor, journal.
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We shall work with the Northern England Cardiovascular Network and specialist palliative care teams to
embed the patient voice into their operational policy for the deactivation of ICDs. We shall also cascade
learning from this study to NICE to inform national guidelines on ICDs.
We shall share our interview findings with a team led by Dr Dawn Stacey at the University of Ottawa to
inform the design and evaluation of a planned pilot RCT of an ICD decision-support tool.
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Appendix 1 Observation letter and opt-out form
Dear Sir/Madam,  
 
I am writing to inform you of a study taking place in the Cardiology Department.  
You do not have to take part in this study.   
 
A researcher from the Institute of Health and Society, Newcastle University is 
interested in the interaction between patients and clinical staff when discussing 
treatment options.  It may be that the researcher is present at your clinic appointment 
to observe the discussion that you have.  To carry out the research, the researcher 
would like to audio record the conversation.   
 
If you do not want your clinic appointment to be audio recorded, or if you would 
prefer that the researcher is not present during your appointment please tell a member 
of the clinical team when you arrive or complete the form below and return it to 
reception on arrival for your appointment.  If you decide not to take part, it will 
have no effect on the care that you receive. 
 
If you are happy to take part in the study, then you don’t need to do anything.  The 
doctor seeing you will tell you if the researcher is present at your appointment. 
 
All data collected will be strictly confidential.  The information will be used to 
understand and improve the information and support available to patients and staff for 
decision making. 
 
If you would like any further information about the study or if you have any questions  
please contact the researcher: 
 
Yours faithfully, 
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Opt-out form
Name: ________________________________     Date: _________________ 
 
 
I would not like to take part in this study.  I understand that this decision will not 
affect the care that I receive in any way. 
 
Opt out:  
 
 
Please return this form to reception or to a member of the clinical team when you 
arrive for your appointment. 
 
If you would like any further information about the study while you consider your 
decision to participate please contact [name of researcher]: 
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Appendix 2 Observation materials
Observation grid
Date: Clinician:
Indication (ICD only or CRT-D)
Information about condition and risk of sudden death
Information about device (what it looks like and how it works)
Device function (does not improve symptoms)
Philosophical/existential discussion around desired mode of death
Benefit of device
Risks of device (complications); risk communication (e.g. absolute/relative risk, natural frequencies,
same denominator)
Risks of device (mental health)
Impact of device on quality of life (physical activity, sexual activity)
What might happen to the device in the future
Observation coding frame
l Implantation.
Understanding views and beliefs
l Understanding of need for ICD/perception of illness.
l Understanding of ICDs:
¢ ICD as prevention not therapy
¢ benefits
¢ improvements.
l Understanding procedure and risks.
l Personalising/anthropomorphising.
l Previous experiences.
l ICD as reminder of heart problems.
l Impact on identity:
¢ disruption to ‘healthy person’ identity
¢ becoming the ‘bionic man’.
l Effects on significant others.
l Reliance on hospitals.
l Feelings about surgery.
l Reconsideration of the device versus one off offer.
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Information giving
l Presentation of the device:
¢ being tested for suitability
¢ comparison to other treatments
¢ risk
¢ difficulties of communicating complex information.
l Misunderstandings of the ICD:
¢ denial of need.
l Prior understandings/understanding at tertiary appointment.
l Gaps in information provision – changes to mode of death.
l Understanding of condition.
l Information needs:
¢ honest and open
¢ tailored
¢ ability to absorb information after heart event.
l Hierarchies of knowledge.
l Written information:
¢ GP letters.
l Support group/other patients.
l Impact of negative information.
Decision-making
l Driving
l Living longer/survival.
l Lack of choice.
l Back-up for the future.
l Improvements in daily life:
¢ quality of life improvements
¢ ability to do mundane daily activities
¢ ability to do valued activities.
l Age.
l Experiential knowledge.
l Time.
l Views of others:
¢ trusted others
¢ other patients.
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l Clinician–patient relationship:
¢ SDM
¢ patient more than ‘file notes’
¢ clinicians power to persuade
¢ trust in clinicians
¢ maintenance of relationship
¢ hierarchies.
Living with the device
l Expectations versus lived experience:
¢ materiality
¢ physical appearance
¢ ability to forget the device
¢ expectation of fix.
l Support:
¢ ongoing support from clinicians/hospital
¢ social support.
l Problems with the device.
l Impacts of device:
¢ impacts on daily life
¢ disruption to other treatments
¢ avoidance of activities
¢ device as reassurance
¢ impact on mind and body
¢ impact on significant others
¢ improvements to quality of life.
l Future with ICD.
l Shocks:
¢ unaware of discharge
¢ experience of others’ discharges
¢ experience of own shocks
¢ shocks = good thing
¢ impact on significant others
¢ expectation/anticipation of shocks.
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Deactivation
l Reversibility of decision.
l Desire to keep it activated.
l Patient decision versus clinical.
l Clinical barriers:
¢ triggers for discussion
¢ identification of potential deactivation patients
¢ difficulties ascertaining where patient is in discussions
¢ negotiation between different clinician groups
¢ clinician avoidance of end-of-life discussions
¢ need to raise profile of ICDs
¢ inappropriate terminology
¢ need to routinise discussions.
l Timing:
¢ advanced discussions
¢ ‘right’ time for discussions.
l Actors involved:
¢ cardiologists
¢ palliative care.
l Ethical issues:
¢ deactivation = suicide
¢ active removal of treatment.
l Understanding of deactivation:
¢ confusion of process
¢ patient misunderstandings
¢ clinician misunderstandings
¢ significance of the heart.
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Appendix 3 Interview materials
Invitation letter
Dear Sir or Madam, 
 
I am writing to invite you to participate in a research study based at Newcastle 
University and funded by the National Institute for Health Research Health Services 
Delivery Research Programme.  The project has been reviewed by Sunderland 
Research Ethics Committee. 
 
I enclose a copy of the participant information sheet which I would be grateful if you 
would read.  If you agree to consider participating I will contact you by telephone or 
email to establish whether or not you would like to take part and to arrange a suitable 
time for the interview.  If you have any questions about the study or wish to advise 
me how you would prefer to be contacted please email [name of researcher] or 
telephone [researcher telephone number].   
 
It is up to you to decide whether or not to take part.  You can change your mind at any 
time and without giving a reason.  Whatever you decide it will not affect the future 
care you receive. 
 
Yours faithfully, 
 
 
 
Enc: 
Information Sheet 
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Participant information sheet
The Newcastle upon Tyne Hospitals 
 NHS Foundation Trust 
 
 
 
Decision-making about implantable defibrillators (ICDs) 
We are conducting a study to better understand how people make decisions about implantable cardioverter
defibrillator (ICD) therapy.  We would like to invite you to take part in our research study.  Before you decide, we
would like you to understand why the research is being done and what it would involve for you.  Please feel free to
talk to other people about the study if you wish and please ask us if there is anything that is not clear or if you would
like further information.  At the end of this information leaflet you will find details on how to contact us and what you
can do if you have any concerns. 
 
What is the purpose of the study? 
Implantable cardioverter defibrillators (ICDs) are complex devices with both benefits 
and risks.  We are conducting this study to better understand the information and 
support needs of those people thinking about having a device and for others who are 
living with an ICD.  The study is led by Professor Richard Thomson and Dr Catherine 
Exley at Newcastle University.   
 
Why have you been chosen and do you have to take part? 
You have been asked to take part because you were identified as someone who may 
be eligible for an ICD.  Participation in the study is entirely voluntary and it is up to 
you to decide whether or not to take part.  You are free to withdraw from the study at 
any time, without giving a reason.  Refusal to take part in the study will not affect the 
care you receive or your legal rights. 
 
What will I have to do? 
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
If you think you want to take part in the study, a researcher, Holly Standing, will be in 
touch with you by phone to ask if you are still interested in participating in the study 
and to arrange a convenient time to conduct the interview.  At this point you can ask 
any questions that you might have and discuss particular aspects of the study further.   
 
The interview will take place at a location most convenient for you (e.g. your home) 
or by telephone if you prefer.  The researcher will introduce herself, answer any 
additional questions and ask you to sign a consent form.  With your permission we 
will record the interview.  The interview will last about 60 minutes, depending on 
how you feel and how much you have to say.   
 
During the interview you will be asked questions about your views of the decision 
making process for an ICD.  If at any time during the interview you feel 
uncomfortable about any of the topics raised, you may choose not to answer a 
particular question or to end the interview and if necessary withdraw from the study.    
 
With your permission we will record your contact details for the purpose of getting in 
touch in the future to share the findings of the study and to offer you the opportunity 
to take part in a workshop to help to design a decision support tool.  
 
What are the possible risks of taking part? 
Every effort will be made to ensure your comfort and well-being, although it is 
possible that taking part in an interview may make you feel tired. If this happens you 
can take a break or you can stop the interview if you wish.  There is a possibility that 
some topics raised during the interview may be difficult or upsetting.  You do not 
have to talk about those topics if you do not want to.  If you would like to discuss any 
distressing or upsetting issues further we can, with your permission, inform a member 
of the clinical team who is responsible for your care.  Please remember that you are 
free to stop taking part in the study at any time, and this will not affect your current 
(or future) care or legal rights. 
 
What are the possible benefits of taking part? 
We cannot promise the study will help you as an individual but the information we 
get from this study may help to improve information and decision support for other 
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people considering (or living with) an ICD and their families.  This may in turn 
deliver benefits for future ICD recipients and their families. 
 
Will my taking part in the study be kept confidential? 
YES - We will follow ethical and legal practice and all information about your 
participation will be confidential. More detail on how we will ensure confidentiality 
can be found in Part 2 of this information leaflet. 
 
This completes Part 1 of this information leaflet.  If the information in part 1 has 
interested you, and you are considering participation, please read Part 2 before 
making a decision. 
 
Part 2: Detailed information about the conduct of this study 
 
What will happen if I change my mind about taking part? 
If you agree to participate in an interview but later decide that you no longer wish to take 
part in this study, please contact a member of the research team using the contact 
details at the end of this leaflet (quoting your unique identification number that is 
printed on the consent form).  
 
You are also free to stop the interview at any time, without giving a reason and without 
your medical care or legal rights being affected. At this point we can also destroy any 
information you have provided in the interview, but we will ask for your permission 
to continue to use the information that we have collected up until this point.  
 
Will my taking part in the study be kept confidential? 
YES.  We will not share details of your participation in the study with anyone outside 
the research team.  However, should anything come to light that would suggest 
malpractice or misconduct, or suggest that any individual was in danger of harm we 
would have to report this to the appropriate personnel.  
 
Your name or any other information that could identify you will not appear in any 
reports, publications or presentations based on findings from the study.  We may want 
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to use direct quotes from participants, but these would only be quoted as coming from 
“a participant” or a participant with a certain label, like “one patient said.”   
In accordance with Newcastle University’s policy on data protection and storage, the 
typed-up information in note books and transcripts of the interviews will have all 
names and other identifiers removed, and will be kept in a locked filing cabinet.  This 
information will also be securely stored on password protected computers in the 
Institute of Health and Society at Newcastle University.  
 
What if there is a problem? 
In the unlikely event that you should lose capacity during the interview and are no 
longer able to participate in the study, any data collected with consent up until that 
point will be retained and used in the study. 
 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  If you have a concern about any 
aspect of this study, you should ask to speak to the study lead, Professor Richard 
Thomson (0191 222 7832), who will do his best to answer your questions.  If you 
remain unhappy and wish to complain formally, you can do this by contacting the 
hospital’s Patient Advice and Liaison Service (0800 032 0202).   
 
What will happen to the results of the study? 
We intend to publish the findings in a report, scientific journals and to present the 
findings at scientific meetings. Any information that could identify you will not be 
included in any report or publication.  We will also hold a dissemination event where 
we will share the findings of the study with participants; you will have the 
opportunity to attend this event if you wish.  With your permission we would also like 
to use the information collected in this study for future research projects and 
educational purposes.  It will not be possible to identify you from this information and 
no further contact will be made with me.   
Who is organising and funding the research?  
The sponsor of the research is Newcastle upon Tyne Hospitals NHS Foundation Trust 
and Newcastle University. The study is funded by the National Institute for Health 
Research (NIHR) Health Services and Delivery Research Programme. 
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Who has reviewed the study?  
The study has been reviewed by the Sunderland Research Ethics Committee and a 
favourable opinion was given. 
 
What happens next?  
 A member of the research team, Holly Standing, will contact you, by phone, to 
explain the study further and to answer any questions you may have.  If you are still 
willing to take part then a convenient time and place to conduct the interview will be 
arranged.  If you prefer the option of a telephone interview you will be asked to 
complete the consent form in the study information pack and to return it to the 
University in the prepaid envelope supplied.  If you would prefer to conduct the 
interview face to face then you do not have to complete and return the consent form in 
advance. 
How to contact us 
If you have any questions about the study, or would like more information, please 
contact:  
 
You can also contact the Patient Advice and Liaison Service (PALS) if have any 
questions or concerns about this study: 
North of Tyne PALS Freepost: RLTC-SGHH-EGXJ 
The Old Stables, Grey's Yard, Morpeth, NE61 1QD 
Freephone: 0800 0320202  
Fax: 01670 511260  
Text: 01670 511098  
Email: northoftynepals@nhct.nhs.uk 
 
Additional information and support is also available at: 
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Arrhythmia Alliance 
24hr HELPLINE: 01789450787  
PO Box 3697,Stratford-Upon-Avon,Warwickshire, CV37 8YL 
info@heartrhythmcharity.org.uk 
Thank you for reading this information sheet 
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Consent form
Site Number:                               Participant Identification Number:   
Decision making about implantable defibrillators (ICDs) 
 
Lead Investigator: Professor Richard Thomson; Researcher: Holly Standing 
                                                                                                                               
Please initial each box  
1. I confirm that I have read and understand the information sheet for the above study. I 
have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily.  
 
 
2. I understand that my participation in this study is voluntary and that I am free to 
withdraw my participation at any time without giving any reason, without my care 
being affected.  
 
 
3. I agree to allow the researchers to audio record the interview. I understand that direct 
quotations may be used in the final report or scientific publications, however these will 
be anonymised and no personal information that could identify me will be used. 
 
 
4. I understand that all data collected during the interview will remain anonymous and 
confidential, and will be stored in a locked filing cabinet and on password protected 
computers located in the Institute of Health and Society at Newcastle University. 
 
 
5. I understand that during the interview if any disclosures are made, which indicate 
malpractice or misconduct, or suggest that any individual is in danger of harm, the 
information will be disclosed to the appropriate personnel. 
 
 
6. I understand that once transcribed, the audio recordings will be destroyed and 
transcripts stored in locked files in accordance with the Data Protection Act.  
 
 
7. I agree to my contact details being recorded on password protected computers located 
in the Institute of Health and Society at Newcastle University for the purposes of 
inviting me to participate in a workshop or event to share the study findings.  
 
 
8. I understand that relevant sections of my medical notes and data collected during the 
study, may be looked at by individuals from regulatory authorities or from the NHS 
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Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
9. I understand that the information I give in this study may be used in the future as part of 
research or for educational purposes.  I understand that it will not be possible to 
identify me from this information and no further contact will be made with me.   
 
 
10. I agree to take part in the above study. 
 
 
 
 
 
 
Name of Participant                                 Date                                     Signature  
 
Name of person taking consent               Date                                     Signature 
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Interview schedules
Interview topic guide (pre-implantation patients)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly. 
 
Plan of interview  
1. Introduction  
• Thank you agreeing to take part in this interview.  As you know, we are 
interviewing people about their decisions around whether to have an ICD 
implanted or not.  We are interested in understanding the types of information and 
support people need when making a decision about having an ICD.   
• With your permission I would like to record the interview; all details will be 
confidential.  I am not a clinician so if there are any questions about your device it 
would be helpful to hear them to understand what you would like more 
information about but they would be best answered by your doctor or 
physiologist. 
• Taking part in the study won’t affect your care.  There are no right or wrong 
answers and if you feel uncomfortable about any question we can move on to 
another topic or stop the interview. 
• Do you have any questions or concerns? 
• Obtain written consent. 
 
2. Referral for an ICD 
• Please would you tell me about the events leading up to your referral for an ICD? 
• What did the doctors tell you about why you needed an ICD? 
• How did you feel when you were told about your condition? 
• How did you feel about the ICD? 
• What is your understanding about the device (what does the device do, what 
doesn’t the device do?)  
3. Information Sources 
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• Can you tell me about any materials you received from your doctor?  Written 
materials or websites? 
• Did you or someone you know get information about ICDs from the internet or 
another source? 
• Have you talked with someone who already has an ICD? 
• Have you talked with your cardiologist about the benefits of getting an ICD? 
• Have you talked with your cardiologist about possible risks (surgical 
complications, experience of shock, risk of depression/anxiety)? 
• Did you talk about the impact on quality of life (daily living, body image)? 
• Do you feel well informed about the ICD (did you have all of the information you 
needed/wanted) 
• Is there anything that wasn’t discussed with your cardiologist that you would 
have liked information about? 
4. Living and Ageing with the device 
• Did you talk about consequences of getting an ICD (living with the device as you 
get older, battery changes etc)? 
• Did you talk about what will happen to your device as you get older? [have you 
discussed what might happen over your lifespan or if your condition changes?] 
• Is there any situation in which you would consider turning the device off?  What 
would those circumstances be? 
 
5. Making the decision  
• Were you able to discuss with your doctor the issues that were most important to 
you about the ICD? 
• Who did you discuss your options with besides your cardiologist (friends, family, 
others)? 
• What were their thoughts and feelings about the device?  
• To what degree were your family/friends involved in the decision-making 
process? 
• What is the most important factor that influenced your decision? Probes: “Some 
people have told us that they wish to [follow doctor’s advice/are acting on advice 
or wishes of family members/wish to prolong life, etc.] 
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· Have you got any outstanding worries or concerns about the device? 
· To what extent did you feel involved in the decision making process? 
 
6. Feedback 
· Thank you for your time. What made you take part in this interview? 
· Are we asking the right questions?  Do these questions allow you to talk about  
the most important issues for you?   
· Is there anything else you think it would be useful for us to know? 
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Interview topic guide (pre-implantation patients)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly. 
 
Plan of interview  
1. Introduction  
• Thank you agreeing to take part in this interview.  As you know, we are 
interviewing people about their decisions around whether to have an ICD 
implanted or not.  We are interested in understanding the types of information and 
support people need when making a decision about having an ICD.   
• With your permission I would like to record the interview; all details will be 
confidential.  I am not a clinician so if there are any questions about your device it 
would be helpful to hear them to understand what you would like more 
information about but they would be best answered by your doctor or 
physiologist. 
• Taking part in the study won’t affect your care.  There are no right or wrong 
answers and if you feel uncomfortable about any question we can move on to 
another topic or stop the interview. 
• Do you have any questions or concerns? 
• Obtain written consent. 
 
2. Referral for an ICD 
 
• Please would you tell me about the events leading up to your referral for your 
heart condition? 
• How did you feel when you were told about your condition? 
• What did the doctor/nurse tell you about why you needed an ICD? 
• How did you feel about the idea of having an ICD? 
 
3.    Information needs  
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• What did your doctor or nurse tell you about ICDs? 
• What is your understanding about the device (what does the device do, what 
doesn’t the device do?)? 
• Can you tell me about any materials you received from your doctor?  Written 
materials or websites? 
• Did you or someone you know get information about ICDs from the internet or 
another source? 
• Have you talked with someone who already has an ICD? 
• Have you talked with your clinician about the benefits of getting an ICD? 
• Have you talked with your clinician about possible risks (surgical complications, 
experience of shock, risk of depression/anxiety)? 
• Did you talk about the impact on quality of life (daily living, body image)? 
• Do you feel well informed about the ICD (did you have all of the information you 
needed/wanted)? 
• Is there anything about ICDs or your condition that you would like more 
information about at this point?  
• Do you have any concerns or worries about the device? 
 
4. Making the decision  
• Who have you discussed your options with besides your clinician (friends, 
family, others)? 
• Who was involved in helping you make your decision to think further about 
having an ICD? 
• Were you able to discuss with your clinician the issues that were most important 
to you about the ICD? 
• What is the most important factor that is likely to influence your decision about 
whether or not to have an ICD? Probes: “Some people have told us that they wish 
to [follow doctor’s advice/are acting on advice or wishes of family members/wish 
to prolong life, etc.] 
5. Living and ageing with an ICD 
• Is there any situation in which you would consider turning the device off?  What 
would those circumstances be? 
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• Did you talk about consequences of getting an ICD (living with the device as you 
get older, battery changes etc)? 
• What are you hoping for if you do decide to have an ICD fitted? 
• Do you expect life to be different? 
 
6.    Feedback 
• Thank you for your time. What made you take part in this interview? 
• Are we asking the right questions?  Do these questions allow you to talk about 
the most important issues for you?   
• Is there anything else you think it would be useful for us to know? 
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Interview topic guide (family)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly. 
 
Plan of interview  
1. Introduction 
2. Your relative’s experience living with an ICD 
3. End of life experiences 
4. Discussions in advance 
5. Improving conversations about deactivation 
6. Feedback 
 
3. Introduction  
· Thank you agreeing to take part in this interview.  As you know, we are 
interviewing family members to understand their views and experiences in 
relation to stopping ICD therapy for a loved one.  We are interested in 
understanding the types of information and support ICD patients and their families  
need.   
· With your permission I would like to record the interview; all details will be 
confidential.  I am not a clinician so if there are any questions about your device it 
would be helpful to hear them to understand what you would like more 
information about but they would be best answered by your doctor or 
physiologist. 
· There are no right or wrong answers and if you feel uncomfortable about any 
question we can move on to another topic or stop the interview. 
· Do you have any questions or concerns? 
· Obtain written consent. 
 
4. Your relative’s experience living with an ICD 
· Please can you tell me a little bit about your loved ones experience of having 
an ICD?  
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· What was yours and your loved ones understanding of the device? 
· Did your loved one experience a shock from their device at any point? 
· What did your loved one think about their device (did they value having it, 
how did it impact on their quality of life?) 
 
5. End of life experiences 
· Can you tell me what happened at the end of your lived one’s life? 
· Did your loved one experience shocks towards the end of life? 
 
6. Discussions in advance 
· Did you have a discussion in advance about turning off the ICD? 
· Who did you discuss turning off the device with? 
· At what stage did you have this conversation? 
· How was this explained to you? 
· Did you receive any other information about this process and what it means? 
 
7. Improving conversations about deactivation 
· From your experiences what aspects worked well? 
· What aspects could have been done better? 
· In your view at what stage should the possibility of turning the device off be 
discussed (offer different scenarios e.g. pre-implant as a hypothetical scenario  
or towards end of life as condition is deteriorating) 
· Do you have any ideas for how we might improve information giving about 
device deactivation? 
· Who do you think should be involved in these conversations? 
8. Feedback 
· Thank you for your time. 
· What made you take part in this interview? 
· Are we asking the right questions? 
· Are these the most important issues for you?   
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• Are there any other issues you would like to discuss to help me to better 
understand yours and your relative’s experiences?   
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Interview topic guide (decliners)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly.   
 
Plan of interview  
1. Introduction 
2. Referral for an ICD 
3. Information sources 
4. Making the decision 
5. Doctor’s role in decision making 
6. Improving information giving 
7. Feedback 
1. Introduction  
• Thank you agreeing to take part in this interview.  As you know, we are 
interviewing people about their decisions around whether to have an ICD 
implanted or not.  We are interested in understanding the types of information and 
support people need when making a decision about having an ICD.  We are 
especially interested in understanding why people decline an ICD and how they 
came to that decision with their doctor. 
• With your permission I would like to record the interview; all details will be 
confidential.  I am not a clinician so if there are any questions about your device it 
would be helpful to hear them to understand what you would like more 
information about but they would be best answered by your doctor or 
physiologist. 
• Taking part in the study won’t affect your care.  There are no right or wrong 
answers and if you feel uncomfortable about any question we can move on to 
another topic or stop the interview. 
• Do you have any questions or concerns? 
• Obtain written consent. 
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2. Referral for an ICD 
· Please would you tell me about the events leading up to your referral for an ICD?  
Were you offered your device after an acute event or as a preventive measure?  
· What did the doctors tell you about why you needed an ICD? 
· How did you feel when you were told you were eligible for an ICD? 
· What is your understanding about your ICD (what does the device do, what 
doesn’t the device do?)  
 
3. Information Sources 
· What materials have you received from your doctor?  Written materials or 
websites? 
· Did you access other sources of information?  If so what?  How useful was this? 
· Have you talked with someone who already has an ICD? 
 
4. Making the decision  
· Who did you discuss your options with besides your cardiologist (friends, 
family, others)? 
· Can you tell me what your cardiologist told you about the benefits of getting 
an ICD? 
· Can you tell me what your cardiologist told you about the risks and 
consequences of getting an ICD (probes: possible surgical complications, 
battery changes, impact on quality of life)? 
· Did your doctor ask you about what was most important to you when thinking 
about getting a device?  
· Did you talk about what happens with the device as you get older? 
· What were your expectations about life with the ICD? 
· To what degree were your family/friends involved in the decision-making 
process?  What concerns about the ICD did they have? 
· What were the main factors that influenced your decision?  
· Were there any other issues that were important to you that we haven’t 
covered? 
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5. Doctor’s role in decision making 
· How would the role your doctor played in helping you to make your decision 
about the ICD? 
· Do you think the doctor had an opinion about what decision you should make 
or not?  Can you tell me about that?    
 
 
6. Improving information giving 
· Is there any type of information you think would have made making your 
decision easier? 
· Looking back at your decision now, have you had any other thoughts about it?  
· Is there anything else you would have liked to discuss with your doctor?   
· If you could tell patients who are considering getting an ICD anything about 
making the decision, what would you tell them? 
 
7. Feedback 
· Thank you for your time 
· What made you take part in this interview? 
· Are we asking the right questions? 
· Do these questions allow you to talk about the most important issues for you?   
· Is there anything else you think it would be useful for us to know? 
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Interview topic guide (post-implantation patients)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly. 
 
Plan of interview  
1. Introduction 
2. Referral for an ICD 
3. Information sources 
4. Making the decision 
5. Living with an ICD 
6. The Future 
7. Improving information giving 
8. Feedback 
 
1. Introduction  
• Thank you agreeing to take part in this interview.  As you know, we are 
interviewing people about their decisions around whether to have an ICD 
implanted or not.  We are interested in understanding the types of information and 
support people need when making a decision about having an ICD.   
• With your permission I would like to record the interview; all details will be 
confidential.  I am not a clinician so if there are any questions about your device it 
would be helpful to hear them to understand what you would like more 
information about but they would be best answered by your doctor or 
physiologist. 
• Taking part in the study won’t affect your care.  There are no right or wrong 
answers and if you feel uncomfortable about any question we can move on to 
another topic or stop the interview. 
• Do you have any questions or concerns? 
• Obtain written consent. 
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· Please would you tell me about the events leading up to your referral for an ICD?  
Were you offered your device after an acute event or as a preventive measure?  
· What did the doctors tell you about why you needed an ICD? 
· How did you feel when you were told you were eligible for an ICD? 
· What is your understanding about your ICD (what does the device do, what 
doesn’t the device do?)  
 
3. Information Sources 
· Can you tell me about any materials you received from your doctor?  Written 
materials or websites? 
· Did you or someone you know get information about ICDs from the internet or 
another source? 
· Have you talked with someone who already has an ICD? 
· Is there anything that wasn’t discussed with your cardiologist that you would have 
liked information about? 
 
4. Making the decision  
· Who did you discuss your options with besides your cardiologist (friends, 
family, others)? 
· Can you tell me what your cardiologist told you about the benefits of getting 
an ICD? 
· Can you tell me what your cardiologist told you about the risks and 
consequences of getting an ICD (probes: possible surgical complications, 
battery changes, impact on quality of life)? 
· Have you talked about what happens with the device as you get older? 
· To what degree were your family/friends involved in the decision-making 
process? 
· What was the most important factor that influenced your decision? Probes: 
“Some people have told us that they wish to [follow doctor’s advice/are acting 
on advice or wishes of family members/wish to prolong life, etc.] 
2. Referral for an ICD
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• What is it like to live with an ICD, what is working well?  What’s not working 
as well?   
• Was anything different to how you expected?  Has anything surprised you? 
• What do you like/value about the device?  
• What do you dislike about the ICD?  
• How has the ICD affected your day to day life?  
• Are there any activities that you avoid?  Which ones and why? 
• How do you feel about your device? 
• How does living with an ICD affect your relationships (with partners, family)? 
• Have you ever received a shock from your device?  If so how would you 
describe that experience? 
• Have you had any other complications related to the device (probe: infections, 
lead fracture? 
• Do you worry about or have concerns about your ICD? 
 
6. The Future  
• Have you talked with your cardiologist or physiologist about what might 
happen in the future with your device as you get older? 
• Is there anything that concerns you? 
• Would you ever consider having your device turned off?  In what 
circumstances would you consider this? 
 
7. Improving information giving 
• Do you have any worries or unanswered questions about your ICD?  How do 
you handle these worries and unanswered questions? 
• If you could tell patients who are considering getting an ICD anything about 
what it’s like, what would you tell them?   What’s most important for them to 
know in making the decision? 
• Is there anything you know now that would have been helpful to know before 
you made your decision to get the ICD? 
5. Life with an ICD 
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• Thank you for your time. 
• What made you take part in this interview? 
• Are we asking the right questions? 
• Do these questions allow you to talk about the most important issues for you?   
• Is there anything else you think it would be useful for us to know? 
8. Feedback 
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Interview topic guide (post-implantation patients)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly. 
 
Plan of interview  
1. Introduction 
2. Referral for an ICD 
3. Information sources 
4. Making the decision 
5. Living with an ICD 
6. The Future 
7. Improving information giving 
8. Feedback 
 
1. Introduction  
• Thank you agreeing to take part in this interview.  As you know, we are 
interviewing people about their decisions around whether to have an ICD 
implanted or not.  We are interested in understanding the types of information and 
support people need when making a decision about having an ICD.   
• With your permission I would like to record the interview; all details will be 
confidential.  I am not a clinician so if there are any questions about your device it 
would be helpful to hear them to understand what you would like more 
information about but they would be best answered by your doctor or 
physiologist. 
• Taking part in the study won’t affect your care.  There are no right or wrong 
answers and if you feel uncomfortable about any question we can move on to 
another topic or stop the interview. 
• Do you have any questions or concerns? 
• Obtain written consent. 
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· Please would you tell me about the events leading up to your referral for an 
ICD?  (establish/confirm diagnosis) 
· Were you offered your device after an acute event or as a preventive measure?  
 
3. Making the decision  
· Can you recall what you were told about the pros and cons of having an ICD 
when you were making the decision to have one fitted? 
· What was the most important factor that influenced your decision? Probes: 
“Some people have told us that they wish to [follow doctor’s advice/are acting 
on advice or wishes of family members/wish to prolong life, etc.] 
 
4. Experience of shocks 
· When did you first experience a shock from your device (was it 
(in)appropriate)? 
· Can you tell me about your experience and how it affected you? 
· Do you feel that you could have received more information about ICD shocks 
pre-implant that could have helped you to cope? 
· Has the experience of your device discharging affected your day to day life?  
· Are there any activities that you avoid?  Which ones and why? 
· Has the experience of device shocks affected your relationships (with partners, 
family)? 
· How do you feel about your device now? 
 
5. Life with an ICD 
· What is it like to live with an ICD, what is working well?  What’s not working 
as well?   
· Was anything different to how you expected?  Has anything surprised you? 
· What do you like/value about the device?  
· What do you dislike about the ICD?  
· Have you had any other complications related to the device (probe: infections, 
lead fracture? 
2. Background info
DOI: 10.3310/hsdr04320 HEALTH SERVICES AND DELIVERY RESEARCH 2016 VOL. 4 NO. 32
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Standing et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
103
• Have you talked with your cardiologist or physiologist about what might 
happen in the future with your device as you get older? 
• Is there anything that concerns you? 
• Would you ever consider having your device turned off?  In what 
circumstances would you consider this? 
7.   Improving information giving
• Do you have any worries or unanswered questions about your ICD?  How do 
you handle these worries and unanswered questions? 
• If you could tell patients who are considering getting an ICD anything about 
what it’s like, what would you tell them?   What’s most important for them to 
know in making the decision? 
• Is there anything you know now that would have been helpful to know before 
you made your decision to get the ICD? 
 
8. Feedback 
• Thank you for your time. 
• What made you take part in this interview? 
• Are we asking the right questions? 
• Do these questions allow you to talk about the most important issues for you?   
• Is there anything else you think it would be useful for us to know? 
6.   The Future 
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Interview topic guide (prospective deactivation)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly. 
 
Plan of interview  
1. Introduction 
2. Your experience living with an ICD 
3. Reasons for deactivating the device 
4. Making the decision 
5. Improving conversations about deactivation 
6. Feedback 
1. Introduction  
· Thank you agreeing to take part in this interview.  As you know, we are 
interviewing ICD recipients who have made the decision to turn off their device.  
We are interested in understanding the types of information and support ICD 
patients need when thinking about device deactivation.   
· With your permission I would like to record the interview; all details will be 
confidential.  I am not a clinician so if there are any questions about your device it 
would be helpful to hear them to understand what you would like more 
information about but they would be best answered by your doctor or 
physiologist. 
· There are no right or wrong answers and if you feel uncomfortable about any 
question we can move on to another topic or stop the interview. 
· Do you have any questions or concerns? 
· Obtain written consent. 
 
2. Your experience living with an ICD 
· Please can you tell me a little bit about your experience of having an ICD?  
· What was your understanding of the device (what does it do/not do)? 
· Did your experience a shock from your device at any point? 
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· How did your ICD impact on your quality of life?) 
 
3. Reasons for deactivating the device 
· Can you tell me a little bit about why you wanted your device turned off? 
· Were there any other reasons for your decision? 
 
4. Making the decision 
· Who did you discuss turning off the device with? 
· At what stage did you realise that deactivation was an option? 
· What type of information did you receive? 
· How was the process of deactivation explained to you? 
· Had you ever thought about what would happen with your ICD as you got 
older? E.g. do you have an advance directive (and was the ICD incorporated 
into this?) 
· What happened after you made the decision to have the device switched off? 
· Did your experience match your expectations (how was it different)? 
 
5. Improving conversations about deactivation 
· From your experiences what aspects worked well? 
· What aspects could have been done better? 
· In your view at what stage of the pathway should the possibility of turning the 
device off be discussed (before/after implantation)? 
· Do you have any ideas for how we might improve information giving about 
device deactivation? 
· Who do you think should be involved in these conversations? 
· If you could tell patients who are considering getting an ICD anything about 
what it’s like, what would you tell them?   What’s most important for them to 
know in making the decision? 
6. Feedback 
· Thank you for your time. 
· What made you take part in this interview? 
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· Are we asking the right questions? 
· Are these the most important issues for you?   
· Are there any other issues you would like to discuss to help me to better 
understand yours and your relative’s experiences?   
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Interview topic guide (cardiologists)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly.  Also, this is a generic guide for all clinicians; the topics discussed will be 
adapted for each of the different clinician groups (e.g. cardiology compared with 
palliative care team). 
 
Plan of interview  
1. Introduction 
2. The referral pathway 
3. Risk communication & patient information 
4. Implantation decisions - current practice 
5. Improving decision making about implantation 
6. Deactivation decisions – current practice 
7. Improving decision making about deactivation 
8. Feedback 
 
1. Introduction  
• Thank you for agreeing to take part in this interview.  As you know, we are 
interviewing clinicians about their views and experiences of decision making 
about ICD implantation and deactivation.  We are interested in understanding the 
types of information and support patients (and clinicians) need when making 
decisions about ICD therapy.   
• With your permission I would like to record the interview; all details will be 
confidential.   
• Do you have any questions or concerns? 
• Obtain written consent. 
 
2. The referral pathway 
• Can you talk me through what happens from the point of referral to a specialist 
centre to implantation please? 
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• From your perspective, what works well in the pathway (what works not so well)? 
• What, if any, understanding do patients have about ICDs when they first meet you? 
• Do you feel that some of the early information sharing about ICDs could be begun 
in secondary care? 
 
3. Risk communication & patient information 
• How do you explain to patients that they need an ICD? 
• How do you communicate information about benefits, risks, prognosis, life 
expectancy? 
• What are the issues that seem to be important to patients? 
• Do you feel that patients have a good understanding of the function of the device?  
• How do you talk about short term complications? 
• Do you talk about any other types of risks (e.g. effects on mental health)? 
• Do you discuss quality of life implications? 
• Is there anything that you would like to talk about in more detail but rarely have 
time? 
• Do you talk about what happens as a patient gets older (battery changes and 
deactivation)?  
• Do patients grasp the role and function of the device? 
• What types of misunderstandings do patients have if any? 
• What are patients’ hopes and expectations about the device? 
• Which information sources do you signpost patients to?  Do you think these are 
appropriate/useful? Do you feel we might rely too much on leaflets? 
• What kind of information/decision support would you rather see was available at 
this time? 
4. Implantation decisions - current practice 
• Currently how does decision making about ICD implantation take place? 
• Who is involved in information sharing? 
• Typically what role do patients tend to want to play in decision making? 
• To what extent are partners/family members involved in decision making? 
• How do you engage and support the patient to make a decision about ICD therapy? 
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• What factors do you think need to be considered when making a decision about 
having an ICD? 
 
5. Improving decision making about implantation 
• How do you feel about patient engagement in decision making? 
• What are the benefits of involving patients and carers in decision making? 
• What are the main facilitators and barriers to meaningful discussions about ICD 
implantation? 
• In your view, how might patients and clinicians be better supported to make 
decisions about ICD implantation? 
• What resources/tools/training are needed? 
• What are the ingredients of a good/ideal model of decision making about ICDs. 
 
6. Deactivation decisions – current practice 
• Can you tell me about a time when you were involved in the care of a patient who 
needed a device deactivated?  Please would you tell me about that experience? 
How was the issue approached, at what point and by whom? 
• How common are conversations with patients about device deactivation? 
• Why do you think that the issue of deactivation is rarely approached in advance? 
• How are these conversations different to others at the end of life? 
• What are the facilitators and barriers to timely discussion about device 
deactivation? 
 
7. Improving decision making about deactivation 
• At what time point do you think that the topic of deactivation should be discussed? 
• In an ideal scenario when and how should device deactivation be discussed?  
• In your view, who should be involved?  
• What are the characteristics of a “good” conversation about deactivation? 
• What type of support for patients/family is required? 
• How can clinicians be better supported to have these conversations 
(resources/tools/training)? 
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8. Feedback 
· Thank you for your time. 
· What made you take part in this interview? 
· Are we asking the right questions? 
· 
· 
Do these questions allow you to talk about the most important issues for you?   
Is there anything else you think it would be useful for us to know? 
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Interview topic guide (physiologists)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly.  Also, this is a generic guide for all clinicians; the topics discussed will be 
adapted for each of the different clinician groups (e.g. cardiology compared with 
palliative care team). 
 
Plan of interview  
 
1. Introduction 
2. The referral pathway 
3. Living with an ICD 
4. Implantation decisions - current practice 
5. Improving decision making about implantation 
6. Deactivation decisions – current practice 
7. Improving decision making about deactivation 
8. Feedback 
 
1. Introduction  
• Thank you for agreeing to take part in this interview.  As you know, we are 
interviewing clinicians about their views and experiences of decision making 
about ICD implantation and deactivation.  We are interested in understanding the 
types of information and support patients (and clinicians) need when making 
decisions about ICD therapy.   
• With your permission I would like to record the interview; all details will be 
confidential.   
• Do you have any questions or concerns? 
• Obtain written consent. 
2. The care pathway 
• Please can you describe your job? 
• Can you describe how you come into contact with people eligible for an ICD? 
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· Are you involved in information sharing prior to implantation? 
· How do you describe an ICD? 
· How do you think patients grasp the idea? 
· What types of issues do patients want to talk about? 
· From your perspective, what works well in the current pathway (what works not 
so well)? 
3. Living with an ICD 
· What are the issues that seem to be important to patients? 
· Are there any common misunderstandings about the function of the ICD? 
· After a patient experiences a shock at home what happens? 
· How does the experience of shock affect patients? 
· How are people who experience psychosocial sequelae supported? 
· Which information sources do you signpost patients to? 
· Do you feel we might rely too much on leaflets? 
 
4. Improving decision making about implantation 
· Thinking back to what happens before people get a device, how might patients 
and clinicians be better supported to make decisions about ICD implantation? 
· What role do patients want to play in decision making? 
· What role do partners tend to adopt? 
· What resources/tools/training are needed? 
· Do you feel that there is a need for additional tools or training (e.g. decision 
aids)? 
· What are the main facilitators and barriers to meaningful discussions about 
ICD implantation? 
 
5. Deactivation decisions – current practice 
· Please can you tell me about an example where deactivation in advance has 
gone well? (who was involved, what happened, why did it go well)? 
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• Please can you tell me about an example where deactivation didn’t go so well 
(what happened, how could this have been avoided)? 
• How common are conversations about device deactivation in advance (who is 
involved)? 
 
6. Improving decision making about deactivation 
• At what time point do you think that the topic of deactivation should be 
discussed? 
• Why do you think that the issue of deactivation is rarely approached in 
advance? 
• In your view, who should be involved and how should the issue be approached?  
• How are these conversations different to others at the end of life? 
• What are the facilitators and barriers to timely discussion about device 
deactivation? 
• What type of support for patients/family is required? 
• How can clinicians be better supported to have these conversations 
(resources/tools/training)? 
 
7. Feedback 
• Thank you for your time. 
• What made you take part in this interview? 
• Are we asking the right questions? 
• Do these questions allow you to talk about the most important issues for you?   
• Is there anything else you think it would be useful for us to know? 
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Interview topic guide (specialist nurse)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly.  Also, this is a generic guide for all clinicians; the topics discussed will be 
adapted for each of the different clinician groups (e.g. cardiology compared with 
palliative care team). 
 
Plan of interview  
1. Introduction 
2. The care pathway 
3. Information and decision support 
4. Living with an ICD 
5. Deactivation decisions – current practice 
6. Improving decision making about deactivation 
7. Feedback 
Introduction  
· Thank you for agreeing to take part in this interview.  As you know, we are 
interviewing clinicians about their views and experiences of decision making 
about ICD implantation and deactivation.  We are interested in understanding the 
types of information and support patients (and clinicians) need when making 
decisions about ICD therapy.   
· With your permission I would like to record the interview; all details will be 
confidential.   
· Do you have any questions or concerns? 
· Obtain written consent. 
 
2. The care pathway 
· Please can you describe your role? 
· Can you describe how you come into contact with people eligible for an ICD? 
· When do you first see ICD patients?  Are you involved in information sharing 
prior to implantation? 
1. 
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• How do you describe an ICD? 
• How do you think patients grasp the idea? 
• Are there any misunderstandings about the function of the ICD? 
• How do patients understand the benefits of an ICD? 
• How do patients understand the risk of an ICD? 
• What types of issues do patients want to talk about? 
• From your perspective, what works well in the current pathway (what works not 
so well)? 
 
3. Information and Decision Support 
• Which information sources do you signpost patients to? 
• Do you feel the information that is available is appropriate/sufficient/useful? 
• What would you rather see was available to support patients in decision making 
about ICDs? 
• What factors do you think need to be considered when making a decision to have 
an ICD fitted? 
• What are the characteristics of the ideal model of decision making about ICD 
implantation? 
 
4. Living with an ICD 
• Living with the device, what are the issues that seem to be important to patients? 
• From your experiences, how does living with an ICD impact on patients’ quality 
of life? 
• Please tell me about any memorable experiences where an ICD has had a positive 
impact on a patient’s mental health and wellbeing?  Likewise for negative impacts? 
• From your experiences, how does the experience of shock/device discharge affect 
patients? (avoidance behaviours/anxiety/depression) 
• How are people who experience psychological sequelae supported? 
• In your experience, how are family members/carers affected (what is the range of 
responses)? 
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· Are you involved in supporting decision making about deactivating a device? 
· Can you tell me about any memorable experiences involving device deactivation? 
· Please can you tell me about an example where deactivation in advance has gone 
well? (who was involved, what happened, why did it go well)? 
· Please can you tell me about an example where deactivation didn’t go so well 
(what happened, how could this have been avoided)? 
· How common are conversations about device deactivation in advance (who is 
involved and at what stage)? 
 
6. Improving decision making about deactivation 
· At what time point do you think that the topic of deactivation should be discussed? 
· Why do you think that the issue of deactivation is rarely approached in advance? 
· In your view, who should be involved and how should the issue be approached?  
· How are these conversations different to others at the end of life? 
· What are the facilitators and barriers to timely discussion about device 
deactivation? 
· What type of support for patients/family is required? 
· How can clinicians be better supported to have these conversations 
(resources/tools/training)? 
 
7. Feedback 
· Thank you for your time. 
· What made you take part in this interview? 
· Are we asking the right questions? 
· Do these questions allow you to talk about the most important issues for you?   
· Is there anything else you think it would be useful for us to know? 
5. Deactivation decisions – current practice
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Interview topic guide (psychologists)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly.  Also, this is a generic guide for all clinicians; the topics discussed will be 
adapted for each of the different clinician groups (e.g. cardiology compared with 
palliative care team). 
 
Plan of interview  
1. Introduction 
2. The care pathway 
3. Information and decision support 
4. Living with an ICD 
5. Deactivation decisions – current practice 
6. Improving decision making about deactivation 
7. Feedback 
 
Introduction  
· Thank you for agreeing to take part in this interview.  As you know, we are 
interviewing clinicians about their views and experiences of decision making 
about ICD implantation and deactivation.  We are interested in understanding the 
types of information and support patients (and clinicians) need when making 
decisions about ICD therapy.   
· With your permission I would like to record the interview; all details will be 
confidential.   
· Do you have any questions or concerns? 
· Obtain written consent. 
2. The care pathway 
· Please can you describe your role? 
· Can you describe how you come into contact with people eligible for an ICD? 
· When do you first see ICD patients?  Are you involved in information sharing 
prior to implantation? 
1. 
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· How do you describe an ICD? 
· How do you think patients grasp the idea? 
· Are there any misunderstandings about the function of the ICD? 
· How do patients understand the benefits of an ICD? 
· How do patients understand the risk of an ICD? 
· What types of issues do patients want to talk about? 
· From your perspective, what works well in the current pathway (what works not 
so well)? 
 
3. Information and Decision Support 
· Which information sources do you signpost patients to? 
· Do you feel the information that is available is appropriate/sufficient/useful? 
· What would you rather see was available to support patients in decision making 
about ICDs? 
· What factors do you think need to be considered when making a decision to have 
an ICD fitted? 
· What are the characteristics of the ideal model of decision making about ICD 
implantation? 
4. Living with an ICD 
· Living with the device, what are the issues that seem to be important to patients? 
· From your experiences, how does living with an ICD impact on patients’ quality 
of life? 
· Please tell me about any memorable experiences where an ICD has had a positive 
impact on a patient’s mental health and wellbeing?  Likewise for negative impacts? 
· From you experiences, how does the experience of shock/device discharge affect 
patients (avoidance behaviours/anxiety/depression?)? 
· How are people who experience psychological sequelae supported? 
· How are family members/carers affected? 
 
5. Deactivation decisions – current practice 
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• Are you involved in supporting decision making about deactivating a device? 
• Can you tell me about any memorable experiences involving device deactivation? 
• Please can you tell me about an example where deactivation in advance has gone 
well? (who was involved, what happened, why did it go well)? 
• Please can you tell me about an example where deactivation didn’t go so well 
(what happened, how could this have been avoided)? 
• How common are conversations about device deactivation in advance (who is 
involved and at what stage)? 
 
6. Improving decision making about deactivation 
• At what time point do you think that the topic of deactivation should be discussed? 
• Why do you think that the issue of deactivation is rarely approached in advance? 
• In your view, who should be involved and how should the issue be approached?  
• How are these conversations different to others at the end of life? 
• What are the facilitators and barriers to timely discussion about device 
deactivation? 
• What type of support for patients/family is required? 
• How can clinicians be better supported to have these conversations 
(resources/tools/training)? 
 
7. Feedback 
• Thank you for your time. 
• What made you take part in this interview? 
• Are we asking the right questions? 
• Do these questions allow you to talk about the most important issues for you?   
• Is there anything else you think it would be useful for us to know? 
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Interview topic guide (palliative care clinicians)
Please note the interview topic guide is a living document.  The design is iterative to 
tailor the interview to the needs of the participant, and the issues that they feel are 
most important.   As analysis occurs concurrently the topic guide is likely to be 
adapted over time - questions might be added, amended or omitted – and used 
flexibly.  Also, this is a generic guide for all clinicians; the topics discussed will be 
adapted for each of the different clinician groups (e.g. cardiology compared with 
palliative care team). 
 
Plan of interview  
 
1. Introduction 
2. Deactivation decisions – current practice 
3. Improving decision making about deactivation 
4. Feedback 
1. Introduction  
· Thank you for agreeing to take part in this interview.  As you know, we are 
interviewing clinicians about their views and experiences of decision making 
about ICD implantation and deactivation.  We are interested in understanding the 
types of information and support patients (and clinicians) need when making 
decisions about ICD therapy.   
· With your permission I would like to record the interview; all details will be 
confidential.   
· Do you have any questions or concerns? 
· Obtain written consent. 
 
2. Deactivation decisions – current practice 
Can you say a little about your role and how you come into contact with patient 
with ICDs? 
Can you tell me about a time when you were involved in the care of a patient who 
needed an ICD deactivated?   
· 
· 
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I am interested in your stories/examples from yours or your colleagues experience.  
Can you tell me about other particularly memorable experiences of ICD patients 
in your care?  
Thinking about those examples, what went well? 
What didn’t go so well? 
How do you approach the topic of deactivation? 
Can you please talk me through how you would have that conversation? 
Do patients tend to be familiar with the concept of deactivation? 
How is deactivation understood by patients? 
Is anyone else involved in these conversations? 
How are these conversations different to others at the end of life? 
Are there any aspects of ICD therapy that make conversations about end of life 
more difficult? 
 
3. Improving decision making about deactivation 
Why do you think that the issue of deactivation is rarely approached in advance 
by cardiologists? 
At what time point do you think that the topic of deactivation should be discussed? 
In an ideal scenario when and how should device deactivation be discussed? 
What are the components of good practice regarding ICDs towards end of life? 
When would be the most appropriate time to begin advance care planning? 
In your view, who should be involved?  
What are the facilitators and barriers to timely discussion about device 
deactivation? 
Do you think the legalities are well understood? (misconceived as 
euthanasia/physician assisted suicide) 
What type of support for patients/family is required? 
How can clinicians be better supported to have these conversations? (e.g. 
resources/tools/training) 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
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· What made you take part in this interview? 
· Are we asking the right questions? 
· Do these questions allow you to talk about the most important issues for you?   
· Is there anything else you think it would be useful for us to know? 
4. Feedback 
· Thank you for your time.
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Clinician cover letter for bereaved relative interviews
The Newcastle upon Tyne Hospitals 
 NHS Foundation Trust 
Dear [   ], 
I am a local site investigator for a research study led by Newcastle University and 
funded by the National Institute of Health Research.  The research is seeking to 
improve the information and support people receive when living with an implantable 
cardiac defibrillator (ICD) and approaching end of life. The research is aiming to 
produce information to better support conversations about turning off an ICD, in order 
to reduce pain and distress for both the patient and their family towards the end of life. 
We are contacting you because we would like to speak with people who have lost a 
loved one, who had an ICD fitted, to discuss experiences and explore your views 
about what worked well and what worked not so well with the ICD towards end of 
life.  Please be assured that the research team do not have access to any of your loved 
one’s clinical data.  I enclose a letter about the research and a copy of the participant 
information sheet, which I would be grateful if you would read.   
If you have any questions about the study please contact either Holly Standing (the 
researcher on the study, details on accompanying letter) or myself, using the contact 
details below.  It is up to you to decide whether or not to take part.  You can change 
your mind at any time and without giving a reason.   
I apologise if this enquiry has caused undue upset. I do appreciate you taking the time 
to consider participating in this study which seeks to improve the experience of ICD 
patients, and their family, towards end of life. 
Yours sincerely, 
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Appendix 4 Workshop slides and materials
Health-care professional workshop slides
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Patient/family member workshop slides and materials
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Structured Task 
 
 
 
TASK 1 (15 MINS):  
Individually write brief notes that relate to each of the following categories (1 
item of information on each post it note) 
 
• What information about the options (ICD, CRTD or doing nothing / active 
monitoring) should be provided to patients/relatives? Green post it notes 
 
• Who should discuss the pros and cons of the options (ICD, CRTD or doing 
nothing / active monitoring) with patients and their relatives? Yellow post it 
notes 
 
• When should a discussion with patients and their relatives about deactivation 
of ICDs/CRTDs take place? Pink post it notes: 
 
TASK 2 (10 MINUTES) 
In your small groups, collate responses for each category (and remove any 
duplicates) on a large piece of paper 
 
TASK 3 (25 MINUTES) 
Group discussion – one or more person from each small group shares the 
findings of task 2 with the other groups 
Form into small 
groups 
 
Referring to the 
summary 
diagram 
provided on 
large [A3] 
sheets – please 
work through 
each of the 3 
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